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Summary 
The RAD9 protein assembles with RAD1 and HUS1 in the 9-1-1 DNA damage sensor 
complex (RAD9-HUS1-RAD1) which plays a crucial role in the activation of the DNA 
damage checkpoints by recruiting repair enzymes to DNA lesions and by initiating a cell 
cycle arrest. Why human cells express two RAD9 proteins, RAD9A and RAD9B, which share 
significant similarity is still very enigmatic. Moreover, both genes encode several splice 
variants with unknown function. While RAD9A is intensively studied, very little information 
is available about RAD9B. To get a deeper insight into the biology of RAD9B, two stable 
HEK293 cell lines were constructed which either over-express full-length human RAD9B-
002 (417aa) or its N-terminally truncated splice variant RAD9B-001 (345aa) from an 
inducible promotor. These studies were complemented by the expression analysis of all five 
RAD9B splice variants at mRNA level in human tissues.  
 
This study revealed for the first time specific activities of the two RAD9B variants. While 
both proteins target the CHK2-p21 signalling module, which regulates cell cycle progression 
from G1 into S phase and the response to DNA damage in  G1/S, they do affect CHK2 kinase 
and the cell cycle regulator p21WAF1/CIP1 in distinct ways. Elevated protein levels of full-length 
RAD9B initiate cell death in G1, cause the moderate hyperposphorylation of CHK2 and delay 
the degradation of p21 in the presence of oxidative stress. On the contrary, high levels of the 
N-terminally truncated variant RAD9B-001 only transiently block G1-S transition, cause a 
strong hyper-phosphosphorylation of CHK2 and delay p21 degradation in the response to UV 
irradiation. While the shorter variant may block p21 degradation in a PCNA-dependent 
manner in S phase, the full-length protein may act through the anaphase promoting complex 
(APC) when cells exit mitosis. The work provides also evidence that the hyper-
phosphorylation of CHK2 is not dependent on the normal upstream kinase ATM, but on the 
mitotic regulator MPS1/TTK kinase. 
 
Dissecting this novel regulatory network formed by the two splice variants of the human 
RAD9B gene may help to understand why RAD9B expression levels change in several human 
cancers including testicular cancer, myelogenous leukaemia, ovarian epithelial carcinoma and 
cervical carcinoma (HeLa) cells.   
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  Chapter 1: INTRODUCTION 
 
 Introduction 
Why the human genome contains two closely related copies of the RAD9 gene, RAD9A and 
RAD9B, is still unclear. RAD9A assembles with HUS1 and RAD1 in a ring complex, which is 
loaded at sites of DNA damage to generate a signal that arrests cell cycle progression, aids 
DNA repair or induces cell death (Parrilla-Castellar et al., 2004). Both, RAD9A and RAD9B 
can form the 9-1-1 ring complex (Perez-Castro & Freire, 2012). While RAD9A encodes three 
protein splice variants (391aa, 247aa, 10aa), RAD9B encodes five variants (429aa, 417aa, 
345aa, 345aa, 341aa). None of these variants has been studied so far. This thesis presents 
evidence that the two RAD9B splice variants RAD9B-001 (345aa) and RAD9B-002 (417aa) 
regulate the phosphorylation status of CHK2, a kinase acting down-stream of the DNA 
damage sensor ATM (Tel1) kinase, in a manner which is independent of ATM. Elevated 
protein levels of RAD9B-002 strongly reduce cell proliferation, cause the accumulation of a 
sub G1 cell population and inhibit the phosphorylation of CHK2 in response to UV light and 
oxidative stress caused by H2O2. High levels of the shorter variant the N-terminally truncated 
splice variant RAD9B-001 (345aa), which misses the first 72 amino acids only transiently 
arrest cells in G1, cause an increase in  the CHK2 phosphorylation in response to H2O2 and 
delay the degradation of the CDK inhibitor p21 in the response to UV light. Interestingly 
RAD9B-001 resembles the N-terminally truncated Rad9-M50 variant from 
Schizosaccharomyces pombe (S. pombe) (Appendix 7). The thesis also presents data showing 
that the yeast variant is recognised when expressed in human cells and contributes to the 
response to oxidative DNA damage.  
 
 Protein Variants  
Many eukaryotic genes encode two or more protein isoforms (Rappsilber & Mann, 2002; 
Kelemen et al., 2013). Such isoforms show variation in length, share common exons, include 
variable exons, or possess different amino acids, as splicing events can alter the translational 
reading frame of the differentially spliced mRNAs (Ahmad et al., 2012).  
 
Several mechanisms exist for generating the enormous diversity of proteins required to fulfil 
all the functions in a multicellular organism. These mechanisms include alternative splicing, 
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post-translational modifications (PTMs) and genetic variation (Ahmad et al., 2012). Protein 
variants can behave in radically different ways than the original proteins.  
 
A good example is the Δ133p53β, a splice variant of the TP53 gene. While TP53 is 
considered a major tumour suppressor, Δ133p53β enhances cancer cell stemness in MCF-7 
breast cancer cells indicating an opposite oncogene role (Arsic et al., 2015). Other important 
factors which are affected by protein variation include PTM, subcellular localisation, 
degradation and complex formation. Even subtle differences in the protein structure can result 
in these different behaviours. (Figure 1.1) (Hinkson & Elias, 2011; Lubec & Afjehi-Sadat, 
2007; Godovac‐Zimmermann et al., 2005). Furthermore, even the same isoform of a protein 
can reveal substantially different functions depending on its subcellular context, time of 
expression, or interaction partners (Ahmad et al., 2012).  
  
 
 
Figure 1.1 Protein variation results in different protein functional roles. Alternative splicing is 
one example of gene variation resulting in different transcripts of the gene with each containing 
different sequence regions of the original gene. This figure displays one type of alternative splicing 
(exon skipping) resulting in the removal of one exon from the original mRNA transcript. Different 
colours represent different exons and their protein products. Gene variation results in different protein 
isoforms leading to different roles as a result of their localisation, post-translational modification, rate 
of synthesis and interaction partners. 
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Gene duplication, a mechanism of which an extra copy of a gene is generated, may also be 
considered a form of protein variation. Duplicate proteins can share extensive sequence 
identity, yet minor alterations within the sequence can deliver novel effects (Ahmad et al., 
2012). The outcomes of  gene  duplication can result in non-functional genes (degenerative 
mutations leading to a completely silenced gene), to subfunctional genes (both copies are 
affected by the accumulation of mutations where their functional capacity is reduced or 
becomes only partially compromised, as each copy partially retains a subset of its original 
function), or to neofunctional genes (one copy retains the original function while the other 
copy gains a preserved novel function) (Figure 1.2). Other outcomes of gene duplication may 
increase gene expression dosage or lead to differential regulation (both copies differ in the 
regulatory region allowing for enhanced expression or temporal functionality) (Ahmad et al., 
2012; Ho et al., 2011; Louis, 2007; Lynch & Conery, 2000; Ohno, 1970)  
 
 
 
Figure 1.2 Different variation outcomes of gene duplication. Nonfunctionalisation results in the 
loss of one of the gene copies by degeneration or deletion. In subfunctionalisation, each copy partially 
functions in a complementary manner retaining the original function. Neofunctionalisation results in 
one gene copy having the original copy but the other copy has a novel function. Increased gene dosage 
results in identical copies of the original gene to fulfil the organism’s requirements. In differential 
regulation, the two gene copies result in different regulator regions for enhanced expression. 
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The human RAD9A and RAD9B genes are a good example of gene duplication. While simple 
eukaryotic organisms like fission yeast (S.pombe) contain only one Rad9 gene, complex 
eukaryotic organisms like mammals have two copies. The human RAD9 genes share 36% 
identity and 48% identity (Dufault et al., 2003). Both RAD9 proteins assemble in the 9-1-1 
ring (Figure 1.3), but due to their sequence diversity are expected to fulfil different functions.  
It should be also mentioned that RAD9A can also act outside of the 9-1-1 ring, for example in 
the context of androgen-regulated gene expression (Wang et al., 2004). 
 
 
Figure 1.3 Structure of the human 9-1-1 ring. RAD9A (red), HUS1 (green), RAD1 (blue). The tail 
domain of RAD9A is missing, (structure ID: 3GGR, the image was produced with Polyview 3D) (Xu 
et al., 2009). The DNA would run through the central opening. 
 
 
1.2.1 Alternative splicing 
In the late 1970s, a comparison of adenovirus mRNA sequence with its corresponding nuclear 
sequence revealed a partial removal of the pre-mRNA sequence prior to its export to the 
cytosol where the remaining elements were joined together. Most mammalian transcripts 
undergo this process of alternative splicing (Kelemen et al., 2013; Berget, Moore & Sharp, 
1977; Chow et al., 1977). Alternative splicing is catalysed by the spliceosome machinery 
consisting of five protein-RNA complexes (U1-U5) plus additional protein factors which bind 
to the pre-mRNA to excise the introns (Wahl et al., 2009). The combined exons form the 
mature mRNA which is exported into the cytoplasm whereas the remaining RNA regions of 
the pre-transcripts (e.g. introns) are degraded by nucleases or converted into small regulatory 
RNAs known as micro-RNAs (Kelemen et al., 2013; Sevignani et al., 2006; Sharp, 2005).  
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Alternative splicing allows for the combination of different protein-coding exons in the 
mature mRNA in different configurations resulting in diverse mature mRNA transcripts and, 
hence, different protein products (Kelemen et al., 2013). The mechanisms of alternative 
splicing include four basic modules: alternative 5’ splice-site target, alternative 3’ splice-site 
target, exon skipping and intron retention (Figure 1.4) (Nilsen & Graveley, 2010). An 
alternative splicing study on humans and mice revealed that exon skipping is the most 
common splice event (38.4% of all splice events), while 18.4% were due to alternative 3’ 
splice events, 7.9% were 5’ alternative splice sites and only 2.8% were due to intron retention. 
The remaining 32.4% were more complicated splice events (Sugnet et al., 2004).  
 
 
 
 
Figure 1.4 Basic mechanisms of alternative splicing in eukaryotic cells. Exon skipping: One 
exon is spliced out of the primary transcript and the other exons are rejoined together. This 
exon skipping mechanism is the most common of these mechanisms. Mutually exclusive 
exons: One of two exons are retained after splicing the primary mRNA transcript but not both. 
Alternative 3’ and 5’ sites: An alternative 5’ or 3’ splice site within one exon is a target for a 
spliceosome. Intron retention: An intron can be spliced out or retained within the mature 
mRNA transcript. 
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An exon-junction microarray study indicated that at least 74% of all human genes are 
alternatively spliced (Johnson et al., 2003). While this number may be surprising, perhaps 
even more notable is that 92–95% of all genes contain more than one coding exon (i.e., all 
genes that could theoretically be alternatively spliced) are indeed alternatively spliced (Pan et 
al., 2008; Wang et al., 2008). Alternative splicing is regulated at tissue level, at different 
developmental stages (Sánchez & Rodríguez, 2008), or during cell differentiation (Boutz et 
al., 2007; Makeyev et al., 2007). Some alternative splicing patterns occur in the response to 
external stimuli like neuronal activity (Xie & Black, 2001), in response to DNA damage 
(Shkreta & Chabot, 2015) (Figure 1.5) and in inhibition or activation of cell death (Mosley & 
Keri, 2006), or upon intracellular signalling (Lee et al., 2010; Lynch, 2007; Shin & Manley, 
2004). 
 
 
 
Figure 1.5 RNA splicing response to cellular stress. The activity of the splicing factors can alter in 
response to DNA damage, resulting in the production of different mRNAs which are used by cells to 
maintain genomic integrity. Image modified from Shkreta & Chabot (2015). 
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Moreover, alternative splicing has been linked with several diseases. A good example is the 
tumour-specific splice events affecting the DMP1/DMTF1 gene which encodes a transcription 
factor that interacts with cyclin D and regulates G1/S transition. The DMP1 gene encodes a 
tumour-suppressor variant DMP1α, and a tumour-promoting variant DMP1β. The ratio 
between both protein forms changes during the transformation of normal cells into malignant 
cells in the context of breast cancer (Tschan et al., 2003). Although more than 20,000 
publications on alternative splicing exist, the functions of most of these splice variants are 
unknown, as most changes caused by alternative splicing are difficult to detect (Kelemen et 
al., 2013).  
 
Regulators of alternative splicing fall into two main categories. The best studied of these 
regulators are the serine arginine protein (SR-protein) and heterogeneous nuclear 
ribonucleoproteins (hnRNPs) families. SR-proteins act by binding to enhancer elements in 
gene cassettes to recruit components of the splicing machinery. hnRNPs, in contrast, are 
RNA-binding proteins that bind silencer elements in gene cassettes to prevent the 
spliceosomal machinery from binding. These enhancers and silencers can be further divided 
into four groups depending on their location and function: exonic splicing enhancer (ESE), 
exonic splicing silencer (ESS), intronic splicing enhancer (ISE) and intronic splicing silencer 
(ISS) (Wang, Cao & Hannenhalli, 2015; Martinez-Contreras et al., 2008; Lin & Fu, 2007). In 
addition, the highly dynamic chromatin structure can influence the rate of transcription and, 
consequently, affect the pattern of transcription. In a study in which heterochromatin was 
induced by transfection with an interfering RNA, a reduction in the transcription elongation 
complex function was seen leading to changes in the alternative splicing pattern (Nilsen & 
Graveley, 2010; Alló et al., 2009). Moreover, DNA methylation has been shown to have a 
role in influencing splicing machinery, as nearly 20% of alternative splicing events occur 
under the regulation of DNA methylation (Yearim et al., 2015).    
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 ATR-CHK1 and ATM-CHK2 pathways in response to DNA damage 
The maintenance of genomic integrity is crucial for all organisms to ensure proper 
development and to protect their cells from tumorigenesis. Cells are constantly exposed to 
endogenous DNA lesions like base deamination or oxidation and DNA breaks that affect their 
genome integrity.  Cells detect these DNA lesions through DNA-damage response pathways 
(DDRs) which are kinase cascades consisting of damage sensors, mediators and executioner 
proteins. The outputs of the DDR pathways include DNA repair, cell cycle arrests, induction 
of cell death and regulation of transcription (Manic et al., 2015; Giglia-Mari, Zotter & 
Vermeulen, 2011; Ciccia & Elledge, 2010) .  
 
The two main DNA damage sensors are the ATM kinase (ataxia telangiectasia mutated 
serine/threonine kinase) and the ATR (ataxia telangiectasia mutated and Rad3-related 
serine/threonine kinase) kinase. While ATM recognises signals induced by DNA double 
strand breaks (DSBs) and signals to CHK2 (checkpoint kinase 2), ATR is activated by single 
stranded DNA (ssDNA) and translates the signal to CHK1 (checkpoint kinase 1).  ATM 
phosphorylates CHK2 at Thr-68, whereas ATR modifies CHK1 at Ser-317 and Ser-345 
(Smith et al., 2010). The structure of ATM kinase has been recently resolved. It shows that 
ATM forms a homodimer in its inactive state which is activated by autophosphorylation at 
Ser-1981 (Wang et al., 2016). 
 
In addition to the CHK1 and CHK2 requirement for the activation of the DDR, both kinases 
play a crucial role in fundamental cellular processes such as DNA replication, chromatin 
structure, neuronal activities and development (Jackson & Bartek, 2009; Bartek & Lukas, 
2003).  
 
Recent work revealed a significant overlap between the ATM-CHK2 and ATR-CHK1 
pathways. A good example of these overlapping roles is the p53, a main cell cycle regulator, 
functioning in DNA repair and apoptosis and also as a major tumour suppressor. Mutations in 
p53 are detected in approximately 50% of all human tumours, strongly reflecting its crucial 
role in defending against cancerous transformation (Hasanzadeh-Nazarabadi et al., 2012). In 
the presence of DNA damage, both ATM and CHK2 phosphorylate p53 at Ser-15 (ATM) and 
Ser-20 (CHK2) leading to its activation as a transcription factor to upregulate the cyclin 
dependent kinase inhibitor p21 thereby arresting the cell cycle in  G1 (Ou et al., 2005; 
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Siliciano et al., 1997). ATR targets four phosphorylation sites in p53 under replication stress 
conditions (Ser-6, Ser-15, Ser-37, Ser-392) (Kulkarni & Das, 2008). CHK1 has also been 
shown to phosphorylate p53 at Ser-15 and Ser-20, the same  sites as for CHK2 kinase, 
inhibiting p53 degradation by MDM2. This stabilizes p53 and allows it to act as transcription 
factor for p21 and a large number of other genes (Figure 1.6) (Ou et al., 2005; Shieh et al., 
2000). The wider impact of these studies are a deeper insight into the molecular causes of 
cancer and the development of personalized medicine (Lu et al., 2014).  
 
 
Figure 1.6 The two main checkpoint signalling pathways in response to genotoxic stress with an 
example of their overlapping functions. ATR kinase is mainly activated by single stranded DNA 
(ssDNA) which targets and phosphorylates CHK1 kinase at Ser-345 leading to its activation. This 
activation requires the 9-1-1 complex which is comprised of three proteins: RAD9, RAD1 and HUS1. 
The 9-1-1 complex facilitates ATR mediated phosphorylation and the activation of CHK1 kinase. In 
contrast, in response to double strand breaks, ATM kinase targets and phosphorylates CHK2 kinase at 
Thr-68. Both kinases, CHK1 and CHK2, have overlapping substrates among which is the tumour 
suppressor p53 which is phosphorylated by the two kinases at multiple sites Ser-15, Thr-18, Ser-20 
and Ser-37. Activated p53 binds to the promoter region of p21 which recruits transcription factors 
leading to the accumulation of p21 protein levels and consequently blocks the cell cycle and allows for 
DNA repair. 
 
1.3.1 The human 9-1-1 complex and paralogs of its component proteins 
Many genotoxic stresses (e.g. UV, IR and replication stress) which result in a junction 
between single-stranded and double-stranded DNA trigger the loading of the 9-1-1 complex 
by RAD17. The 9-1-1 complex plays a role in the initiation of the DNA-damage checkpoint  
which results in a G1/S or G2/M arrest in addition to the onset of DNA-repair and apoptosis. 
The 9-1-1 complex acts as a DNA clamp to provide a stable basis for the assembly of DNA 
damage repair complexes. Significant homology exists with the PCNA sliding clamp, a clamp 
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that binds the DNA replication polymerases (e.g., POL δ) to the replication machinery. The 
PCNA clamp and the 9-1-1 complex are both loaded onto DNA by two clamp loaders: the 
Replication factor C (RFC) loads PCNA, whereas the RAD17-RFC complex loads the 9-1-1 
ring. Both loading complexes share the four small subunits RFC (p36, p37, p38 and p40) 
which interact with a larger subunit (pl40) to form an ATPase. In the 9-1-1 clamp loader, the 
larger subunit (p140) is replaced with the RAD917 protein which interacts with the same 
small subunits (p36, p37, p38 and p40) as the PCNA clamp loader (Figure 1.7) (Parrilla-
Castellar et al., 2004).  
 
The 9-1-1 complex acts in ATR-CHK1 kinase signalling process when single-stranded DNA 
is exposed at stalled DNA replication forks or processed DNA breaks. ATR phosphorylates 
CHK1 at serine-345 in a chromatin complex that contains 9-1-1, Claspin and TOPBP1 (Tuul 
et al, 2013). In addition to its role in checkpoint activation, 9-1-1 also recruits DNA repair 
proteins such as DNA ligase I (LIGl), DNA polymerase β (POL β), the endonucleases FEN1 
and APE1, and the base excision repair (BER) protein hMYH. The 9-1-1 complex stimulates 
the function of POL β and APE1 after a physical interaction, resulting in the efficient 
cleavage of the damaged sites and the promotion of the long patch BER (LP-BER) pathway. 
In addition, translesion DNA polymerase and FEN1 proteins interact with 9-1-1 and the 
PCNA clamp which also stimulates LP-BER. Why both clamps are needed for DNA repair 
remains unclear (Kai, 2013; Balakrishnan et al., 2009). One possibility is that PCNA provides 
a moving platform for these proteins during ongoing DNA replication whereas 9-1-1 is a 
stationary platform at damaged sites. The 9-1-1 complex also enhances the cleavage of 
damaged DNA by directly stimulating the activity of DNA2 and EXO1 nucleases to resect 
DNA. The DNA replication clamp PCNA similarly showed a role in stimulating EXO1 but 
not DNA2 nucleases (Ngo et al., 2014) .  
 
The 9-1-1 complex also plays a role in the homologous repair of DSBs. A knockdown of 
human RAD9 showed strong cell sensitivity to ionizing radiation. However, RAD9-depleted 
cells did not show any effect on CHK2 phosphorylation in the response to DSBs indicating 
that the 9-1-1 complex does not initiate the ATM-CHK2 kinase pathway as it does for the 
ATR-CHK1 pathway (Kai, 2013; Roos-Mattjus et al., 2003).  
 
The 9-1-1 complex also contributes also to mismatch repair (MMR). The mismatch 
recognition dimers MSH2-MSH3 (MUTSβ) and MSH2-MSH6 (MUTSα) interact with the   
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9-1-1 complex. The binding activity of MUTSα to DNA was stimulated by each subunit of 
the 9-1-1 complex. Following treatment in RAD9 knockdown cells with N-methyl-N'-nitro-
N-nitrosoguanidine, a DNA-methylating agent, the MSH6 complex failed to locate to nuclei 
with  abnormal nuclear morphologies. This strongly suports a role of the 9-1-1 ring in these 
MMR pathways (Bai et al., 2010).     
 
In a recent study, the 9-1-1 complex in the C. elegans germline was found to interact with the 
ZTF-8 protein which plays an important role in the DNA repair of both mitotic and meiotic 
DSBs, as well as in the checkpoint activation in meiotic cells. In the presence of DSBs, the 
ZTF-8 protein co-localised to the damaged site where it interacted with the Rad1 subunit of 
the 9-1-1 complex. The ZTF-8 protein may act through the 9-1-1 complex pathway to repair 
stalled replication forks and DSBs (Kim & Colaiácovo, 2014).  
 
While most of the literature focuses on Rad9 as part of the 9-1-1 complex, Rad9 has been 
shown to act outside the 9-1-1 ring. Some insights into Rad9 specific functions came from 
activities not shared by the other two subunits. The S. pombe Rad9 was found to have a role in 
the regulation of apoptosis after DNA damage by its interaction with proteins from the anti-
apoptotic Bcl-2 family (mainly, Bcl-2 and Bcl-xl). However, Rad9 did not interact with pro-
apoptotic proteins such as Bad and Bax. Moreover, over-expression of S. pombe Rad9 protein 
induced apoptosis in human cells suggesting that Rad9 can regulate cell death independently 
of the 9-1-1 complex (Komatsu et al., 2000). Indeed, during the onset of apoptosis in human 
cells, RAD9 is cleaved by caspase 3 and the N-terminal RAD9 section translocates to the 
cytoplasm where it interacts with the anti-apoptotic BCL-2 and BCL-XL proteins (Zhan et al., 
2012; Lee et al., 2003). Another interaction partner of the human RAD9 protein is protein 
kinase C delta (PRKCD), a serine/threonine protein. PRKCD also appears to have contrasting 
roles in DNA damage-induced apoptosis. This protein has been noted to have an anti-
apoptotic role during cytokine receptor-initiated cell death. Following UV irradiation, 
PRKCD initiates the G2/M DNA-damage checkpoint, whereas in the presence of extended 
DNA damage, it plays a role in the activation of p53 leading to cell death. In addition, 
PRKCD localizes to different sub-cellular sites (Golgi, mitochondria, nucleus, endoplasmic 
reticulum) which affects its pro- and anti-apoptotic functions (LaGory, Sitailo & Denning, 
2010; Gomel et al., 2007). PRKCD interacts with and phosphorylates human RAD9 after 
DNA damage. The activation of PRKCD is necessary for the formation of the 9-1-1 complex 
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and for the RAD9-BCL-2 interaction to induce apoptosis. Cells lacking PRKCD showed a 
significant reduction in Rad9-mediated apoptosis (Yoshida et al., 2003).  
 
The Abelson (ABL) protein is a nonreceptor tyrosine kinase (in contrast with PRKCD). ABL 
is responsible for the phosphorylation and activation of proteins involved in cytoskeletal 
dynamics. It also regulates cell adhesion and motility molecules (Yogalingam & Pendergast, 
2008; Sossey-Alaoui, Li & Cowell, 2007; Hu et al., 2005). When severe DNA damage is 
present, ABL activates cell death through interactions with RAD9 resulting in the 
phosphorylation of the N-terminal BH3 domain thereby promoting the interaction between 
RAD9 and BCL-XL. In contrast, this phosphorylation had no impact on the formation of the 
9-1-1 complex. These results suggest that ABL and PRKCD are two crucial proteins that 
target RAD9 outside of the 9-1-1 ring to induce apoptosis via BCL-2/BCL-XL (Yoshida et 
al., 2003).   
 
Another important activity of RAD9 outside of the 9-1-1 ring is the androgen-induced 
activation of genes. Human RAD9 interacts with the androgen receptor through its C-terminal 
tail domain thereby inactivating the transcription complex (Wang et al., 2004).  
 
Little is known about the functions of Rad1 and Hus1 outside the 9-1-1 complex. Both, human 
RAD1 and HUS1 form a 9-1-1 related complex with the RAD9 paralog, RAD9B, as will be 
discussed next. In addition, HUS1B, a paralog of human HUS1, was also reported to interact 
with RAD9 and RAD1 replacing HUS1 in a related 9-1-1 complex (Hang et al., 2002). Recent 
studies have linked HUS1 to 9-1-1 independent functions. HUS1 had a strong correlation with 
the cyclin-dependent kinase inhibitor p21Waf1/CIP1 (p21). Hus1-deficient mouse embryonic-
fibroblast cells failed to proliferate but cells continued to grow when p21 was inactivated 
suggesting a functional relation between Hus1 and p21 (Zhao et al., 2015). The Hus1 role in 
proliferation was also observed in mouse testicular germ cells as the loss of Hus1 resulted in 
meiotic defects (Lyndaker et al., 2013). Moreover, human HUS1 has been found to be linked 
with fragile sites as the protein regulates the abundance of FHIT/FRA3B which binds to 
fragile sites (Pichiorri et al., 2008). 
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Figure 1.7  Similarity between PCNA and 9-1-1 clamps. The p140-RFC clamp loader loads the 
PCNA onto DNA replication sites. This clamp loader consists of four small subunits (p36, p37, p38 
and p40) and one large subunit (p140). The RAD17-RFC clamp loader loads the 9-1-1 complex onto 
DNA damage sites similarly to PCNA. The two clamp loaders are similar, except that RAD17 
replaced the p140 in the 9-1-1 clamp loader. Modified from Parrilla-Castellar et al. (2004). 
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1.3.1.1 RAD9B  
As Given the importance of Rad9 for the activation of the ATR-Chk1 pathway, the gene is 
conserved in most eukaryotic cells and organisms. While single cell organisms like fission 
and budding yeast have only one Rad9 gene, multicellular organisms have two closely related 
genes, Rad9a and Rad9b. Gene duplication is an important mechanism for creating genetic 
novelty and often new functions are acquired through genetic mobility caused by unequal 
crossing over during DNA recombination or retroposition (Magadum et al., 2013). At which 
stage the Rad9 gene underwent gene duplication is not known, but it is likely linked with the 
transition from unicellular to multicellular organisms. In line with gene duplication both 
human RAD9 genes have 10 introns and 11 exons, which encode several protein coding splice 
variants. Three in the case of RAD9A, and five in the case of RAD9B. Rad9 and its role in 
radio-resistance was first discovered in the fission yeast S. pombe (Murray et al., 1991). 
Higher eukaryotic organisms may require more diverse functions of Rad9 which would 
explain the need for gene duplication. For instance, human RAD9 controls gene expression as 
it supresses the androgen receptor in prostate cells and also regulates cell death (Lieberman et 
al., 2011). The human RAD9B gene was identified in 2003 by a cDNA blast search revealing 
a short sequences on chromosome 12 with high similarity to RAD9A (Dufault et al., 2003).  
While RAD9A is found in most organisms, ranging from yeast to humans, RAD9B only exists 
in multicellular organisms (i.e. cow, horse, chimpanzee, mouse, platypus, human, dog, rhesus 
macaque, cat, carolina anole, wild boar, grey short-tailed opossum, red jungle fowl, western 
clawed frog, zebra fish, brown rat) (PANTHER Classification System, 
http://www.pantherdb.org. Accessed 31 January 2016). RAD9A seems to be more closely 
related to the yeast Rad9 protein since its expression partially complements the cell cycle 
checkpoint defects and restores radioresistance when expressed in the S. pombe rad9 mutant 
and mouse ES Rad9 deleted cells (Lieberman, 2006). 
 
 
Human RAD9B has high homology with RAD9A in its N-terminal domain but much poorer 
homology in its C-terminal domain. It should be noted that the N-terminal portion of RAD9A 
is the domain that participates in the PCNA-like clamp complex. Therefore, RAD9B may also 
participate in a PCNA-like complex while providing complementation or different activities. 
Indeed, RAD9B was found to interact with HUS1, RAD1 and RAD17, indicating the 
formation of a 9-1-1-like complex. In addition, RAD9B interacted with the HUS1 paralog 
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Hus1B; however, the role of this interaction is still unclear (Perez-Castro & Freire, 2012 & 
Hopkins et al., 2003). 
 
The predicted molecular mass of the RAD9A protein is around 42 kD. However, on a sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), RAD9A appeared larger 
with a molecular weight of 65 kD due to its rich C-terminal phosphorylation. When treated 
with phosphatase, RAD9A migrated faster and displayed its predicted molecular size. An 
analysis of RAD9B showed also many potential phosphorylation sites in its tail with 26 Ser 
and Thr residues. Unlike RAD9A, over-expressed RAD9B runs as a single band at its 
predicted size (46 kD) without a phosphorylation dependent shift. Treatment with 
phosphatase did not affect the migration of RAD9B, suggesting that RAD9B does not 
undergo extensive phosphorylation like RAD9A (Dufault et al., 2003).   
 
In the latest study on RAD9B in human cells, RAD9B initiated a delay in G1/S transition in 
an ATR and JNK signalling-dependent manner (Perez-CastroFreire, 2012). Cells over-
expressing RAD9B showed a G1 arrest 36 hr post-induction and this arrest was reversible as 
the cell entered G2 between 48 hr and 60 hr after induction. This arrest was specific to 
RAD9B as RAD9A over-expression failed to cause an arrest. The G1 arrest caused by 
RAD9B did not cause any checkpoint activation as no phosphorylation of CHK1, CHK2, p53, 
or p21 was observed. RAD9B was coimmunoprecipitated with RAD1, HUS1, RAD17 and the 
unphosphorylated form of RAD9A. However, unlike RAD9A, RAD9B did not interact with 
TOPBP1 and is therefore unlikely to contribute to the ATR-CHK1 signalling. RAD9B does 
respond to DNA damage since RAD9B localised to the nucleus under normal condition and 
re-localised to the nucleolus in the response to UV light in an ATR-JNK-dependent manner. 
In contrast, RAD9A remained outside the nucleolus after DNA damage (Perez-Castro & 
Freire, 2012). In another study, the cell cycle regulator p21 was reported to bind to 
intranucleolar bodies (INoBs), a structure in disturbed nucleoli (Abella et al., 2010). 
Interestingly, RAD9B and p21 proteins compartmentalised to these INoB structures after 
treatment with Adriamycin; induces reactive oxygen species (ROS), but they did not co-
localise. RAD9B also physically interacted with the p21 protein under normal and stress 
conditions suggesting that RAD9B plays a role in checkpoint signalling or cell cycle arrest or 
DNA repair as p21 acts in all three pathways (Perez-Castro & Freire, 2012). 
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A northern blot analysis displayed the expression of RAD9B in only two tissues: intense 
expression in testis and lower expression in skeletal muscle. In addition, reverse transcription 
PCR (RT-PCR) analysis showed that RAD9B mRNA was expressed in human embryonic 
kidney (HEK293), myelogenous leukaemia (K562), ovarian epithelial carcinoma (OVCAR5) 
and cervical carcinoma (HeLa) cells. In a comparison between original mouse and human  
Rad9b expressed sequence tag (EST) sources, mouse Rad9b was derived from brain, liver and 
mammary gland tissues, whereas human RAD9B had one EST derived from fetal eye and five 
ESTs derived from testis tissue. This suggests that Rad9b is expressed in fewer tissues 
compared to Rad9a (Table 1.1) (Dufault et al., 2003). 
 
 
Table 1.1 Human and mouse Rad9b expression tissues and possible function  
 
 
 
 
 
 
 
 
 
 
 
 
In a study investigating the functional role of Rad9b in mice, Rad9b revealed a different role 
from that observed in human cells. When Rad9b was partially deleted from embryonic stem 
cells (ES), embryos were completely resorbed in week 7.5 (E.7.5) while heterozygous 
embryos can live longer, up to E.12.5 or until a few days after birth. This suggests that Rad9b 
plays a role in the development of the embryo after E.7.5. Rad9b was also expressed in 
embryonic brain cells and the deletion of Rad9b in these tissues resulted in abnormal neural 
tube closure. In addition, the deletion of Rad9b in ES cells revealed a high sensitivity to 
mitomycin C and to gamma radiation compared to normal positive control cells although 
these cells showed a normal G2/M checkpoint and cell cycle arrest. These results suggest that 
Name  Tissue Detection level Function 
Human RAD9B Testis, skeletal 
muscle, fetal eye, 
embryonic kidney 
cells, myelogenous 
leukaemia, ovarian 
epithelial carcinoma, 
cervical carcinoma  
mRNA Unknown, 
(possibly in 
response to DNA 
damage) 
Mouse Rad9b Brain, liver, mammary 
gland, embryonic 
brain 
mRNA Stimulates 
growth and 
embryonic 
development 
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Rad9b plays an important role in embryonic development in addition to having a function in 
DNA-damage resistance (Leloup et al., 2010).   
 
 
1.3.1.2 HUS1B 
Human HUS1B shares 69% similarity to HUS1A and only 48% identity. HUS1B is thought 
to have a similar function to its paralog, HUS1A, as both are expressed in the same human 
tissues, with high expression of HUS1B in testis tissue. HUS1B was found to bind to Rad1, to 
which it is adjacent in the ring-like clamp complex. However, the two-hybrid system showed 
that HUS1B did not bind to RAD9A or HUS1. HUS1B co-immunoprecipitated however with 
both proteins suggesting weak interactions between HUS1B, RAD9 and HUS1 (Hang et al., 
2002).  
 
Interestingly, over-expression of HUS1B in HEK239 cells resulted in a strong increase in cell 
death with only 0.46% of the cells surviving, whereas over-expression of HUS1 showed 
100% survival. These results suggest that HUS1B may have a role in cell death and may 
interact in different ways with RAD9 and RAD1 (Hang et al., 2002). A recent study linked 
the HUS1B function to fetal development and growth. The study focused on the analysis of 
DNA methylation of some genes linked with a low birth weight (LBW) among infants. DNA 
methylation play a crucial role in the control of gene expression, and aberrant methylation is 
responsible for various human diseases (Gapp et al., 2014; Heyn & Esteller, 2012). Analysis 
of the HUS1B gene in some placentas from LBW infants revealed that HUS1B was 
hypomethylated suggesting aberrant expression of the gene. In cell lines derived from 
trophoblastic cells, the HUS1B promotor was highly methylated, and an increase in gene 
expression was observed when the promotor was demethylated. These findings suggest that 
elevated HUS1B expression reduces fetal growth and that the effects of this dysregulation 
contributes to LBW. This is interesting since the function of RAD9B in mice was also linked 
to the growth and development of embryos. Hence, HUS1B may perform a specific role in 
embryos. Whether RAD9B is regulated in a similar manner is yet unclear and any role of 
human RAD9B in early development remains to be explored (Rumbajan et al., 2016).   
 
 
 
 18 
 
1.3.1.3 Rad9-M50 
The Rad9 protein is the conserved subunit of the 9-1-1 complex and found in higher and 
lower eukaryotic cells like fission yeast. Interestingly, fission yeast cells expresses a novel 
Rad9 variant that plays a role in the cellular response to heat stress. Elevated temperatures 
between 37–40°C result in the induction of Rad9-M50 as the mutation of the ATG codon 50 
(M50) inhibited its expression. Thus, Rad9-M50 is an N-terminally truncated Rad9 protein 
which initiates from an internal translational start site at AUG-50 and may not substitute for 
Rad9A in the 9-1-1 complex. The expression of this variant under heat stress is independent 
of the mitogen-activated protein kinase (MAPK) which has a temperature-sensing role 
(Figure 1.8) (Janes et al., 2012).  
 
Expression of Rad9-M50 correlates with the heat-induced dephosphorylation of Chk1 at     
Ser-345 in the presence of DNA damage. Later work by Rabiaa Oun in Caspari’s group 
showed however that Chk1 dephosphorylation and Rad9-M50 inductions are parallel events 
which are not causatively linked (Oun & Caspari, unpublished). However, loss of Rad9-M50 
shortens the heat-induced G2 arrest and regulates the MAP kinase Sty1/Spc1 (Janes et al., 
2012; Oun & Caspari, unpublished). Interestingly, Rad9-M50 resembles the N-terminally 
truncated human RAD9B variants 001 (Appendix 7). 
 
 
Figure 1.8 Heat inducible Rad9-M50. The yeast Rad9-M50 is induced by elevated 
temperatures through the alternative translation of a cryptic initiation codon at methionine-50 
within the Rad9 transcript sequence. 
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1.3.2 CHK1 kinase 
Checkpoint kinase 1 (CHK1) protein plays a major role in the DNA-damage response 
pathway, representing a connection between the master regulators of the cell cycle cyclin-
dependent kinase and cyclins (CDK/cyclins), and the cell cycle major upstream sensors ATM 
and ATR serine/threonine proteins. CDC25A and CDC25C, two members of the CDC25 
family, are a target for the CHK1 checkpoint regulator leading to the inhibition of cell cycle 
transition (Zhao et al., 2002; Mailand et al., 2000; Peng et al., 1997). CHK1 is a ~200 amino 
acid protein containing an N-terminal kinase domain and a C-terminal domain that share 
limited homology across species (Kosoy & O'Connell, 2008). CHK1 protein can respond to 
DNA DSBs but it mainly responds to DNA damage that causes single strand breaks, such as 
in UV light or replication stress, leading to its phosphorylation on the C-terminal residues 
Ser-317 and Ser-345 in an ATM-ATR-dependent manner. At the damage sites, replication 
protein A binds and directs the RAD17 RFC clamp loader complex to load the 9-1-1 complex 
on the 5’ junction of the single stranded DNA. As a consequence of loading the 9-1-1 
complex onto the damaged sites, the ATR activator topoisomerase-binding protein-1 
(TOPBP1) is led to the damaged sites in an interaction among the C-terminus of the Rad9 
protein and two C-terminal BRC1 (BRCT) motifs of the TOPBP1. The TOPBP1 then 
activates the ATR by a direct binding in an ATR interaction protein (ATR-ATRIP)-dependent 
manner leading to the phosphorylation and activation of its downstream checkpoint effector 
kinase, CHK1 (Figure 1.9) (Cimprich & Cortez, 2008; Jazayeri et al., 2006).  
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Figure 1.9 CHK1 activation in response to single stranded DNA (ssDNA). In response to 
single stranded DNA, the 9-1-1 complex is loaded onto the damaged sites by the clamp 
loader Rad17-RFC. The loading of the checkpoint clamp recruits the TOPBP1, which 
interacts with the clamp subunit RAD9 tail. The TOPBP1 then binds and activates the ATR 
protein in an ATRIP-ATR-dependent manner leading to the activation of CHK1 by ATR by 
direct phosphorylation at Ser-317 and Ser-345.   
 
 
Human CHK1 has one alternative isoform: isoform 2. The CHK1 main isoform displayed a 
molecular weight of 56 kD on an SDS-PAGE gel whereas the smaller isoform 2 migrated 
faster revealing a size of 43 kD. CHK1 isoform 2 is an N-terminal truncated protein, termed 
CHK1 short (CHK1-S), containing 282 amino acids. CHK1-S was expressed at the mRNA 
level in multiple human tissues with high expression in fetal tissues. An immunoblot also 
detected CHK1-S in these fetal tissues. CHK1-S is an endogenous repressor of isoform 1, as 
isoform 2 interacts with and antagonizes isoform 1 at the N-terminal in a CHK1-dependent 
manner to block its kinase activity where they dissociate in response to DDRs. The interaction 
between the two isoforms is disrupted by ATR phosphorylation, which fits well with the 
activation of CHK1 isoform 1 partners by ATR. ATR is, therefore, able to disinhibit isoform 
1 and allow the cell to enter into arrest when sufficient DNA damage is present (Pabla, Bhatt 
& Dong, 2012).  
 
CHK1-S is also found in higher-than-normal levels in various cancers, suggesting that CHK1-
S may accelerate the cell cycle and enhance the proliferation of the cells under these 
conditions. However, the overexpression of CHK1-S in the cancer cell lines resulted in early 
mitotic entry and the reduction of cellular proliferation, suggesting that CHK1-S plays a role 
in cellular proliferation (Pabla, Bhatt & Dong, 2012).  
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1.3.3 CHK2 kinase 
DNA damage upregulates the checkpoint protein kinase 2 (CHK2), which itself plays a role in 
regulating cell cycle arrest, DNA repair, and apoptosis. The structure of CHK2 contains a 
SQ/TQ cluster domain (SCD) at the N-terminus composed of serine-glutamine and threonine-
glutamine repeats. The SCD region is a phosphorylation target for the ATM protein after 
DNA damage. The SCD N-terminal region is followed by a forkhead-associated (FHA) 
domain and a carboxyl-terminal kinase catalytic domain. The CHK2 FHA domain serves as a 
binding region for CHK2-phosphorylated substrates, including other CHK2 SCD-
phosphorylated molecules (Buscemi et al., 2006; Li et al., 2002; Ahn et al., 2000). 
    
In a different role than CHK1, CHK2 mainly responds to DSBs and arrests the cell cycle at 
G1/S or G2/M through various mechanisms. An inactive form of CHK2 is mainly present in 
the nucleus during cell growth. After DNA damage, CHK2 is phosphorylated by the ATM 
protein on the Thr-68 phosphorylation site in addition to other sites within the SCD. The 
activation of CHK2 causes to its dimerization through the binding of the FHA domain of one 
monomer with the SCD domain of another, leading to CHK2 autophosphorylation on its 
kinase domain, followed by dissociation of the dimers into fully active monomers (Figure 
1.10) (Zannini, Delia & Buscemi, 2014; Ahn et al., 2002; Xu, Tsvetkov & Stern, 2002).  
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Figure 1.10 CHK2 activation and inactivation. In response to double stranded breaks (DSBs), the 
ATM protein phosphorylates and activates CHK2 at the rich SQ/TQ regions. The active CHK2 
monomers associate with each other, leading to autophosphorylation at the kinase domain. The 
interacted monomers then successfully dissociate into single active monomers. CHK2 can be 
inactivated by being degraded or dephosphorylated or by inactivating phosphorylation. Modified from 
Zannini, Delia & Buscemi’s study (2014). 
 
 
Compared to members of the 9-1-1 complex and CHK1, a striking number of isoforms for 
CHK2 exist. The tumour suppressor CHK2 protein was revealed to have around 90 splice 
variants in breast cancer tissue. These splice variants were expressed in parallel with the main 
CHK2 transcript. In addition, normal tissues also expressed these various splice variants: 
however, the number was much less compared to breast cancer tissue. The majority of the 
CHK2 splice variants detected in breast cancer tissues were of four specific splice variants 
(Figure 1.11). These four CHK2 splice variants were selected and further analysed for their 
functional roles. The cellular localisation of the wild type (WT) CHK2 is linked to its 
biological function in the nucleus. When the four splice variants were integrated and 
overexpressed, they revealed a similar localisation to WT Chk2 in HCT116 and MCF-7 breast 
cancer cell lines. Two of these splice variants were enzymatically active while the other two 
were enzymatically inactive; however, all four splice variants had a significant impact on the 
WT CHK2 kinase activity through heterodimersation when there were overexpressed. Taken 
together, the functions of these isoforms are not clear; however, they do have a suppression 
role on WT CHK2 activity (Berge et al., 2010; Staalesen et al., 2004).   
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Figure 1.11 WT CHK2 and its splice variants. (A) CHK2 main structure representing the three 
domains (SCD, FHA and kinase domains). (B) Overview of CHK2 14 exons on the mature transcript 
and its four splice variants with the missing regions shown in gaps. Modified from Berge et al. (2010).    
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1.3.3.1 The p21Waf1 cyclin dependent kinase inhibitor, a major component of 
the ATM-CHK2-p53-p21 pathway        
In the response to many stimuli, p21 promotes cell cycle arrest by directly interacting and 
inactivating the cyclin dependant kinases such as CDK1 and CDK2. The p21 protein can act 
as a sensor or as an effector of multiple anti-proliferative signals. Upon DNA damage, the 
ATM-CHK2 DDR pathway phosphorylates p53 at Ser-15 and Ser-20 which stabilizes the 
transcription factor resulting in the up-regulation of p21 and a G1 cell cycle arrest (Zannini, 
Delia & Buscemi, 2014; Bunz et al., 1998). The p21 protein also acts as an effector of 
multiple tumour suppressor pathways independently of p53 (Abbas & Dutta, 2009). 
 
While the N-terminal domain of p21 serves as a binding site for its specific interaction with 
CDKs, its C-terminal domain associates with the co-factor of DNA polymerases, the PCNA 
ring complex, which is essential for DNA synthesis. This disrupts the PCNA interaction with 
the polymerases and stops DNA replication (Figure 1.12) (Abbas & Dutta, 2009; Soria et al., 
2008; Moldovan, Pfander & Jentsch, 2007). 
 
While the up-regulation of p21 by the p53 transcription factor is a specific and crucial cellular 
response to genotoxic stress which causes DNA breaks like gamma radiation, many studies 
have shown that a similar increase in p21 levels does not happen when DNA replication forks 
stall (Soria & Gottifredi, 2010). Treatment of cells with DNA replication stress agents such as 
HU, UV and MMS do not trigger an increase in the p21 expression levels. On the contrary,  
levels of p21 are down-regulated at both the mRNA and the protein level. The drop in p21 
protein is initiated by the attachment of ubiquitin by the E3-ligase CRL4CDT2 complex leading 
to p21 proteolysis. This disrupts the p21-PCNA complex and allows PCNA to be mono-
ubiquitinylated to initiate translesion DNA synthesis to bypass bulky nucleotides after UV 
irradiation or chemical treatment with MMS. During translesion synthesis the two standard 
DNA polymerases epsilon (leading strand) and delta (lagging strand) are replaced by special 
polymerases from the Y family on the PCNA complex (Zhao & Washington, 2017). Since the 
TLS process is not expected to occur outside of S phase, it is really interesting that PCNA and 
POL η from the Y family polymerases also form nuclear foci outside of the S phase in the 
response to UV irradiation. This indicates the existence of unknown functions of the Y family 
polymerases outside of the S phase (Soria & Gottifredi, 2010). 
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Depending on its expression levels, p21 has different impacts on the cell cycle and DNA 
replication. Very high levels of p21 impair PCNA-driven DNA replication, whereas basal 
expression of p21 during S phase selectively block the interaction of the PCNA ring with the 
TLS DNA polymerases without altering the loading and activity of the replicative polymerase 
δ (Figure 1.12-B). Therefore, p21 degradation is a crucial step for the success of TLS 
indicating that p21 plays a critical role in the control of the TLS polymerases under normal 
conditions preventing mutagenesis due to the poor proofreading activity of the TLS 
polymerases (Soria & Gottifredi, 2010; Abbas et al., 2008; Mattia et al., 2007). 
 
In addition to its  main activities related to the CDKs and the PCNA complex, p21 has other 
functions. p21 has been found to have both a positive and a negative impact on the expression 
of certain genes. For example, p21 has a positive impact on the induction of genes that 
regulate cellular senescence, and a negative impact on the transcription factor E2F1 which is 
important in G1-S transition. Moreover, p21 supresses the transcription of apoptotic genes in 
the response to DNA damage (Figure 1.12-C) (Kumari et al., 2015; Abbas & Dutta, 2009;  
Chang et al., 2000; Delavaine La & Thangue, 1999). In addition, p21 phosphorylation at Thr-
145 by AKT Kinase  results in its cytoplasmic localisation where it directly binds and inhibits 
the activity of pro-apoptotic proteins such as procaspase 3, caspase 8 and caspase 10 (Figure 
1.11-D) (Roninson, 2002; Dotto, 2000). Contrary, p21 is believed to promote apoptosis and 
many other cellular functions through the large group of p21 activated kinases (PAK). 
Especially PAK2 is able to phosphorylate caspases after being activated by p21 binding 
(Suzuki et al., 2013). This may explain why the deletion of p21 in mice fibroblast cells results 
in a significant reduction in apoptosis after treatment with multiple stimuli (Abbas & Dutta, 
2009). 
 
In malignant tissues, p21 is expressed at different levels depending on the type of cancer. 
Very low expression of p21 correlates with a poor prognosis in colorectal, small-cell lung, 
head and neck cancers because the low expression of p21 correlates with the absence of p53. 
A possible role of p21 as an oncogene was reported after the detection of elevated levels of 
p21 which correlated with aggressive growth of cervical, breast, prostate and ovarian cancers. 
A number of studies reported genetic variants in the p21 gene that can increase cancer 
development in individuals. Polymorphisms in p21 were reported to be linked with the 
increased risk of oesophageal, head and neck cancers. These polymorphisms in p21 are 
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believed to influence the expression of p21 leading to a reduction of p21 protein levels in 
these cancers (Piccolo & Crispi, 2012; Wang et al., 2012; Yang et al., 2010).  
 
 
 
 
Figure 1.12 The different cytoplasmic and nuclear functions of the p21 protein. (A) p21 promotes 
cell progression through G1 by enhancing the kinase activity of cyclin dependent kinase 4 (CDK4) or 
CDK6 in a complex with cyclin D. During the G1 phase, p21 can block the kinase activity of CDK2-
cyclin E or CDK2-cyclin A, an essential complex activity required for the progression into the S 
phase, thus causing G1/S arrest. p21 also inhibits the kinase activity of CDK1-cyclin A, required for 
cell progression through G2. Moreover, p21 inhibits the progression through G2 and G/M by 
inhibiting the kinase activity of CDK1-cyclin B1. (B) p21 interacts with the proliferative cell nuclear 
antigen (PCNA) through its C-terminal and inhibits DNA replication, allowing the cell to switch to 
PCNA-dependent DNA translesion synthesis. (C) p21 oncogenic activity acting as an anti-apoptotic 
through a direct binding and inhibition of the transcriptional activity of the transcription factor E2F1, 
whose transactivation activity is required for the transcription of apoptotic pathway genes. (D) The 
cytoplasmic p21 phosphorylation by AKT1 kinase prevents its translocation to the nucleus thus 
blocking its interaction with PCNA. The cytoplasmic p21 also shows an anti-apoptotic role by directly 
binding and inhibiting the activity of the pro-apoptotic proteins such as procaspase3, caspase 8 and 
caspase 10. Modified from Abbas & Dutta (2009). 
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1.3.3.2 The mitotic regulator monopolar spindle 1 (MPS1) and its relation 
to the CHK2 kinase                                                                                             
The kinase monopolar spindle 1 (MPS1) regulates centrosome duplication, chromosome 
segregation and the mitotic checkpoint. Centrosomes are microtubule organising centres 
consisting of two centrioles which are surrounded by pericentriolar material, a mass of protein 
responsible for the microtubule nucleation. G1 cells possess one centrosome which divides in 
S phase and moves to opposite poles in the cell in G2 to regulate the mitotic spindle in M 
phase (Figure 1.13). Because centrosomes regulate the mitotic spindle any misregulation or 
extra copies of centrosomes leads to abnormal chromosome segregation, a hallmark of cancer 
cells (Kasbek, Yang & Fisk, 2009; Fukasawa, 2007). 
 
The activity of MPS1 kinase peaks at the G1-S transition initiating centrosome duplication in 
human cells. This was shown in HeLa cells where depletion of MPS1 is sufficient to prevent 
centrosome duplication. The oscillation of MPS1 kinase levels throughout the cell cycle are 
controlled by the E3 ligases APC-Cdc20 and APC-Cdh1 during mitosis and G1, respectively. 
The levels of MPS1 peak in mitosis before they gradually drop again when cells enter G1 
(Cui et al., 2010; Kasbek et al., 2007). The prevention of MPS1 degradation or MPS1 over-
expression can lead to centrosome re-duplication, a phenotype frequently observed in a 
number of human tumours, such as prostate and breast cancer. It also leads to chromosome 
segregation errors during mitosis and aneuploidy (Pihan et al., 2003; Lingle & Salisbury, 
1999).  
 
The mammalian spindle assembly checkpoint (SAC) consists of multiple proteins that sense 
the absence of an attached spindle at the kinetochore of the condensed chromosomes thereby 
delaying chromosome segregation and mitotic progression. This checkpoint is crucial  to 
ensure the equal segregation of sister chromatids to maintain genomic stability (Yeh et al., 
2014). Failure in the mitotic checkpoint results in chromosomal imbalance (aneuploidy) and 
causes chromosomal instability (von Schubert et al., 2015; Thompson, Bakhoum & Compton, 
2010). This checkpoint is dependent on MPS1 kinase as the protein accumulates at the 
unattached kinetochores following its activation by polo-like kinase 1 (PLK1), a key regulator 
of mitotic entry, chromosome segregation and mitotic exit. Activated MPS1 leads to the 
activation and recruitment of the mitotic checkpoint components to kinetochores like KNL-1, 
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MAD1:C-MAD2 and BUB3:BUBR1 resulting in the activation of the spindle checkpoint and 
subsequent mitotic delay (Von Schubert et al., 2015; Liu, Davydenko & Lampson, 2012). 
 
Recent studies revealed a close link between MPS1 and CHK2 kinase. CHK2 localises to 
centrosomes early in mitosis and to the midbody in late mitosis. A number of studies have 
now shown that PLK1 kinase targets and phosphorylates CHK2 at Thr-68 (Tsvetkov et al., 
2003). In the presence of DNA damage, MPS1 phosphorylates CHK2 also at Thr-68 and 
activated CHK2 binds to and phosphorylates MPS1 on Thr-288. This suggests a feedback 
loop between the two kinases which may be regulated by PLK1. CHK2 is also required for 
the attachment of MPS1 to the kinetochores at the condensed chromosomes (Yeh et al., 2014; 
Yeh et al., 2009; Tsvetkov et al., 2003).  
 
 
 
 
 
Figure 1.13 The centrosome duplication cycle. First, in the mitotic exit and the early G1 phase, the 
centrosome contains two centrioles associated by interconnecting fibres enclosed by the pericentrioles 
matrix (PCM; orange), which is essential for the nucleation and growth of the microtubules (Spindle 
fibres). Second, in the late G1/S, the centrioles start duplicating with the nucleation of daughter 
centrioles. During the late G2 phase, the procentrioles elongate and increase in size forming mature 
centrosomes and their PCM expands. Finally, at the G2/M transition, the centrosomes mature and 
separate orthogonally, oriented opposite each other and localised at opposite sides of the cell. The 
centrosomes then organise mitotic poles where they attach to the kinetochores of sister chromatids and 
evenly segregate into two cells. The mother and daughter centrioles disengage and the centrosomes 
duplication cycle is repeated again. Modified from Bettencourt-Dias & Glover (2007). 
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 Cross talk between the DNA damage detection system and the mitotic 
regulators 
It is increasingly apparent that the DDR communicates closely with the mitotic regulators. For 
instance, two main regulators of the mitotic phase, PLK1 and PLK3, are both regulated by 
DNA damage, and both are reported to interact with CHK2 kinase. In the response to ionising 
radiation, PLK3 interacts with and phosphorylates CHK2 kinase at Ser-62 and Ser-73, and 
this phosphorylation facilitates the subsequent phosphorylation of CHK2 on Thr-68 by ATM 
kinase leading to full checkpoint activation and cell cycle arrest (Bahassi et al., 2006; 
Tsvetkov et al., 2003). 
 
The main regulators of the DDR, ATM, ATR, CHK1, CHK2 and p53, have all been reported  
to localise to the centrosome (Golan et al., 2010; van Vugt et al., 2010; Krämer et al., 2004; 
Tsvetkov et al., 2003). Mitosis is distinct from the remaining cell cycle phases as the DDR is 
inactivated during this stage (van Vugt et al., 2010). The question here is how mitotic cells 
manage to prevent the activation of the DNA damage response to allow cells to progress 
through mitosis. A good example of this relationship is 53BP1 which is a main regulator of 
the DDR and forms foci at DNA breaks together with γ-H2AX. During mitosis, and in the 
response to ionising radiation, mitotic kinases (CDK1 and PLK1) target and phosphorylate 
53BP1 prevents 53BP1 from localising to the DNA lesions. PLK1 also phosphorylates CHK2 
which inactivates the ATM-CHK2 signalling pathway. The involvement of mitotic kinases in 
silencing the DDR may explain their over-expression in many cancers (van Vugt et al., 2010; 
Sur et al., 2009; Gautschi et al., 2008; Strebhardt & Ullrich, 2006). 
 
 
 Aims of the project  
Human cells contain two RAD9 genes, RAD9A and RAD9B, which both encode highly related 
subunits of the RAD9-RAD1-HUS1 ring complex. The 9-1-1 ring is loaded at sites of DNA 
damage to aid DNA repair and to arrest cell cycle progression.  Depletion of Rad9a in mice 
leads to skin cancer and human RAD9A promotes prostate cancer. While RAD9A is 
intensively, studied, very little is known about its paralog RAD9B. RAD9B assembles in the 
9-1-1 ring and co-localises with the cell cycle regulator p21Waf1 in the nucleolus after UV-
induced DNA lesions. The human RAD9B gene encodes five protein splice variants of which 
one, RAD9B-001, resembles the N-terminally truncated Rad9 variant, Rad9-M50, found in   
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S. pombe cells. Rad9-M50 expression is induced by heat-stress and some forms of DNA 
damage from a cryptic translational start site within the rad9 mRNA (Janes et al., 2012). 
While full-length Rad9 forms the 9-1-1 ring, Rad9-M50 regulates cell cycle progression at 
elevated temperatures in yeast.  
 
To investigate the cellular roles of full-length RAD9B and its variant RAD9B-001, and to 
find out whether the yeast Rad9-M50 protein also functions in human cells, three stable 
HEK293 cell lines will be constructed in this project.  
 
Induction with doxycycline will allow for the over-expression of the three Rad9 proteins. This 
system will be used to analyse the impact of elevated Rad9 protein levels on cell cycle 
progression, the response to heat and other environmental stresses, and to different types of 
DNA damage. The work will focus on the ATR-CHK1 and ATM-CHK2 kinase pathways. 
While ATR-CHK1 signalling is activated by single-stranded DNA, for example, at stalled 
DNA replication forks, ATM-Chk2 activity is stimulated by unprocessed DNA double-strand 
breaks. 
 
These biochemical studies will be complemented by the analysis of the expression profiles of 
all five RAD9B splice variants at mRNA level in a panel of different human tissues. The 
outcomes of this project may help to understand the complex network of splice variants in 
healthy and malignant cells, and may provide an answer of why human cells express two 
close related RAD9 genes. 
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Chapter 2: MATERIALS AND METHODS   
 
 Human cell lines 
Table 2.1 Human cell lines used in this project 
Cell Line Name Genotype Source 
HeLa (human cervix epithelioid carcinoma 
cells) 
- Purchased from the 
Health Protection 
Agency (HPA) 
culture collection, 
cat.no 93021013 
Kelly (human neuroblastoma cells) - Purchased from 
Sigma, cat.no. 
9110411 
Flp-In TREx HEK 293 
(human embryonic kidney cells) 
FRT integration 
site 
A kind gift from Dr. 
Fumiko Isahsi, 
Oxford University 
Flp-In TREx HEK 293-EGFP-RAD9B-001 FRT::EGFP-
RAD9B-001 
In current project 
Flp-In TREx HEK 293-EGFP-RAD9B-002 FRT::EGFP-
RAD9B-002 
In current project 
Flp-In TREx HEK 293-EGFP-Rad9-M50 FRT::EGFP-
Rad9-M50 
In current project 
Flp-In TREx HEK 293-EGFP FRT::EGFP In current project 
 
 
 
 Plasmids   
Table 2.2 Plasmids used in this project 
Plasmid Source 
pcDNA5/FRT/To-EGFP Kind gift from Dr. Fumiko Isahsi, Oxford 
University 
pOG44 Kind gift from Dr. Fumiko Isahsi, Oxford 
University 
phRAD9B-002 (MHS1010-202804714) Thermo Fisher Scientific 
pRFP-C-RS-shRNA-RAD9A (HT129859A) OriGene 
pRFP-C-RS-shRNA-RAD9A (HT129859B) OriGene 
pRFP-C-RS-shRNA-RAD9A (HT129859C) OriGene 
pRFP-C-RS-shRNA-RAD9A (HT129859D) OriGene 
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 Cell Line Growth and Maintenance  
 All cell lines in this project were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 1% penicillin-streptomycin antibiotics, 
and with or without 200 mM L-glutamine solution in a humidified 37°C incubator. The 
medium was also supplemented with selective antibiotics depending on the growing cell line  
(Table 2.3). When the cells reached 80–90% confluency, they were passaged, as described in 
Section 2.3.3. 
 
Table 2.3 Cell line growing media and conditions 
Cell Line Name CO2 Media Selective Antibiotic 
Flp-In TrEx HEK293 
(human embryonic 
kidney cells) 
5% DMEM, 10% FBS, 1% 
penicillin-streptomycin, 
200 mM L-glutamine 
100 µg/ml zeocin, 15 µg/ml 
blasticidin 
HeLa (human cervix 
epithelioid 
carcinoma cells) 
5% DMEM, 10% FBS, 1% 
penicillin-streptomycin 
 
- 
Kelly (human 
neuroblastoma cells) 
5% DMEM, 10% FBS, 1% 
penicillin-streptomycin, 
200 mM L-glutamine 
 
- 
 
 
2.3.1 Sources of cell line growth materials 
Table 2.4 Sources of essential growth medium, reagents and antibiotics 
Material Source Cat. No 
DMEM Lonza BE12-614F 
FBS Sigma F0804 
Penicillin-streptomycin Lonza DE17-602E 
L-Glutamine Lonza 17-605C 
Zeocin Thermo Fisher Scientific R25001 
Blasticidin Thermo Fisher Scientific R21001 
Doxycycline  Sigma 9891-5G 
PBS Lonza BE02-017F 
Trypsin Lonza CC-5012 
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2.3.2 Cell thawing 
The vials of cells were removed from the liquid nitrogen container and placed immediately in 
a 37°C water bath until the last ice crystal was visible. Then the outside of the vials were 
decontaminated using 70% industrial methylated spirits and the cells were transferred to 10-
cm plates containing 9 ml of DMEM free of antibiotics. The cells were allowed to attach and 
spread overnight in the 37°C incubator. The following day, the medium was aspirated off and 
replaced with fresh complete medium containing blasticidin and zeocin. Then the cells were 
incubated at 37°C and checked daily until the cells reached 80–90% confluency. The cells 
were then passaged as described next. 
 
2.3.3 Cell passaging 
The medium was removed from the plates when the cells were approximately 80–90% 
confluent. The cells were washed with 5 ml of 1x phosphate-buffered saline (PBS) to remove 
any medium or FBS residue (FBS inhibits trypsin). The PBS was removed and 1 ml of 
trypsin-ethylenediaminetetraacetic (trypsin-EDTA) was added directly to the cells and then 
the plates were placed in the incubator at 37°C for 5 min. After incubation, the plates were 
banged briefly to dislodge the remaining attached cells. The cells were then mixed by 
pipetting up and down to break up any clumps. The trypsinisation was inhibited by adding     
9 ml of complete DMEM to the plates. Then 1 ml of the cell suspensions was transferred to 
new 10-cm plates containing 9 ml of complete DMED supplemented with blasticidin and 
zeocin (the dilution can be lowered if faster confluence is required). The plates were placed in 
a 37°C, humidified, CO2 incubator until the cells reach 80–90% confluency at which point 
they were split again.   
 
2.3.4 Cell freezing  
Before starting, fresh freezing medium was prepared and then kept on ice (Table 2.5). 
Table 2.5 Preparation of freezing medium 
DMEM complete medium 0.9 ml 
DMSO (dimethyl sulfoxide)  0.1 ml 
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The medium was removed from the plate once the cells reached approximately 80% 
confluency, and the cells were washed with 5 ml of 1x PBS. Trypsin (1 ml) was added 
directly to the cells and the plates were placed in a 37°C incubator for 5 min until the cells 
became unattached. Then the cells were pipetted up and down to break up any clumps. The 
trypsinisation was stopped by adding 9 ml of complete DMEM and the cells were counted       
(Section 2.3.5). All the cells were transferred to 15-ml tubes to be centrifuged for 5 min at 
1,500 rpm at room temperature. A clear visible pellet was obtained, and the medium was 
aspirated off carefully. A density of 3 x 106 of cells was suspended in 1 ml of cold freezing 
medium (Table 2.5). The cell suspensions in freezing medium were transferred into labelled 
cryovials. All the cryovials were placed in the Mr. Frosty Freezing container and placed in the 
-80°C freezer overnight. The following day all cryovials were transferred to liquid nitrogen 
containers for long-term storage.  
 
2.3.5 Cell counting 
The medium was aspirated from the plates and the cells were washed with 1x PBS. The cells 
then were trypsinised and collected in 15-ml tubes, followed by centrifugation at 1,500 rpm 
for 5 min. The pellets were resuspended in 1 ml of 1x PBS, and 10 µl of the cell suspensions 
was mixed with 10 µl of 0.4% Trypan Blue solution (Sigma) by pipetting up and down. The 
mixtures were left for 2–3 min at room temperature. Then 10 µl of the mixtures was inserted 
into the outer opening of the counting slide chamber. The cell number count was obtained 
using the Bio-Rad TC20 Automated Cell Counter. 
 
 RNA Extraction  
2.4.1 TRIzol RNA extraction 
The cells were grown in their appropriate medium and at least 1 x 106 of cells were harvested. 
The medium was aspirated from the plate and the cells were washed twice with 1x PBS. 1 ml 
of TRIzol (Thermo Fisher Scientific) was added directly to the cells and then cells were 
removed gently from the plate using a cell scraper. The whole lysate was transferred to a 1.5 
ml Eppendorf tube and the tube was left at room temperature for 5 min. Chloroform (250 µl) 
was added to the cell lysate and the tube was shaken vigorously for 15 s. The sample was 
allowed to sit at room temperature for 5 min, followed by centrifugation at 10,000 rpm for 5 
min.  
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At this stage, three layers were obtained: clear aqueous (top layer), precipitated DNA (middle 
layer) and pink organic (bottom layer). The aqueous layer was carefully removed and placed 
in a new Eppendorf tube (approximately 1 mm of the aqueous layer was left to avoid DNA 
contamination). Isopropanol (550 ml) was added to the aqueous layer with gentle mixing and 
the tube was left at room temperature for 5 min. Then the sample was centrifuged at 4°C at 
full speed for 30 min. After centrifugation, the tube was placed on ice and the isopropanol 
was removed. The pellet was dissolved in 1 ml of 70% ethanol (ETOH) and 0.1% 
diethylpyrocarbonate (DEPC)-treated H2O, followed by centrifugation at 9,000 rpm for 5 min. 
All the ETOH was removed from the tube and the pellet was allowed to air dry. The pellet 
then was resuspended in 30 µl of DEPC-treated H2O. The concentration of the sample was 
measured using the NanoDrop ND-1000 (Thermo Fisher Scientific), and the RNA was stored 
at -80 °C until further use. 
 
2.4.2 Column purification RNA extraction  
Total RNA was isolated from the human cell lines using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. The RNA concentration and quality were 
obtained using the NanoDrop ND-1000. The RNA samples were stored at -80 °C until the day 
of use. 
 
 
 DNA extraction  
DNA was extracted from at least 1 x 106 cells using the GenElute Mammalian Genomic DNA 
Miniprep (Sigma) according to the manufacturer’s instructions. The extracted DNA 
concentration and quality were obtained using the NanoDrop ND-1000. 
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 Polymerase Chain Reaction  
2.6.1 Primers for expression detection 
Table 2.6 Primers designed for the expression detection of RAD9B splice variants, RAD9A, 
C12ORF32 and ACTB 
Primer Name / 
detected variant 
Primer Sequence *Ta Amplicon size 
 
(L-001) 
RAD9B-001 
 
Forward  
AAAGCCGTTTGGGAACTTGTGGA 
Reverse 
**ctacgatggaatctcgagTTAGAATATAGAGAAACTGC
CAT 
 
50°C 
 
1363 bp 
 
(L-001-002-005) 
RAD9B-001, 002, 
005 
 
Forward 
*atccgttacattatgcggccgcATGAGTGAAAATGAACTTG
ACAC  
Reverse 
**ctacgatggaatctcgagTTAGAATATAGAGAAACTGC
CAT 
 
50°C 
 
1038 bp 
 
(L-002-005) 
RAD9B-002, 005 
 
Forward 
*atccttacaatgcggccgcATGGCAGCCATGCTGAAGTG 
Reverse 
**atagttacgttctcgagTTAGAATATAGAGAAACTGCCA 
 
52°C 
 
1254 bp 
 
(L-003-009) 
RAD9B-003, 009 
 
Forward 
*atccttacaatgcggccgcATGGCAGCCATGCTGAAGTG 
Reverse 
**atagttacgttctcgagTTAGAATATAGAGAAACTGCCA 
 
52°C 
 
003 (1290 bp) 
009 (974 bp) 
 
(S-001) 
RAD9B-001 
Forward  
AAAGCCGTTTGGGAACTTGTG 
Reverse 
CGTGATAGAGCTTGAACTGC 
 
50°C 
 
215 bp 
 
(S-001-002-005) 
RAD9B-001, 002, 
005 
Forward 
GTCAGCAACACAGAGGAAGTG 
Reverse 
TGCTTAATGATGGCTGAGCTGG 
 
50 °C 
 
196 bp 
 
(S-003-009) 
RAD9B-003, 009 
Forward 
GTCAGCAACACAGAGGAAGTG 
Reverse 
CATAGAACAGTATCCTCCACTG 
 
50 °C 
 
003 (233 bp) 
009 (123 bp) 
 
RAD9A 
Forward 
TCGCGGAGAGCTGGGCAG 
Reverse 
TCGCGGAGAGCTGGGCAG 
 
52°C 
 
196 bp 
 
C12ORF32 
Forward 
ATGCCTCCCAGAAAAAAACGCCGCC 
Reverse 
TCAGCTTTTCACAAGGAATTGGCTTC 
 
55°C 
 
717 bp 
 
ACTB 
Forward 
ACCAACTGGGACGACATGGAG 
Reverse 
TGCCAGTGGTACGGCCAGAG 
 
52°C 
 
223 bp 
Ta: annealing temperature. S: short fragment. L: long fragment.  
* indicates additional sequence contains Not1 recognition site designed in forward primer.   
** indicates additional sequence contains Xho1 recognition site designed in reverse primer. 
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2.6.2 Two-step RT-PCR  
2.6.2.1 cDNA synthesis 
Total RNA was extracted from the cell lines using the RNeasy Plus Mini Kit, as mentioned in 
Section 2.4.2, or purchased from Clontech Laboratories (Human Total RNA Master Panel II). 
The quality and concentration of the RNA were obtained using the NanoDrop ND-1000. Then 
1–2 µg of total RNA was converted to cDNA with the Tetro cDNA Synthesis Kit (Bioline) 
according to the manufacturer’s instructions. Random and hexamer primers were used for the 
cDNA synthesis.  
 
2.6.2.2 PCR reaction mixture and running program 
The cDNA was used as a template for the amplification of the desired gene with BioMix Red 
(Bioline) as seen in Table 2.7. 
 
Table 2.7 Two-step RT-PCR reaction mix 
BioMix Red 25 µl 
Forward primer 250 nM 
Reverse primer 250 nM 
cDNA                                5 µl 
DEPC-treated water Up to 50 µl 
 
The PCR reaction mixture was run using the standard PCR program seen in Table 2.8. 
 
 
Table 2.8 Standard PCR program 
Hot start 98°C 2 min 
Denaturing 98°C 10 s 
Annealing Depends on primer pair 10 s 
Extension 72°C 1 min/1 Kb  
Final Extension 72°C           10 min 
Number of cycles 35 - 
     
The amplified PCR products were run on agarose gels as described in Section 2.7. 
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2.6.3 One-step RT-PCR 
Total RNA samples extracted in the lab or the purchased from Clontech Laboratories (Human 
Total RNA Master Panel II) were used as a template in the one-step RT-PCR reaction using 
the MyTag One-Step RT-PCR Kit, (Bioline) using a concentration of 200 ng of total RNA per 
PCR. Specific primers for each gene and their expected size can be seen in (Table 2.6). The 
one-step RT-PCR reaction was set up as following: 
 
Table 2.9 One-step RT-PCR reaction mix 
MyTag One-Step mix (2x) 25 µl 
Forward primer 250 nM 
Reverse primer 250 nM 
Total RNA 200 ng 
Reverse transcriptase 0.5 µl 
RiboSafe RNase Inhibitor 10 U/µl 1 µl 
DEPC-treated water Up to 50 µl 
 
The one-step RT-PCR reaction mixture was run using the PCR program shown in Table 2.10. 
 
Table 2.10 One-step RT-PCR program 
Stage Temperature Time           Cycles 
Reverse transcription 45°C 30 min 1 
Polymerase 
activation 
95°C 1 min 1 
Denaturing 
Annealing 
Extension 
95°C 
55°C 
72°C 
10 s 
10 s 
30 s 
 
 
40 
Final Extension 72°C 10 min 1 
 
The amplified PCR products were analysed on agarose gels as mentioned in Section 2.7.1. 
 
 
2.6.4 Real-time quantitative reverse transcription (qRT)-PCR  
Total RNA was extracted from subconfluent cells and 1–2 µg of total RNA was reverse 
transcribed into cDNA, as previously mentioned in Sections 2.4.2 and 2.6.2.  
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2.6.4.1 qRT-PCR primers 
All primers for the qRT-PCR were purchased from Qiagen (Table 2.11). The primers were 
chosen to be intron-spanning and designed to avoid any DNA contamination. All amplicons 
were smaller than 160 bp. The TBP and TuBA primers were used as a qRT-PCR positive 
normalisation control for the qPCR results. 
 
Table 2.11 qRT-PCR primers 
Gene Source Cat. No Amplicon size 
RAD9B Qiagen QT00016471 131-160 bp 
RAD9A Qiagen QT00216846 141 bp 
HUS1 Qiagen QT00025165 105 bp 
RAD1 Qiagen QT00091287 113 bp 
TBP Qiagen QT00000721 132 bp 
TUBA Qiagen QT00062720 116 bp 
 
 
2.6.4.2 qRT-PCR plate setup 
The GoTaq qPCR master mix (Promega) was used for the qPCR. In a 96-well plate, the qPCR  
was set up in triplicate. Each reaction was set up as seen in Table 2.12.  
 
Table 2.12 qPCR reaction mix 
SYBR Green master mix 10 µl 
cDNA 5 µl 
qPCR primer 2 µl 
Nuclease-free H2O 3 µl 
 
For the negative control, the qPCR was set up as seen in Table 2.13. 
 
Table 2.13 Negative qPCR control mix 
SYBR Green master mix 10 µl 
NTR cDNA (No Reverse Transcriptase) 5 µl 
qPCR primer 2 µl 
Nuclease free H2O 3 µl 
   
 
2.6.4.3 qRT-PCR program 
The 96-well plate was placed in the Bio-Rad CFX machine and the qPCR program was run as 
seen in Table 2.14. 
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Table 2.14 qPCR amplification program 
Pre-denature 95°C 
Denature 95°C 
Annealing 60°C 
Extension 72°C 
Number of cycles 40 
   
The qPCR results were analysed using the Bio-Rad CFX Manager Software (Version 2.1). 
 
 Agarose Gel Electrophoresis 
Gel electrophoresis was used for the analysis of RNA, DNA, PCR products, amplified and 
digested plasmids. Different percentages of agarose gels were used depending on the 
fragment size as seen in Table 2.15. 
 
Table 2.15 Agarose gel concentration vs fragment size 
Size (bp) Percentage Agarose (g) *1x TEA Buffer  
 
100–250 2% 3 150 ml 
250–1000 1.5% 2.25 150 ml  
1000–10000 0.8% 1.2 150 ml  
*1x TEA Buffer: 40 mM Tris (pH = 8), 20 mM acetic acid, 1 mM EDTA  
Note: These volumes are prepared for the midi tanks. 
The appropriate concentration from the above table was prepared and mixed by swirling. The 
gel mixture was microwaved for 2–3 min with swirling every 45 s. The gel was allowed to 
cool to 50°C and then 0.5 µg/ml of ethidium bromide was added to the gel. Then the gel was 
poured into the Bio-Rad trays and combes were placed immediately. The gel was allowed to 
set for at least 30 min. The set gel was placed in the BIO-RAD tank and filled with 500 ml of 
1X TEA (Tris-acetate-EDTA) buffer. 
 
2.7.1 Sample preparation and loading 
The DNA and RNA samples were mixed with 6x Blue/Orange Loading Dye (Promega) just 
before loading onto the agarose gel. The first lane of the gel was loaded with either the DNA 
1 kb standard (Promega) or the 100 bp Standard (Promega) depending on the size of the 
fragments loaded onto the gel. The gels were run at 100 V for 1 hr. Analysis of the agarose 
gels was carried out using the Doc200 machine (Bio-Rad) and the Quantity One 1-D analysis 
software (Bio-Rad). 
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2.7.2 DNA purification 
The whole PCR sample (50 µl) was run and separated on agarose gel electrophoresis. The 
band of interest was cut out of the gel under the UV light and placed in a new Eppendorf tube. 
The DNA purification was performed using the ISOLATE II PCR and Gel Kit (Bioline) 
according to the manufacturer’s instructions. 
 
 Western Blot 
2.8.1 Protein Extraction  
2.8.1.1 Whole cell extract 
When cells were approximately 80% confluent, the medium was removed and cells were 
washed with 5 ml of cold 1x PBS. The cells then were trypsinised, collected in complete 
medium, and counted as mentioned in Section 2.3.5. The cells were centrifuged at 1,500 rpm 
for 5 min and the cell pellet was washed with cold 1x PBS. The cells were spun down again at 
1,500 rpm for 5 min and the pellet was resuspended in whole protein lysis buffer                  
(50 mM Tris-HCl (pH = 7.4), 200 mM NaCl, 0.5% Triton X-100) at a ratio of 100 µl lysis 
buffer for each 1 x 106 of cells. The cell lysate was supplemented with 1x protease inhibitor 
cocktail III for mammalian cells (1 µl/100 µl of lysis buffer, Melford), 125 U/ml Benzonase           
(Merck Millipore) and 1.5 mM MgCl2. The extracts were kept on ice for 1 hr with vortexing 
every 15 min. The extracts were then centrifuged at full speed for 10 min at 4°C. The 
supernatant was transferred to a new Eppendorf tube and stored at -20°C until further use.  
 
2.8.1.2 Protein fractionation 
Subconfluent cells were washed with 1x cold PBS, trypsinised, and collected in cold complete 
medium. Then the cells were centrifuged at 1,500 rpm for 5 min and counted as mentioned in 
Section 2.3.5. For the cytoplasmic fraction, the pellet was resuspended in hypotonic buffer 
(50 mM Tris-HCl pH = 7.4, 0. 1 M sucrose) combined with an equal volume of Buffer C   
(1% Triton-X100, 10 mM MgCl2) in a ratio of 100 µl of both buffers for each 1 x 10
6 cells. 
The cell lysate was supplemented with 1 µl protease inhibitor per 100 µl of combined lysis 
buffer, mixed gently and left on ice for 30 min. Then the lysate was centrifuged at 6,000 x g 
for 2 min at 4°C and the supernatant (cytoplasmic fraction) was transferred to a new 
Eppendorf tube. The remaining pellet (nuclear fraction) was washed once with 1x PBS to 
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remove any cytoplasmic protein residue and the cell pellet was collected again by 
centrifugation at 6,000 x g for 2 min at 4°C. The pellet was resuspended in 100 µl of Buffer N 
(50 mM Tris-HCl pH = 7.4, 100 mM KAc) per 1 x 106 cells. The nuclear fraction was 
supplied with protease inhibitor (1 µl/ 100 µl), 125 U/ml Benzonase and 1.5 mM MgCl2. 
Both fractions were stored at -20 °C until analysed on an SDS-PAGE gel.  
 
2.8.2 Protein concentration 
Before the protein samples were run on an SDS-PAGE gel, the concentration of each protein 
sample was measured using the BCA Protein Assay Kit (Thermo Fisher Scientific) according 
to the supplier’s instructions. For the normal SDS-PAGE, native protein electrophoresis and 
Phos-tag electrophoresis, 30 µg of protein was loaded onto the gel.   
 
2.8.3 Normal SDS-PAGE 
2.8.3.1 SDS-PAGE Concentration 
The protein samples were run on different concentrations of SDS-PAGE gels according to 
their size. The four SDS-PAGE concentrations used are shown in Table 2.16. 
 
Table 2.16 Preparation of lower separation gel 
Concentration 8% 10% 12% 15% 
Number of gels 4 4 4 4 
1 M Tris-HCl pH = 8.8 7.5 ml 7.5 ml 7.5 ml 7.5 ml 
40% Acrylamide/Bis 37.5:1 4 ml 5 ml 6 ml 7.5 ml 
20% *SDS  150 µl 150 µl 150 µl 150 µl 
H2O 8.5 ml 7.5 ml 6.5 ml 5 ml 
10% *APS  100 µl 100 µl 100 µl 100 µl 
*TEMED  30 µl 30 µl 30 µl 30 µl 
Total 20 ml 20 ml 20 ml 20 ml 
*SDS: Sodium dodecyl persulfate. 
*APS: Ammonium Persulfate. 
*TEMED: Tetramethylethylenediamine.   
 
The prepared gels were cast between the Bio-Rad Blotting System glass plates and the gels 
were overlaid with drops of isopropanol to remove any bubbles. The gels were allowed to set 
for 30 min at room temperature. Once the separation gels were set, the isopropanol layer was 
washed using dH2O. The stacking gels were then prepared as seen in Table 2.17. 
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                                       Table 2.17 Preparation of upper stacking gel 
Concentration 4% 
Number of gels 4 
1 M Tris-HCl pH = 6.8 1.5 ml 
40% Acrylamide/Bis 37.5:1 1 ml 
20% SDS 50 µl 
H2O 7.5 ml 
10% APS 100 µl 
TEMED 10 µl 
Total 20 ml 
 
The stacking gels were placed on top of the separation gel layers and combs were inserted 
immediately. The gels were allowed to set for 15 min at room temperature.  
 
2.8.3.2 Protein sample preparation 
Just before loading the protein extracts onto the SDS-PAGE gel, the samples were mixed with 
4x Laemmli buffer (40% glycerol, 240 mM Tris-HCl pH = 6.8, 8% SDS, 0.04% bromophenol 
blue and 5% B-mercaptoethanol). Then the samples were denatured by boiling at 95°C for 5 
min. 
 
2.8.3.3 Running samples on SDS-PAGE 
The gels were placed in Bio-Rad protein electrophoresis tanks filled with 1x SDS buffer (28.8 
g glycine, 6.04 g Tris base, 2 g SDS, up to 2 L dH2O). The combs were removed and the 
protein standard ladder (Thermo Fisher Scientific) was loaded onto the gels in parallel with 
the protein extracts. The electrophoresis gels were run at 100 V for 1.45 hr. When the 
electrophoresis was finished, the gels were removed from the tanks and transferred onto 
blotting membranes (See Section 2.9). 
 
2.8.4 2D isoelectric focusing 
2.8.4.1 2D sample preparation 
Expression was induced by adding doxycycline (1 µg/ml) and then incubating overnight. 
After incubation, the cells were washed with 1x PBS, trypsinised, and spun down at 1,500 
rpm for 5 min. The cell pellet was resuspended in IEF (isoelectric focusing) Buffer (7 M urea, 
2 M thiourea, bromophenol blue) supplemented with protease inhibitor cocktail (1 µl/ 100 µl), 
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125 U/ml Benzonase and 1.5 mM MgCl2  in a ratio of 100 µl of IEF buffer per 1 x 106 of 
cells. 
 
2.8.4.2 Running samples on a 2D isoelectric focusing machine 
The 2D sample lysate (15 µl) was further diluted in 110 µl of IEF buffer and the total 125 µl 
was loaded onto the 2D tray. The immobilized pH gradient (IPG) strips nonlinear (pH 3–10, 
Bio-Rad) were carefully lowered onto the protein solution, making sure the protein solution 
was in contact with both electrodes. The strips were then overlaid with 2 ml of mineral oil and 
the 2D program was set up as seen in Table 2.18. 
Table 2.18 2D electrophoresis program 
Running Active dehydration at 50 V for 12 hr 
Focusing Rapid method, 10,000 V, hold to 500 V 
 
Once the run was finished, the strips were placed in 2D normal trays with the gel facing up. 
The strips were incubated for 10 min in 2D solution I (6 M urea, 0.375 M Tris-HCl (pH = 
8.8), 2% SDS, 20% glycerol, 2% (w/v) Dithiothreitol (DTT)) and then they were incubated 
for another 10 min in 2 ml of 2D solution II (Tris-HCl pH = 8.8, 2% SDS, 20% glycerol, 
2.5% (w/v) iodoacetamide). Both incubations were performed on the rocking platform at 
room temperature.  
 
2.8.4.3 Running 2D strips on SDS-PAGE  
The 2D strips were run on a 10% normal SDS-PAGE gel (Table 2.16). The electrophoresis 
gels consisted of only the lower separation layer. The separation gels were cast right to the top 
of the glass plates, leaving approximately 5 mm space to apply the strip. The electrophoresis 
gels were run at 100 V for 1.5 hr and the transfer and staining were performed as mentioned 
in Sections 2.9 and 2.10.  
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2.8.5 Native protein electrophoresis 
2.8.5.1 Preparation of native PAGE 
The native PAGE consisted of one gel layer prepared as seen in Table 2.19. 
 
Table 2.19 Native gel components 
Component Volume 
Polyacrylamide 2.5 ml 
1.5 M Tris-HCl pH = 8.8 2.5 ml 
H2O 5.5 ml 
10% APS 50 µl 
TEMED 10 µl 
*These volumes are sufficient for two gels. 
 
2.8.5.2  Native protein sample preparation 
The protein extracts were mixed with 2x native sample buffer (0.187 M Tris-HCl pH = 6.8, 
30% glycerol, 80 µg/ml bromophenol blue) just before loading onto the native SDS-PAGE 
gel. The native gels were placed in electrophoresis tanks filled with 1x native gel running 
buffer (28.8 g glycine, 6 g Tris base, up to 2 L H2O, final pH = 8.3).  The native samples were 
loaded onto gels without boiling. The gels were run at 150 V for 1 hr.  
 
2.8.6 Phos-tag gels 
The lower separation gels were prepared as seen below (Table 2.20). The Phos-tag prepared 
gels were cast between the Bio-Rad Blotting System glass plates and the gels were overlaid 
with drops of isopropanol to remove bubbles. The gels were allowed to set for 30 min at room 
temperature. Once the separation gel was set, the isopropanol layer was washed using dH2O. 
The stacking gel was then prepared as previously shown in (Table 2.17). 
   
Table 2.20 Phos-tag PAGE lower gel preparation 
Component Concentration 
Acrylamide/Bis 29:1 1.4 ml 
1 M Tris-HCl pH = 8 1.8 ml 
5 mM Phos-tag 70 µl 
10 mM MnCl2 70 µl 
20% SDS 27 µl 
TEMED 15 µl 
10% APS 70 µl 
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The gels were run normally, as described in Section 2.8.3.3. After electrophoresis, the gels 
were washed three times in 1x transfer buffer supplemented with 20 mM EDTA to remove 
the Mn++ ions, as they interfere with the transfer. The transfer was performed as mentioned 
in Section 2.9 overnight at 10 V.   
 
 Membrane Transfer 
In a tray containing 1x transfer buffer (28.8 g glycine, 6.04 g Tris base, 200 ml methanol, up 
to 2 L H2O), the transfer sandwich was set up in the following order: black cassette on the 
bottom, pre-wet sponge, filter paper, equilibrated gel, PVDF or nitrocellulose membrane, 
filter paper, pre-wet sponge and red cassette on top. The transfer sandwiches were placed in 
the transfer tank filled with 1x transfer buffer, and the transfer was run at 65 V for 2.5 hr or at 
10 V overnight. The PVDF, nitrocellulose and filter paper purchased from GE Health Life 
Sciences.  
 
 Membrane Blocking, Antibody Staining and Developing 
The membranes were incubated in 3% milk blocking buffer (3% milk powder in 1x PBS, 
0.05% Tween 20) for 1 hr on the rocking platform. The corresponding primary antibodies 
were diluted (for antibody concentrations see section 2.11) in blocking buffer. The diluted 
primary antibodies were added to the membranes in sealed plastic bags and incubated 
overnight. The primary antibodies were removed and the membranes were washed three times 
with 1x washing buffer (1x PBS with 0.05% Tween 20). Each wash was for 10 min at room 
temperature. The membranes were then incubated with the diluted secondary antibodies 
(see 2.11) in blocking buffer in sealed plastic bags for 1 hr. The membranes were then washed 
three times in 1x washing buffer, with each wash for 10 min. 
  
The white (0.5 ml) and brown (0.5 ml) Western lightening ECl-plus solutions (PerkinElmer) 
were added to the membranes, making sure the mixed solution covered the whole membrane. 
Then the membranes were placed in plastic wallets in X-ray film boxes. In the dark 
developing room, one X-ray film (Thermo Fisher Scientific) was placed on top of each 
membrane with the plastic sheet between.  The X-ray film box was closed firmly and the film 
was exposed for a few min (depending on the antibody and protein concentrations). The film 
was then developed using the OptiMax X-ray Processor machine. 
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 Antibodies 
Table 2.21 list of primary antibodies used in this project 
Name  Company Dilution Product number 
Anti-Fibrillarin Abcam 1:500 AB5821 
ATM  Cell Signalling 1:1000 2837 
ATR Cell Signalling 1:1000 2790 
BAK Cell Signalling 1:1000 3814 
Bcl-2 Cell Signalling 1:1000 15071 
Chk1 Cell Signalling 1:1000 2360 
Chk2 Cell Signalling 1:1000 3440 
GAPDH Cell Signalling 1:5000 2118 
GFP Thermo Fisher Scientific 1:1000 MA5-15256 
GFP Santa Cruz 1:1000 B-2 
Histon H3 Abcam 1:5000 AB1791 
Hus1 Abcam 1:10000 AB96297 
Lamin B Santa Cruz 1:2000 M-20 
p21 Cell Signalling 1:1000 2947 
p53  Cell Signalling 1:1000 9282 
PARP Cell Signalling 1:1000 9542 
p-ATM (Ser-1981) Cell Signalling 1:1000 5883 
p-ATR (Ser-428) Cell Signalling 1:1000 2853 
p-Chk1 (Ser-345) Cell Signalling 1:500 2341 
p-Chk2 (Thr-68) Cell Signalling 1:500 2661 
PCNA Abcam 1:2000 AB29 
p-p53 (Ser-15) Cell Signalling 1:1000 9284 
Rad1 Abcam 1:1000 AB5363 
Rad9A Fisher Scientific 1:1000 PA5-212 75 
 
 
 
 
 
Table 2.22 list of secondary antibodies used in this project  
Name  Company  Dilution  Product number 
Alexa Flour 488 Thermo Fisher Scientific 1:500 A11059 
Alexa Flour 532 Thermo Fisher Scientific 1:500 AB5821 
Anti-Goat Abcam 1:10000 AB6741 
Anti-Mouse Millipore  1:10000 402335 
Anti-Rabbit Millipore 1:10000 401315 
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 Immunofluorescence Microscopy  
2.12.1  Cell growth 
In the tissue culture hood, coverslips (Chemglass) were placed in 24-well plates with enough 
covers for the antibody conditions. The coverslips were exposed to UV light (5 J/m2) for 30 s 
to make sure all the coverslips were sterilised before use. Then the cells were seeded onto the 
coverslips at a confluency of 40–50% (approximately 50,000 cells per well) in 1 ml medium, 
and the cells were allowed to grow and spread for 1 day. 
 
2.12.2  Cell fixation 
After 24 hr of seeding, the medium was carefully aspirated and the cells were washed with 1 
ml of warm 1x PBS. The cells were fixed by adding 0.5 ml of fixing solution to the wells (4% 
paraformaldehyde in 1x PBS) and the plates were left in the hood for 10 min for the cells to 
be fixed. Then the fixing solution was aspirated and replaced with 0.5 ml of permeabilisation 
solution (0.2% Triton in 1x PBS) and the plates were left in the hood for 10 min. The cells 
were then washed three times in 1x PBS, with each wash for 10 min on the rocking platform. 
The cells were blocked by adding 0.5 ml of FBS blocking solution (5% FBS in 1x PBS) and 
the plates were left on the rocking platform at room temperature for 1 hr. 
 
2.12.3  Immunostaining 
The blocking solution was aspirated off and 0.5 ml of the primary antibodies diluted in 
blocking solution was added directly to the cells, with all the coverslips well immersed. The 
cells were incubated overnight on the rocking platform at 4°C. The following day, the primary 
antibodies were aspirated off and the cells were washed three times in 1x PBS, with each 
wash for 10 min. Then, in a dark hood, 0.5 ml of secondary antibody Alexa Fluor 488 (green) 
or Alexa Fluor 532  (red) (depending on the co-staining) diluted in blocking solution was 
added to the cells, making sure all coverslips are immersed well. For concentrations of the 
primary and secondary antibodies, please refer to the antibodies table (Table 2.21). The plates 
were covered with foil and left on the rocking platform for 2 hr at room temperature.  
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2.12.4  Microscope slides mounting 
On glass microscope slides, 10 µl of 4',6-diamidino-2-phenylindole (DAPI) mounting 
solution (Vector Laboratories) was placed where the sample coverslips were fixed. The 
coverslips were removed from the plates and the excess fluid was removed before the 
coverslips were carefully inverted onto the mounting solution. The coverslips then were 
surrounded on the edges with clear nail varnish and the slides were kept at 4°C until the 
samples were analysed. The samples were analysed with a LSM 710 Confocal Microscope 
using the 40x objective. The images were analysed and processed by Zen lite software. 
 
 
 Cell Synchronisation  
2.13.1  Serum starvation  
HEK293 and HeLa cells were seeded at 40% confluency onto 15-cm plates containing 
complete DMEM and allowed to attach for a few hours at 37°C. The cells were washed twice 
with 1x PBS to remove any remaining serum residue, followed by incubating the cells in 
FBS-free medium at 37°C for 24 hr. The cells then were stimulated by releasing the cells into 
complete medium. Whole protein extract and fixed samples were taken before and 6 hours 
post-release.  
 
2.13.2  Cell senescence 
Oxidative stress was applied to HEK293 and HeLa cells to induce cellular senescence. The 
cells were plated in 15-cm plates at ~40% confluency and were allowed to attach to the plates 
for a few hours. The medium then was aspirated from the plates and the cells were washed 
twice with warm 1x PBS to remove any FBS residue, followed with adding 15 ml of FBS-free 
medium supplemented with 200 µM H2O2 to the plates. The cells were incubated at 37°C for 
1 hr. The medium then was removed, the cells were washed twice with warm 1x PBS 
followed by incubation in complete medium at 37°C for 3 days. Images were taken using the 
CMEX-5000 Camera (Euromex) placed on an Eclipse TS100 Microscope (Nikon). Protein 
and RNA were extracted 24, 48 and 72 hr after the treatment.  
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 RAD9B Expression in Subconfluent and Superconfluent Cells 
Cells were plated at a density of 1 x 106 and they were allowed to grow at 37°C in their 
appropriate medium. On day 4, total RNA was extracted from the subconfluent cells, as 
described in Section 2.4.2. For the superconfluent samples, the cells were allowed to grow for 
approximately 7 days with changing the medium on day 4. Total RNA was extracted from the 
subconfluent cells, as described in Section 2.4.2. The extracted RNA (200 ng) was used as a 
template for the amplification of full-length transcripts using one-step RT-PCR. Then 1 µg of 
total RNA was reverse transcribed into cDNA, which was used as a template for the detection 
of RAD9B splice variants using short internal primers.    
  
 
 Preparation and Analysis of Flow Cytometry Samples 
Cells were seeded at 40% confluency and allowed to attach for a few hours at 37°C. The cells 
then were treated with the experiment-corresponding treatment. The cells then were incubated 
at 37°C until their sample extraction time. At the time of extraction, the cells were centrifuged 
at 1,500 rpm for 5 min, followed by washing the pellets with 1x PBS. The pellets then were 
resuspended in 100 µl of 1x PBS and fixed dropwise with ice-cold 100% methanol while the 
samples were vortexed. Then the samples were kept at -20°C for at least 24 hr. Just before 
analysis on the CyFlow CUBE 8 flow cytometry machine (Sysmex), the cells were spun 
down at 1,500 rpm and washed twice with 1x PBS to remove any remaining methanol 
residue. The cells were resuspended in staining solution (100 µg/ml RNAse and 50 µl/ml 
propidium iodide resuspended in 1x PBS) and incubated at 37°C for 30 min. the cells then 
were run through the flow cytometer machine and the samples were analysed using the 
Flowing Software 2.  
  
 
 Construction of Stable Human N-Terminal EGFP-Tagged Cell Lines 
2.16.1  Cassette amplification 
All primers used for the cloning of RAD9B-001, RAD9B-002 and Rad9-M50 were designed to 
have an NotI restriction site at the 5’ end of the forward primer and an XhoI restriction site at 
the 3’ end of the reverse primer to create sticky ends for cloning. 
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2.16.1.1 RAD9B-001 amplification 
The RAD9B-001 was amplified by amplifying each of its nine exons individually, followed by 
fusion of the nine amplified exons using fusion PCR. The primers were designed to have an 
overlapping extension sequence allowing for the fusion. Table 2.23 shows the primers used. 
 
Table 2.23 RAD9B-001 construction primers 
Primer 
Region 
and 
orientation 
 
Sequence 
Exon 1 (F) *atccgttacattatgcggccgcATGAGTGAAAATGAACTTGACAC 
Exon 1 (R) AGACATCTAAAGATGGGCAAAATTGACTTCATTCCCAATTTGCATTTTAAATGG 
Exon 2 (F) TTTAAAATGCAAATTGGGAATGAAGTCAATTTTGCCCATCTTTAGATGTCTG  
Exon 2 (R) CATATATTATGAGTTCTTTTAATACCATGTCTGTAGAAGAATTGAATAACTACC 
Exon 3 (F) AGTTATTCAATTCTTCTACAGACATGGTATTAAAAGAACTCATAATATATGT  
Exon 3 (R) AAAAGAACAATGGCATCAGCAAGCAATCTTGGTTGAATCATTAGCGTATTAGTT 
Exon 4 (F) TAATACGCTAATGATTCAACCAAGATTGCTTGCTGATGCCATTGTTCTTTTT  
Exon 4 (R) TCACTGTGTACAGCATTGCTCAAATCCATTGATTCCTCATTAGAACTCTTGAGG 
Exon 5 (F) CAAGAGTTCTAATGAGGAATCAATGGATTTGAGCAATGCTGTACACAGTGAG  
Exon 5 (R)  GTAGCTTCTGAAAATGTCAGTATTCCCTTCAATTCTTTGAAACAAAATGTTATT 
Exon 6 (F) AACATTTTGTTTCAAAGAATTGAAGGGAATACTGACATTTTCAGAAGCTACA  
Exon 6 (R) ATATCATCAATACTCAAAGCCAGAGGTTTCCCAGGGAAATCAAAATAAATGGAA 
Exon 7 (F) CATTTATTTTGATTTCCCTGGGAAACCTCTGGCTTTGAGTATTGATGATATG  
Exon 7 (R) CCAGCCTTTTTTTCAATCAGATCTGACCTTTTTCGTTTCTGTGAAAGACACAGG 
Exon 8 (F) GTGTCTTTCACAGAAACGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGC  
Exon 8 (R) ACTGCTCCAAAGAACATGCAAGAAAACTTTCTGAGACACAGAGACCCTGGCACC 
Exon 9 (F) GCCAGGGTCTCTGTGTCTCAGAAAGTTTTCTTGCATGTTCTTTGGAGCAGTT  
Exon 9 (R) **ctacgatggaatctcgagTTAGAATATAGAGAAACTGCCAT 
(F): forward. (R): reverse. 
*atccgttacattatgcggccgc: additional sequence contains Not1 recognition site designed in     
forward primer.**ctacgatggaatctcgag: additional sequence contains Xho1 recognition site 
designed in reverse primer. 
 
RNA was extracted from HEK293, as described in Section 2.4.2, and then it was converted to 
cDNA, as described in Section 2.6.2.1. The nine exons of RAD9B-001 were amplified using 
the nine primer pairs from (Table 2.24). The PCR was set up as following: 
 
Table 2.24 amplification of RAD9B PCR reaction mix  
Forward primer 250 nM 
Reverse primer 250 nM 
cDNA  5 µl 
5x GC buffer 10 µl 
2 mM dNTPs 5 µl 
HF Phusion polymerase 1 µl 
Nuclease-free H2O 24 µl  
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All amplified exons were purified from the agarose gel, as mentioned in Section 2.7.2 and 
fused to one fragment, creating the RAD9B-001 cDNA using the fusion PCR, as seen in 
Tables 2.25, 2.26, 2.27 and 2.28. 
 
Table 2.25 First fusion PCR reaction 
Forward primer 
*atccgttacattatgcggccgcATGAGTGAAAATGAACTTGACAC 
250 nM  
Reverse Primer 
**ctacgatggaatctcgagTTAGAATATAGAGAAACTGCCAT 
250 nM 
Amplified exon 3–5 µl 
5x GC buffer 10 µl 
2 mM dNTPs 5 µl 
HF Phusion polymerase 1 µl 
Nuclease-free H2O Up to 50 µl H2O 
*atccgttacattatgcggccgc: additional sequence contains Not1 recognition site designed in     
forward primer.**ctacgatggaatctcgag: additional sequence contains Xho1 recognition site 
designed in reverse  primer. 
 
The fusion PCR consisted of two stages as following: 
 
Table 2.26 First stage of fusion PCR  
Pre-denature 98 °C 2 min 
Denature 98 °C 30 s 
Anneal 55 °C 30 s 
Extend 72 °C 1 min 
Number of cycles 10 - 
 
Once the first PCR reaction stopped, the second fusion reaction mix was added to the same PCR tube 
as following: 
Table 2.27 Second fusion PCR reaction mix 
Forward primer 500 nM 
Reverse primer 500 nM 
5x HF buffer 15 µl 
2 mM dNTPs 10 µl 
HF Phusion polymerase 1 µl 
Nuclease-free H2O 14 µl H2O 
 
The fusion PCR reaction was then run using the program shown in Table 2.28. 
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Table 2.28 Second stage of the fusion PCR 
Pre-denature 98 °C 2 min 
Denature 98 °C 30 s 
Anneal 55 °C 30 s 
Extend 72 °C 1 min 
Final extension 72 °C 10 min 
Number of cycles 30 - 
 
The amplified RAD9B-001 was analysed on agarose electrophoresis, purified, and sent for 
sequencing. 
 
2.16.1.2 Amplification of RAD9-002 
The RAD9B-002 was amplified from the purchased plasmid (Thermo Fisher Scientific, 
MHS1010-202804714) as mentioned in 2.6.2.2 using the cloning primers seen in Table 2.29. 
 
Table 2.29 RAD9B amplification primers 
Primer  Sequence 
Forward atccttacaatgcggccgcATGGCAGCCATGCTGAAGTG 
Reverse atagttacgttctcgagTTAGAATATAGAGAAACTGCCAT 
 
The amplified RAD9B-002 was analysed on agarose electrophoresis, purified, and sent for 
sequencing. 
 
2.16.1.3 Amplification of Rad9-M50 
RNA extracted from yeast was used as a template to amplify Rad9-M50 as mentioned in 
section 2.6.2.2 using the cloning primers shown in Table 2.30. 
 
Table 2.30 Rad9-M50 amplification primers 
Primer Sequence 
Forward atccttacaatgcggccgcATGATTAAATCCGAGAACAGTC 
Reverse atagttacgttctcgagCTAACTCGAAGAATTGAGCTG 
 
The amplified Rad9-M50 was analysed on agarose electrophoresis, purified and was sent for 
sequencing. 
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2.16.2  PCR Fragment and vector digestion 
The primers used to amplify the inserts were designed to contain a restriction site for NotI 
(gcggccgc) and XhoI (ctcgag). Both the pcDNA5/FRT/TO vector and the PCR product were 
purified from agarose and the digestion was carried out according to NEB (New England 
Biolabs’ (NEB) basic protocol as seen in Table 2.31. 
 
Table 2.31 Restriction digest reaction mix 
Restriction Enzyme 5 units 0.5 µl 10 units 1 µl 
DNA 0.5 µg 1 µg 
10X NEB buffer 2.5 µl 5 µl 
Nuclease-free water Up to 25 µl  Up to 50 µl 
Incubation time 1–1.5 hr 1–1.5 hr 
Temperature 37°C 37°C 
 
The digestion reaction was inactivated by loading the total reaction onto an agarose gel 
followed by gel purification. The 50 µl reaction was used for cloning purposes whereas the 25 
µl reaction was used to confirm of the cloning.  
 
2.16.3   Insert and vector ligation 
The EGFP tag was inserted into the N-terminal of the pcDNA5/FRT/TO plasmid at the KbnI 
site by Dr. Fumiko Isashi’s research group (Oxford University). The RAD9B-001, RAD9B-
002 and Rad9M-50 insert cDNAs were ligated into the pcDNA5/FRT/TO plasmids in a 3:1 
ratio respectively. The ligation reactions were performed as shown in Table  2.32. 
 
Table 2.32 Insert and vector ligation reaction 
Component Volume 
Vector DNA X µl 
Insert DNA X µl 
T4 ligase buffer 2 µl 
T4 ligase enzyme 1 µl 
Nuclease-free water Up to 20 µl 
 
The ligation mixtures were mixed gently and left at 16°C overnight. The mixtures were then 
saved at -20°C until needed for transformation into E. coli cells. 
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2.16.4  Transformation 
2.16.4.1 Transformation of ligated plasmid into E. coli-competent cells 
The Alpha-Select Gold Efficiency Competent Cells (Bioline) were transfected with 5 µl of the 
ligated plasmid in a tube placed on ice. The tube was flicked gently without vortexing and 
incubated on ice for 30 min. The cells were then heat shocked at 42°C for 30 s, followed by 
placing the tube on ice for 5 min. Luria-Bertani (LB) medium (1 ml of 10 g Tryptone, 10 g 
NaCl, yeast extract 5 g, up to 1 L H2O) was added to the cell mixture, mixed gently and 
placed on a 37°C shaker for 1 hr. Several 10-fold serial dilutions were prepared and 100 µl of 
each dilution was spread on LB ampicillin agar plates (10 g Tryptone, 10 g NaCl, yeast 
extract 5 g, 50 µg/ml ampicillin (Amp), up to 1 L H2O). The plates were incubated at 37°C for 
24 hr. 
 
2.16.4.2 Plasmid extraction from E. coli cells 
The plasmid DNA was extracted from E. coli cells with either the ISOLATE II Plasmid Mini 
Kit (Bioline) if a high concentration of plasmid DNA was not required or the GenElute 
Plasmid midiprep Kit (Sigma) if a high concentration of DNA plasmid was required. Both 
extraction types were done according to the manufacturer’s instructions. 
 
2.16.4.3 Insertion confirmation 
The resulting plasmids described in Section 2.16.3 were digested with NotI and XhoI 
restriction enzymes, as described in Section 2.16.2  for the 25 µl reaction. Only 10 µl of the 
digestion reaction was loaded onto agarose gel and successful insertion was determined by 
corresponding band size. 
 
2.16.5  RAD9B-001 repair 
The sequenced form of the cloned RAD9B-001 revealed a four-base pair deletion at the         
3’ end. This was corrected by designing primers containing the missing base pairs and 
binding a few base pairs before the deletion at the 5’end and a few base pairs before the 
deletion at the 3’ end. The PCR was done by using the cloning forward primer with the 
reverse fixing primer and the forward fixing primer with the reverse cloning primer         
(Table 2.33). Both amplified fragments were purified from the agarose gel. The purified 
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fragments were then fused together and amplified using the fusion PCR as mentioned 
previously (Section 2.16.1.1). The fusion PCR product was then recloned into 
pcDNA5/FRT/TO-EGFP and sent for sequencing.  
 
Table 2.33 Primers for the repair of RAD9B-001 
*atccgttacattatgcggccgc: additional sequence contains Not1 recognition site designed in     
forward primer.**ctacgatggaatctcgag: additional sequence contains Xho1 recognition site 
designed in reverse primer. 
 
2.16.6  Rad9-M50 repair 
The cloned Rad9M-50 displayed two substitution mutations within the sequence. These 
substitutions were corrected by designing primers in which the forward primer contained the 
change codon approximately 10 nucleotides from the 3’ end of the primer to allow for correct 
binding. The reverse primer started at the 5’ end with one base pair next to the beginning of 
the forward primer (Table 2.34). These substitutions were corrected using the Q5 Mutagenesis 
Kit (New England Biolabs) according to the manufacturer’s instructions. 
 
 
Table 2.34 Primers for the repair of Rad9-M50 
Primer  Sequence 
Rad9-M50 forward fixing primer 1 cttgcaactgTagttggatcagatg        
Rad9-M50 reverse fixing primer 1 aatgaactgcgcttcaatttc 
Rad9-M50 forward fixing primer 2 ggaaatagaTggcagcacagttc 
Rad9-M50 reverse fixing primer 2 catcatagatgacacctcttg 
-The sequences highlighted in red represent the substitution mutations. 
 
 
 
 
Primer Sequence 
RAD9B-001 forward **atccgttacattatgcggccgcATGAGTGAAAATGAACTTGACAC 
Fixing primer reverse GCCAGAGGTTTCCCAGGGAAATCAAAATAAATGGATATAGGAGCAT
GTGTAG 
Fixing primer forward GCTACACATGCTCCTATATCCATTTATTTTGATTTCCCTGGGAAACCT
CTGGC 
RAD9B-001 reverse  *atagttacgttctcgagTTAGAATATAGAGAAACTGCCAT 
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2.16.7  Transfection of constructed plasmid into the Flp-In TREx HEK 293 
cell line 
The four plasmids pcDNA5/FRT/TO-EGFP-RAD9B-001, pcDNA5/FRT/TO-EGFP-RAD9B-
002, pcDNA5/FRT/TO-EGFP-Rad9M-50 and the empty control pcDNA5/FRT/TO-EGFP 
were transfected into the Flp-In TrEx HEK293 cell line in parallel with the pOG44 plasmid in 
a 1:9 ratio, respectively. The transfection was established using the LyoVec transfection 
reagent (InvivoGen) according to the product’s instructions. The transfected cells were 
allowed to grow in antibiotic-free medium for 24 hr. After 24 hr, the medium was removed 
and replaced with warm medium supplemented with 1 µg/ml hygromycin used as the 
transfection selective marker. Then the cells were left to grow for two weeks until single cell 
clones appeared. The medium containing the selective marker was replaced every 3–4 days. 
 
2.16.8  Isolation of hygromycin-resistant colonies 
Approximately 2 weeks post-transfection, single hygromycin-resistant colonies were isolated 
using cloning cylinders (Sigma). The medium was removed from the plates and the cells were 
washed once with 1x PBS. The cloning cylinder was then replaced gently over the colony, 
making sure the cylinder was attached firmly to the plate with no space between the cylinder 
and the plate. The cylinder was filled with 100 µl of trypsin and the plates were incubated for 
5 min at 37°C. Individual colonies then were removed to 6-well plates and allowed to grow in 
hygromycin-supplemented medium until the cells were confluent. Once cells reached 
confluence, the cells were spilt into 10-cm plates where they were either checked for their 
integrations or frozen down. 
 
2.16.9  Integration confirmation 
Confirmation of the plasmid integration into the genome of the HEK293 cells was confirmed 
using three methods. First, the genomic DNA was extracted from each cell line as mentioned 
in 2.5 and PCRs were carried out with the extracted DNA using two sets of primers. The first 
set were the same flanking primers used for cloning the variant whereas the second set was a 
combination of the forward CMV promotor and the specific reverse variant primer (Table 
2.35). Second, total protein was extracted (See 2.8.1.1) from either induced cells using 
doxycycline (1 µg/ml) or non-induced cells. The protein extracts were subjected to western 
blot (2.8.3) and immunoblotted with the GFP antibody. Third, induced and non-induced cells 
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were immunostained with the GFP antibody and analysed under the confocal microscope 
(2.12). Untransfected HEK293 were used as a second negative control. 
 
 
Table 2.35 Primers to confirm integration 
Gene Primer sequence Amplicon 
size (bp) 
RAD9B-001 Forward*atccgttacattatgcggccgcATGAGTGAAAATGAACTTGAC 
Reverse**ctacgatggaatctcgagTTAGAATATAGAGAAACTGCCAT 
1038 bp 
CMV 
promotor-
RAD9B-001 
Forward CGCAAATGGGCGGTAGGCGTG 
Reverse 
**ctacgatggaatctcgagTTAGAATATAGAGAAACTGCCAT 
2081 bp 
RAD9B-002 Forward *atccttacaatgcggccgcATGGCAGCCATGCTGAAGTG 
Reverse **atagttacgttctcgagTTAGAATATAGAGAAACTGCCAT 
1254 bp 
CMV 
promotor-
RAD9B-002 
Forward CGCAAATGGGCGGTAGGCGTG 
Reverse **atagttacgttctcgagTTAGAATATAGAGAAACTGCCAT 
2297 bp 
Rad9M-50 Forward *atccttacaatgcggccgcATGATTAAATCCGAGAACAGTC 
Reverse **atagttacgttctcgagCTAACTCGAAGAATTGAGCTG 
1134 bp 
CMV 
promotor-
Rad9M-50 
Forward CGCAAATGGGCGGTAGGCGTG 
Reverse **atagttacgttctcgagCTAACTCGAAGAATTGAGCTG 
2177 bp 
* indicates additional sequence contains Not1 recognition site designed in forward primer.   
** indicates additional sequence contains Xho1 recognition site designed in reverse primer. 
 
 
 Time course induction of the FRT system 
The EGFP-RAD9B-001 constructed cell line was seeded at 30% confluency and allowed to 
grow overnight. The following day, the cells were induced by adding doxycycline (1 µg/ml) 
to the same growing medium. Then either whole protein extraction (Section 2.8.1.1) or total 
RNA extraction (Section 2.4.2) was performed at 2, 4, 8, 12, 18, 24 and 48 hr post-induction. 
The protein extracts were analysed on normal SDS-PAGE gels (Section 2.8.3) and probed 
with the GFP antibody. Total protein was extracted from non-induced cells and used as a 
negative control. The RAD9B-001 mRNA was amplified from the extracted RNA using one-
step RT-PCR, as mentioned in Section 2.6.3. ACTB primers were used as a positive control.     
 
 
 Expression stability after the removal of the doxycycline inducer 
The four constructed cell lines were plated at 20% confluency and incubated overnight. The 
growing medium was then injected with 1 µg/ml of doxycycline and the cell lines were 
further incubated for 18 hr. Whole protein extracts were prepared (Section 2.8.1.1) at this 
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point for the 0 hr sample. The medium was then removed from the plates and the cells were 
washed twice with 1x PBS for the removal of doxycycline residue. The cell were incubated in 
doxycycline-free medium until whole protein was extracted at 12, 24 and 48 hr after the 
inducer was removed. Protein extracts were run on normal SDS-PAGE gels (Section 2.8.3) 
and immunoblotted with the GFP antibody.   
 
 
 Cellular localisation of the EGFP-recombinant proteins 
The cellular localisation of the EGFP-RAD9B-001, EGFP-RAD9B-002, EGFP-Rad9M-50 
and the control EGFP was tested under normal and UV damage conditions. The localisation 
of the recombinant proteins was analysed by protein fractionation (Section 2.8.1.2) or by 
immunostaining (Section 2.12) using the GFP antibody. Other proteins were tested for their 
localisation in the constructed cell lines with their corresponding antibodies as indicated in the 
experiment.  
 
 
 Influence of overexpressed recombinant proteins on desired targets 
The constructed cell lines were induced for different durations, as indicated in the experiment, 
reaching a maximum confluency of 90% on the day of harvesting. Other cells were left 
without induction as a control. At the desired induction time, either whole protein 
(Section 2.8.1.1) or total RNA (Section 2.4.2) was extracted from the cell lines. Either qPCR 
(Section 2.6.4), RT-PCR (Section 2.6.3), or western blotting (Section 2.8.3) was done to 
investigate the influence of the recombinant protein overexpression on the genes or proteins 
indicated in the experiment.  
 
 
 Effect of recombinant protein overexpression on cell cycle progression 
EGFP-RAD9-001 and EGFP-RAD9-002 constructed cell lines were seeded at 30% 
confluency and the cell were allowed to attach for a couple of hours, followed by induction by 
adding 1 µg/ml of doxycycline to the medium. A plate from each cell line was left without 
induction as a control. Flow cytometry samples were extracted 24, 36 and 48 hr post-
induction and analysed on the flow cytometry machine, as mentioned in Section 2.15.  
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 HuSH shRNA Knockdown system 
HuSH RAD9A knockdown plasmids were purchased from Origen. The four plasmids are 
listed in (Table 2.2). 
 
2.22.1  Amplification of HuSH knockdown plasmids 
All RAD9A-shRNA plasmids were amplified using the Alpha Select Gold Efficiency 
Component Cells growing on selective chloramphenicol plates (34 µg/ml). The 
transformation steps are the same as mentioned in Section 2.16.4. 
 
2.22.2  Transfection of shRNA plasmids into HEK 239 cells 
The shRNA-RAD9A vector was transfected into HEK293 cells using the Lipofectamine 2000 
transfection reagent (Thermo Fisher Scientific). The Opti-MEM reduced serum medium 
(Thermo Fisher Scientific) was used to mediate the transfection as per the supplier’s 
instructions. The cells were transfected with a single shRNA vector of the four supplied 
shRNAs or a mixture of the four shRNA vectors as a transient transfection. The transfected 
cells were grown in puromycin (3 µg/ml) selective medium for 72 hr, followed by either 
whole protein or total RNA extraction (Sections 2.4.2 and 2.8.1.1). 
 
  
  RAD9B-001 immunoprecipitation 
The EGFP-Rad9B-001 cell line was either left without induction or induced overnight by 
adding doxycycline (1 µg/ml). The cell were washed with 1x PBS, trypsinised, and spun 
down at 1,500 rpm for 5 min. RAD9B-001 was immunoprecipitated from the cell pellet with 
the GFP nap agarose resin kit (allelebiotech) according to the manufacturer’s instructions.  
 
2.23.1  Immunoprecipitation buffers 
1x Lysis buffer: 20 mM Tris-HCl pH = 7.5, 150 mM NaCl, 1 mM EDTA and 0.5% NP-40. 
1x Binding buffer: 10 mM Tris-HCl pH = 7.5 and 150 mM NaCl. 
1x Wash buffer: 10 mM Tris-HCl pH = 7.5 and 500 mM NaCl. 
1x Elution buffer: 200 mM glycine pH = 2.5. 
1x Neutralization buffer: 1 M Tris Base.  
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 DNA-Damage Treatments 
2.24.1  UV light treatment 
Cells were grown in their appropriate medium until they reached 70-80% confluency. For the 
constructed cell lines, cells were induced using doxycycline (1 µg/ml) 18 hr before treatment. 
Just before the cells were exposed to UV light, the medium was removed from the plate and 
the cells were washed with 5 ml of warm 1x PBS. The removal of the medium is essential as 
the medium will reflect the UV light. The plates were placed in the UV radiation machine and 
the cells were treated at a dose of  40 J/m2. The medium was added again to the plates, and the 
cells were left to recover in the incubator at 37°C. Protein or RNA was extracted 
(Sections 2.4.2 and 2.8.1.1) at different times post treatment, as indicated in the experiment. 
 
2.24.2  Heat treatment 
For the constructed cell lines, cells were induced for 18 hr by adding doxycycline (1 µg/ml) 
before starting the treatment. Subconfluent cells were placed in a 43°C incubator for 1 hr, 
followed by recovery at 37°C for different length of times. Whole protein or total RNA was 
extracted at indicated times in the experiment (Section 2.4.3, 2.8.1.1).      
 
2.24.3  H2O2 treatment 
Cell were grown in complete medium until cells reached 80% confluency. With the 
constructed cell lines, cells were induced for 18 hr by adding doxycycline (1 µg/ml) before 
treatment. The complete medium was replaced with FBS-free medium supplemented with  
500 µM H2O2 and the plates were incubated at 37°C for 1 hr. The medium then was replaced 
with complete DMEM, and the cells were allowed to recover at 37°C for different lengths of 
time. Whole protein or total RNA was extracted at the indicated times in the experiment 
(Section 2.4.3, 2.8.1.1).      
  
 
 Apoptosis Induction 
Protein expression was induced overnight with 1 µg/ml doxycycline. The following day, the 
induced and non-induced cells were exposed to two UV light doses (15 J/m2 and 40 J/m2), as 
mentioned in Section 2.24.1. The cells were further incubated and whole protein was 
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extracted at 12, 24 and 48 hr after UV treatment (See Section 2.8.1.1). Protein extracts were 
run on normal SDS-PAGE gels and immunoblotted with the indicated antibodies (See 
Section 2.8.3). 
 
 
 Cell viability post induction 
The four constructed cell lines were plated at density of 3 x 105 and allowed to grow in either 
medium supplemented with 1 µg/ml doxycycline or medium free of the inducer. Every 24 hr, 
the induced and non-induced cells were washed, trypsinised, and collected for counting, as 
mention in Section 2.3.5.    
 
 
 MPS1 Inhibition 
Cells were seeded at 10% confluence and allowed to grow for 24 hr. Medium containing        
2 µM MPS1 inhibitor (Selleck Chemicals) was added directly to the cells, and the cells were 
further incubated for 72 hr with replacing the medium with warm fresh medium containing 
the MPS1 inhibitor every 24 hr. Whole protein was then extracted from the treated and 
normal cells. The protein extracts were analysed on normal SDS-PAGE gels (See 
Section 2.8.3).    
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Chapter 3: ANALYSIS OF THE HUMAN RAD9B 
SPLICE VARIANTS AT mRNA LEVEL IN VARIOUS 
HUMAN TISSUES 
 
 Introduction  
Human cells contain two RAD9 genes: RAD9A and RAD9B, in addition to the RAD9-like 
locus C12ORF32 (chromosome 12 open reading frame 32). While RAD9A has been 
extensively studied, little is known about RAD9B and C12ORF32. RAD9B and C12ORF32 
are both located on chromosome 12 while RAD9A is located on chromosome 11. RAD9B 
variants resemble the N-terminal truncated Rad9-M50 yeast protein. Interestingly, the 
C12ORF32 protein is shorter than the normal RAD9A protein, more closely resembling the 
yeast Rad9-M50 variant (Appendix 9). In contrast to S. pombe, all human isoforms are 
alternative splice variants rather than alternative translation products. 
 
According to the National Centre for Biotechnology Information’s (NCBI, 
http://www.ncbi.nlm.nih.gov. Accessed 26 September 2016) database, human RAD9B (RAD9 
checkpoint clamp component B, also known as Rad9 homolog B (S. pombe)) has nine splice 
variants: RAD9B-001, RAD9B-002, RAD9B-003, RAD9B-004, RAD9B-005, RAD9B-006, 
RAD9B-007, RAD9B-008 and RAD9B-009. Of these, only five protein isoforms are produced 
(Table 3.1). 
The RAD9B transcripts differ from each other in a couple of points. The RAD9B-001, 
RAD9B-002 and RAD9B-005 transcripts have very long 3’ UTR tails distinguishable from the 
other two variants RAD9B-003 and RAD9B-009. The RAD9B-003 isoform encodes the largest 
protein (429 aa) while RAD9B-009 is the smallest (341 aa) of the isoforms. The long 3’ UTR 
tails of RAD9B-001, RAD9B-002 and RAD9B-005 encompass nearly 50% of the length of the 
mRNA which could harbour an additional open reading frame (Figure 3.1). The RAD9B-001 
and RAD9B-005 transcripts share an identical coding region with 72 aa missing from the 
RAD9B-001 5’ end compared to the other isoform.  
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Table 3.1 Human RAD9B transcripts in the Ensemble database  
Name Number of 
exons 
Transcript 
length 
(bp) 
cDNA 
length 
(bp) 
Protein predicted 
Protein 
size (aa) 
RAD9B-001 11 2794 1038 yes 345 
RAD9B-002 11 2732 1254 yes 417 
RAD9B-003 12 1846 1290 yes 429 
RAD9B-004 12 2843 264 Nonsense 87  
RAD9B-005 11 2727 1038 yes 345 
RAD9B-006 5 463 - No - 
RAD9B-007 5 506 - No - 
RAD9B-008 6 556 - No - 
RAD9B-009 9 1373 1026 yes 341 
 
This table illustrates the nine splice variants of the RAD9B gene. Only the RAD9B-001, 002, 003, 005 
and 009 transcripts code for protein whereas RAD9B-004 transcripts produce a nonsense-mediated 
decay protein. The information in this table was obtained from the Ensemble database 
(http://www.ensembl.org. Accessed 26 September 2016).  
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Figure 3.1 Structure analysis of RAD9B and its splice variants. (A) Diagram obtained from the 
Ensemble database, showing the structure and total number of exons of the RAD9B gene and 
its splice variants. The filled boxes indicate the coding exons while the blank boxes reflect the 
noncoding exons. The lines linking the boxes represent the introns. The name of the variant is 
shown to the left side. (B) The transcriptional sequence of the RAD9B variants. The black 
colour indicates the untranslated region of the transcript while the blue colour reflects the 
coding region of the transcript. All information was obtained from the Ensemble data base  
(http://www.ensembl.org. Accessed 26 September 2016). 
 
 
Unlike RAD9A, RAD9B is only expressed in a few tissues with high expression in the testis 
and low expression in skeletal muscle at the mRNA level (Dufault et al., 2003). The Human 
Transcriptome Database for Alternative Splicing showed that Rad9B is only expressed in 
testis tissue (http://h-invitational.jp. Acssessed 26 Spetember 2016).      
 
A report by Kim and colleagues (2010) detected very low expression of C12ORF32 in  
normal human tissues except for the small intestine, testis, ovary, prostate and thymus. 
Interestingly, C12ORF32 was highly expressed in 11 breast cancer cell lines with a 
remarkable difference at expression level when compared to normal tissues.  
A 
B 
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Knockdown of C12ORF32 expression in two breast cancer cell lines showed an inhibition of 
G1/S transition and an increase in the sub-G1 population probably due to cell death. The 
C12ORF32 protein was found to be processed from a 35 kDa precursor to a 16 kDa protein 
which accumulated in breast cancer (Kim et al., 2010).  
 
As mentioned in the introduction, alternative splicing could be specific to a certain cell phase 
or inducible by a certain treatment, such as UV light or heat stress. Splice variant expression 
was also reported to be elevated at the end of the cellular life span, a stage known as cellular 
senescence (Blanco et al., 2008). Cells continually experience exogenous and endogenous 
stress, and their response could lead to complete recovery; alternatively, in some cases, it 
could be fatal. Cells can also undertake a different response, a mechanism in which cells enter 
permanent, irreversible cell cycle arrest. These cells can remain in a nonproliferative viable 
state known as cellular senescence for months (Campisi, 2013; Campisidi & Fagagna, 2007; 
Ben-Porath & Weinberg, 2005). One of the main regulators of senescence is the p21 protein, 
which shows a significant up-regulation under these conditions and is a primary marker of 
stress-senescence induction. Since p21 was reported to share a role with RAD9B in response 
to DNA damage beside their reported physical interaction, in this chapter, cell senescence was 
induced in normal and carcinoma cells, and the expressions of RAD9B splice variants were 
investigated (Perez-Castro & Freire, 2012; Cmielova & Rezacova, 2011).    
 
The latest study on RAD9B showed that the overexpression of RAD9B results in G1 cell 
cycle arrest (Perez-Castro & Freire, 2012). It is likely that RAD9B has a functional role in this 
phase of the cell cycle. Therefore, in this chapter, cell populations were collected in the 
desired cell cycle phase through cell synchronisation followed by the analysis of the mRNA 
levels in different RAD9B splice variants. This was designed to help to reveal changes in 
RAD9B expression throughout the cell cycle. 
 
Although it has been reported in various databases that RAD9B is poorly or not expressed at 
all in most human tissues, except in the testis, and since the RAD9B splice variants have never 
been fully studied, the expression of the RAD9B splice variants were investigated in various 
human tissues in addition to different cell lines at the mRNA only since no validated antibody 
for the detection of RAD9B was available. Moreover, in addition to the aforementioned tested 
conditions for the expression levels of RAD9B such in senescence cells and cell cycle 
specificity, the expression of RAD9B was also investigated under other conditions such as cell 
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super confluency and heat stress, as RAD9B may be an inducible gene as in the case of the 
yeast Rad9-M50.   
 
    
 Results 
3.2.1 Primer design to distinguish among the RAD9B splice variants 
With the very high identity amongst RAD9B-001, RAD9B-002, RAD9B-003, RAD9B-005 and 
RAD9B-009 (Appendix 1) in mind, two sets of primers were designed to distinguish between 
them. The first set amplifies the full length transcript whereas the other set was designed to 
amplify short regions of the different RAD9B transcripts.  
 
To amplify short regions of each splice variant (Figure 3.2-B), three pairs of primers were 
designed. The first pair (S-001-002-005) binds to RAD9B-001, RAD9B-002 and RAD9B-005 
and amplifies the same 196 bp region. The second pair of primers (S-003-009) share the same 
forward primer of the first pair but utilize a different reverse primer that goes across a long 
gap present in RAD9B-003 and RAD9B-009 and binds to the 3’ end of all the transcripts. This 
pair (S-003-009) binds to all five variants, amplifying short fragments for RAD9B-003 (233 
bp) and RAD9B-009 (123 bp) and amplifying long regions (1172 bp) of RAD9B-001, RAD9B-
002 and RAD9B-005. The last pair (S-001) was unique for RAD9B-001, amplifying a short 
region (215 bp) of its 5’ end. 
 
The primers designed across long regions were unique for each splice variant, except for 
RAD9B-002 and RAD9B-005 (Figure 3.2-A). The first pair of primers (L-001) amplifies the 
RAD9B-001 coding sequence (CDS) and part of the 5’ untranslated region (UTR) with a size 
of 1363 bp.  
 
The other pair (L-001-002-005) detects three variants (RAD9B-001, RAD9B-002 and RAD9B-
005) at the same size (1038 bp), amplifying the whole RAD9B-001 CDS and only a part of the 
CDS for RAD9B-002 and RAD9B-005. This pair of primers was used to amplify the full-
length (CDS) sequence of the RAD9B-001 for the construction of the stable cell lines (Chapter 
4). In addition, another pair of primers (L-002-005) were designed for the construction of the 
RAD9B-002 stable cell line, amplifying the CDS of both RAD9B-002 and RAD9B-005 nearly 
at the same size (~1254 bp) as the amplified RAD9B-005 is only seven bp shorter than the 
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RAD9B-002. The last pair of primers (L-003-009) was designed to detect the full-length 
expression of RAD9B-003 and RAD9B-009 by amplifying 1290 bp and 974 bp sized 
fragments, respectively. All primers designed across long regions can specifically amplify all 
RAD9B splice variants with the exception of RAD9B-002 and RAD9B-005.  The primers 
sequence table can be seen in Table 2.6.   
 
 
 
Figure 3.2 Primer design to amplify RAD9B and its splice variants. (A) Sites of primer binding 
across RAD9B splice variants and amplifying full length transcripts. (B) Sites of primer 
binding across RAD9B splice variants and amplifying short regions. The colours (brown, 
black, red, blue and purpule) indicate the amplified splice variants and their expected size 
(bp). The letters and numbers in green indicate the name of primers, L (long), S (short). 
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3.2.2 Expression levels of the RAD9B splice variants 
The expression levels of the RAD9B splice variants was investigated in three human cell lines: 
HEK293 (non-malignant embryonic kidney cell line), HeLa (cervical cancer) and Kelly 
(neuroblastoma cell line).  All five variants of RAD9B were tested using intron-spanning 
primers to amplify long and short regions. RNA at two concentrations was reverse transcribed 
into cDNA and different concentrations of cDNA were used as the RT-PCR template. The 
ACTB (Beta Actin) gene expression was used as a control for the cDNA quality and to 
compare Rad9B variant expression levels.   
 
The set of primers (S-001-002-005 & L-001-002-005), (Figure 3.2-A & B),  amplifying long 
and short identical regions of the RAD9B-001, RAD9B-002 and RAD9B-005 variants showed 
evidence of some or all these three variants in all cell lines whereas no amplification was 
obtained for the full length mRNA of RAD9B-003 and RAD9B-009 (Figure 3.3). However, 
using the primers (S-003-009), (Figure 3.2-A & B), amplifying the short regions of the 
variants showed the expression of the RAD9B-009 variant but not of RAD9B-003 in all the 
three cell lines. The primers used for the long regions seemed to have less amplification copy 
efficiency than the primers for the short regions. The HEK293 cells had the highest 
expression of all variants while very low expression was obtained in the brain carcinoma 
cells. Having expression in all three cell lines, they were used in most of this project’s 
experiments. DNA sequencing confirmed the identity of the identical short and long region of 
the RAD9B-001/002/005 and the specific region of RAD9B-009.  
  
The increased concentration of the template cDNA enhanced the amplification of the RAD9B 
variants indicating that they are expressed at low levels. The increase in the template 
concentration correlated directly with the amplification of the variants, especially when 
amplifying the small regions. This proportion was observed among all three cell lines (Figure 
3.3).  
 
The cDNA dilution factor is usually from 1:5 to 1:10 in most RT-PCR protocols. The results 
obtained here show that the cDNA dilution factor plays an important role in the detection of 
the variants, and apparently this might have been the reason for the negative RT-PCR results 
obtained in the early stages of the project. The best intensity was observed when the 2 µg 
reverse transcribed RNA was used and only two-fold diluted.  
 70 
 
 
Higher dilutions than two-fold resulted in either negative PCRs in some cell lines or weak 
signals in other cell lines. Conversely, the expression of ACTB, as seen in (Figure 3.3-B), can 
be detected up to a dilution factor of 100-fold. This implies that the expression levels of the 
RAD9B splice variants are at least 50 times lower compared to ACTB. Taking together, the 
detection or amplification efficiency of low expressed genes such in the case of the RAD9B 
splice variants can be enhanced by controlling the templated concentration.  
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Figure 3.3 Analysis of RAD9B splice variants amplification using different template 
concentrations. (A) RT-PCRs of the RAD9B variants in three different cell lines (HEK293, HeLa and 
Kelly) using different RT-PCR template concentrations. Reversed transcribed RNA concentration and 
cDNA dilution factor is seen above the figure. The amplified variant and its expected size (bp) are 
shown on the right side. A volume of 10 µl of the RT-PCR was loaded on agarose gel for all the 
RAD9B variants and ACTB. (B) 1 µl of RNA extracted from HEK293 cells was reverse transcribed 
into cDNA, followed by a series of dilutions. RT-PCRs of RAD9B-001, 002 and 005 in HEK293 cells 
with primers to amplify short and long regions with varying RT-PCR template concentrations (up to 
100-fold dilution). ACTB was used for cDNA quality and as a high expression control gene. RT-PCRs 
amplifying long regions for RAD9B-001, 002, 005, 003 and 009 were run on 0.8% agarose gels. RT-
PCRs amplifying short regions for RAD9B-001, 002, 005, 003 and ACTB were run on 1.5% agarose 
gels. RT-PCR amplifying short regions for RAD9B-009 was run on a 2% agarose gel. For the RT-
PCRs, 10 µl was loaded on the agarose gel for all the RAD9B variants and only 5 µl for the ACTB.   
 
B 
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3.2.3 Column vs. TRIzol RNA extraction 
Since the expression of RAD9B is extremely low as observed using the two-step RT-PCR, 
two RNA extraction methods were compared to enhance the detection of RAD9B variants.  
Both the column and the TRIzol method resulted in high-quality RNA (Figure 3.4); however, 
the TRIzol method resulted in DNA contamination, even without disturbing the interphase 
containing the genomic DNA. Several attempts to remove the DNA from the RNA samples 
with DNase resulted in either failure or RNA quality loss. Using genomic DNA contaminated 
RNA for RT-PCR, and especially for qPCR, can be a problem, even when using intron-
spanning primers. These primers cannot guarantee accurate RNA quantification, as it might 
result in a false positive. Therefore, all future RNA samples will be extracted using the 
column method.  
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Figure 3.4 Comparison of column and TRIzol RNA extractions. Agarose gel analysis of RNA 
extracted from HEK293, HeLa and Kelly cell lines by either column or TRIzol extraction. The 
RNA extracted by both methods show high quality RNA represented in the ribosomal RNA 
(rRNA) 18S and 28S. DNA contamination is observed within all RNA extracted from the 
three cell lines with the TRIzol method. RNA extracted by both methods were reverse 
transcribed into cDNA. The cDNA was used for the amplification of RAD9B splice variants 
using flanking primers. Both methods resulted in very weak amplification of the RAD9B 
splice variants. ACTB was used as a positive control. Name of the amplified splice variant and 
its expected size can be seen on the right side.      
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3.2.4 One-step and two-step RT-PCR 
Due to the insufficient amplification results of RAD9B obtained from the RT-PCR 
experiments, the amplification of the RAD9B splice variants was investigated using two 
different amplification methods to search for the best amplification conditions. Here two kits 
(the one-step RT-PCR method and the previously used two-step RT-PCR method) were 
compared for their amplification efficiency using the HEK293, HeLa and Kelly cell lines. The 
first method (one step), was performed including both the reverse transcriptase step of the 
RNA template and the PCR reaction in the same tube. However, the second method (two-
step) involved creating the reverse transcription step separately, and then the cDNA template 
was added to the PCR reaction. Interestingly, almost all samples were positive for the RAD9B 
variants when using the one-step RT-PCR method. The exception was the RAD9B-009 
variant, which was not expressed in any of the cell lines. In comparison, only the primer pair 
(L-001-002-005) (Figure 3.2-A), amplifying RAD9B-001/002/005, gave a weak positive PCR-
amplification signal in the HEK293 and HeLa cell lines when using the two-step RT-PCR 
method, and no positive reaction was obtained for the other primer pair detecting RAD9B-
002/005 or the primers detecting RAD9B-003 and RAD9B-009. The one-step RT-PCR method 
confirmed the expression of RAD9B variants in both HEK293 and HeLa cells but at a much 
lower level in the neuroblastoma cells (Figure 3.5). The identities of the RAD9B fragments 
were confirmed by DNA sequencing. 
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Figure 3.5 Analysis of RAD9B variants amplification following RNA extraction via one-step RT-
PCR and two-step RT-PCR methods. (A) For lanes 1, 2 and 3, 200 ng of total human RNA 
extracted from three different cell lines were reverse transcribed and amplified by the Bioline One-
Step RT-PCR Kit using specific primers for the RAD9B variants. For lanes 4, 5 and 6, 1 µg of total 
RNA extracted from three different cell lines were reverse transcribed by the Bioline cDNA synthesis 
kit, followed by amplification using Bioline Red Mix polymerase in two separate steps. ACTB was 
used as a positive control for cDNA quality. (B) For lane 1, 1 µg of total RNA extracted from 
HEK293 cells was reversed transcribed by the Bioline cDNA synthesis kit, followed by RAD9B 
amplification with Bioline Red Mix polymerase in two separate steps. Lane 2, 200 ng of total human 
RNA extracted from HEK293 cell were transcribed and amplified by Bioline One-Step RT-PCR kit 
using specific primers for RAD9B-001. For lane 3, 1 µg of total RNA extracted from HEK293 cell was 
transcribed by the Bioline cDNA synthesis kit, followed by RAD9B amplification using the Bioline 
One-Step polymerase in two separate steps. All RAD9B variants were run on a 0.8% agarose gel. The 
ACTB control was run one a 1.5% agarose gel. The size of each amplified variant is shown to the right 
side. 
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3.2.5 A possible novel RAD9B splice variant expressed in HEK293 and 
HeLa cell lines 
The (L-003-009) primers (Figure 3.2-A) designed to amplify RAD9B-003 (1290 bp) also bind 
to RAD9B-009 but amplify a shorter fragment (974 bp). This pair of primers also binds to 
RAD9B-001, RAD9B-002 and RAD9B-005, resulting in a larger amplicon of ~ 2220 bp. 
However, no other fragment can be amplified when aligning the pair of primers to all nine 
RAD9B splice variants. Interestingly, RT-PCR experiments using the (L-003-009) primers 
revealed a novel, shorter RAD9B splice variant with a size of 540 bp (Figure 3.6). This short 
fragment was sequenced a number of times using the same forward and reverse primers. This 
revealed an identical region (500 bp) to the RAD9B-003 5’ region but with some alterations at 
the very end of the RAD9B-S003 3’ end (40 bp) (Appendix 11). The new splice variant will be 
referred to as RAD9B-S003. 
 
 
Figure 3.6 Expression of short RAD9B-003 fragment in HEK293 and Hela cells. Total RNA was 
extracted from HEK293 and HeLa cells and 200 ng was used for the amplification of RAD9B-003 
using the One-Step RT-PCR Kit. The RT-PCR revealed a new short RAD9B-003 (RAD9B-S003) with 
an approximate size of 540 bp. (B) Diagram showing the RAD9B-S003 sequence seen in (Red), 
covering 500 bp of the RAD9B-003 5’ end. No expression of RAD9B-009 can be seen in the HEK293 
or HeLa cell lines. The top band on the agarose gel represents RAD9B-001, RAD9B-002 and RAD9B-
003.   
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3.2.6 Expression of RAD9B variants in several human tissues 
Having identified the right conditions to amplify the RAD9B splice variants, the differential 
expression of the RAD9B variants was validated among 20 different human tissues to discover 
any tissue specificity as indicated by the published data (Table 3.3), (Hopkins et al., 2003; 
Dufault et al. 2003). For this, the primers (S & L) were used (Figure 3.2). The first primers set 
(L) amplified the long regions of the RAD9B variants using the one-step RT-PCR and the 
other set (S) amplified small regions of the variants with the two-step RT-PCR protocol. The 
primers used are specific for each of the RAD9B-001, RAD9B-003 and RAD9B-009 variants, 
but RAD9B-002 and RAD9B-005 were amplified with an almost identical sequence and size 
(Figure 3.2-A).  
 
The RT-PCR revealed the expression of RAD9B-001 and RAD9B-002/RAD9B-005 in most of 
the 20 tissues tested whereas RAD9B-003 was detected only in few tissues (Figure 3.7). The 
primers designed for the RAD9B-003 variant also detects the RAD9B-009 variant (974 bp) 
and, as in the previous RT-PCRs across the HEK239, HeLa and Kelly cell lines, the full 
length RAD9B-009 variant was not detected in any of the 20 tissues. Among all the tissues, all 
RAD9B splice variants were highly expressed in testis tissue relative to the other tissues. 
Surprisingly, testis tissue did not express the full-length RAD9B-009 transcript.  
 
The RAD9B-001 variant was expressed in 19 of the 20 normal tissues, and the highest 
expression levels were detected in the testis and whole brain. No expression could be detected 
in the placenta tissue and only minor expression was seen in the bone marrow, adrenal gland, 
salivary gland, spleen and small intestine issues. The rest of the tissues had a moderate 
expression of this variant. 
 
The expression of RAD9B-002 or RAD9B-005 was not seen in placenta tissue but was 
detected in the other tissues in a similar tissue-specificity to RAD9B-001. Interestingly 
RAD9B-003 expression was detected in fetal brain and testis tissue, and it was almost 
undetectable in salivary gland, brain (whole) and lung tissue. The small inducible transcript 
(RAD9B-S003) of this variant was highly detected in testis and almost undetectable in the 
salivary gland, fetal brain, fetal liver and lung.  
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Since the expression of the RAD9B-009 full-length transcript was not detected, primers 
detecting a small region at the 3’ end of this variant were used (Figure 3.2-B). The two-step 
RT-PCR protocol gave interesting results as the RAD9B-009 3’ end region was expressed in 
most tissues, with the highest expression levels detected in testis and colon tissues. The 
primers designed to amplify the RAD9B-009 variant (123 bp) also amplifies a 233 bp sized 
fragment at the 3’ end region of the RAD9B-003 variant (Figure 3.2-B). Interestingly, It seems 
that both variants are jointly expressed in both colon and testis tissue. This 3’ end region of 
the RAD9B-003 variant was not amplified in any of the other tissues. 
 
Table 3.3 Source of total RNA for the amplification of the RAD9B splice variants 
TISSUE SOURCE AGE 
Heart Pooled from 3 male Caucasians 30, 30, 39 
Adrenal gland Pooled from 62 male/female Caucasians 15–61 
Salivary gland Pooled from 24 male/female Caucasians 16–60 
Bone marrow Pooled from 4 male/female Caucasians 58–76 
Brain (whole) Pooled from 4 male Asians 21–29 
Foetal brain Pooled from 21 spontaneously aborted male/female 
Caucasians 
26–40 
Foetal liver Pooled from 3 male/female Asians 20–38 
Kidney 40-year-old female Caucasians - 
Liver Pooled from 3 male Asians 24–64 
Lung Pooled from 3 male/female Caucasians 32–61 
Placenta Pooled from 3 Caucasians 23–30 
Prostate Pooled from 12 male Caucasians 20–58 
Skeletal muscle 20-year-old male Caucasians - 
Spleen Pooled from 15 male/female Caucasians 22–69 
Testis Pooled from 7 Asians Caucasians 24–87 
Thymus Pooled from 2 male Caucasians 18–57 
Uterus Pooled from 8 Caucasians 23–63 
Colon Pooled from 3 male Asians 24–29 
Small intestine Pooled from 5 male/female Caucasians 20–61 
Spinal cord Pooled from 7 male Asian/Caucasians 20–59 
Stomach 50-year-old male Caucasians - 
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Figure 3.7 Expression of RAD9B splice variants in multiple human tissues. The diagram is 
based on the expression of RAD9B in several human tissues (Human Total RNA Master Panel II, 
Clontech Laboratories) was analysed using two amplification methods; the sensitive one-step RT-
PCR method to amplify long transcripts and the less sensitive two-step RT-PCR method to amplify 
short regions of RAD9B. (A) The expressions of RAD9B-001, 002/005, 003 and 009 across several 
normal human tissues based on the detection of the full length CDS of the RAD9B splice variants 
using the sensitive one-step RT-PCR method. (B) The expressions of RAD9B in the same tissues 
based on the detection of small internal regions of the RAD9B splice variants. The amplification 
was performed using the less sensitive two-step RT-PCR method. The values (0–3) represent the 
expression levels, where 0 signifies no expression and 3 indicates very high expression. The 
expression levels were based on the intensity of the amplified PCR fragments detected on agarose 
gel. The intensity of the bands was estimated using the ImageJ 2.0 software program. The full 
results of the agarose gel analysis can be seen in Appendix 1. 
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3.2.7 Expression of the Rad9-Rad1-Hus1-interacting nuclear orphan 1 
(C12ORF32) in normal human tissues 
The C12ORF32/RHINO protein co-localises with the 9-1-1 ring in human cells after UV 
treatment interacts physically with the ring and is required for the full phosphorylation of 
CHK1 at Ser-317 (Cotta-Ramusino et al., 2011). A previous study reported that C12ORF32 
expression is hardly detectable in 16 normal human tissues that were tested in their study 
(Kim et al., 2010). Since 13 of the 16 tested normal tissues were the same tissues used for the 
detection of the RAD9B variants (Figure 3.7), the expression of C12ORF32 was further 
analysed in all the 20 human tissues used to test the expression of the RAD9B variants. This 
will help to further test the efficiency of the modified RT-PCR conditions used to amplify 
such weakly expressed genes, and also to compare the expression of these two genes 
searching for any tissue-dependent expression similarity. 
 
Interestingly C12ORF32 was expressed in 19 of the 20 normal human tissues. The expression 
was relatively good in some tissues (Brain (whole), fetal brain, fetal liver, kidney, prostate, 
testis, thymus and small intestine) and less so in others, contrary to the results of the 2010 
study (Figure 3.8).  
 
Similarly to RAD9B-001 and RAD9B-002/005, elevated expression levels of C12ORF32 were 
detected in both brain and testis. C12ORF32 was also highly expressed in the thymus in 
contrast to the RAD9B variants, and liver was the only tissue not showing any expression of 
the C12ORF32 gene. The rest of the tissues reflected moderate to weak expression of this 
gene. These outcomes show that C12ORF32 and RAD9B expressions do not share tissue-
dependent similarity, and that C12ORF32 is expressed in non-malignant human tissues. 
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Figure 3.8 Expression analysis of human C12ORF32 in various normal human tissues. Agarose 
gel shows the RT-PCR of the Rad9-Rad1-Hus1-interaction nuclear orphan across various human 
tissues. cDNA was reverse transcribed from the Human Total RNA Master Panel II (Clontech 
Laboratories). ACTB was used as a positive control for cDNA quality. The expected size (bp) of the 
amplified gene name is shown to the right. 
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3.2.8 RAD9B-001 and RAD9B-002 expression is downregulated in 
confluent HEK293 cells but not HeLa cells 
In previous experiments, expression of the RAD9B variants was low in dividing cells of 
normal and cancer cell lines. Therefore, it was investigated whether their levels change once 
cells have ceased division and entered the confluent state. Normal HEK293 and cancer HeLa 
cell lines were used. To obtain confluent conditions, both cell lines were grown for seven 
days until the cells stopped dividing due to contact inhibition.  
 
The one-step RT-PCR results for the confluent cells when compared to dividing cells revealed 
a confluence-dependent mRNA decrease for RAD9B-001. The expression of the RAD9B-001 
variant seemed negatively influenced by confluency in HEK293 cells, but not in HeLa cells 
(Figure 3.9-B). The RAD9B-002/005 variants also seemed to have lower expression in post-
confluent HEK293 cells. However, it is unknown which of the two variants is affected as the 
(L-002-005) primers (Figure 3.2-A) detects both variants nearly at the same length (1254 bp). 
The levels of RAD9B-003 did not show any changes, neither did RAD9B-S003 (Figure 3.9-B).  
 
As in the previous experiments, full length RAD9B-009 could not be detected. Two-step RT-
PCR amplifying the short region of RAD9B-009 revealed no changes under these cellular 
confluent conditions (Figure 3.9-C).  
 
The ACTB expression did not change in the confluent cells confirming the accuracy of the 
low expression results obtained for RAD9B-001 and RAD9B-002/005. 
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Figure 3.9 RT-PCR analysis of the RAD9B splice variants in subconfluent and confluent cells. 
(A) HEK293 and HeLa cell lines were plated and allowed to grow for 3–4 days until the subconfluent 
stage or for 7 days until the confluent stage. Images were taken with a CMEX-5000 Camera 
(Euromex) placed on an Eclipse TS100 Microscope (Nikon). (B) One-step RT-PCR analysis of 
RAD9B variants in HEK293 and HeLa subconfluent and confluent cells. Primers to amplify full-length 
variant transcripts were used. (C) Total RNA extracted from HEK293 and HeLa subconfluent and 
confluent cells was reverse transcribed, followed by PCR amplification of RAD9B-009 variants. ACTB 
was used as a control for RNA and cDNA quality. Name of amplified gene and the expected size (bp) 
can be seen to the right. 
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3.2.9 Cellular senescence up-regulates RAD9B-001 and RAD9B-009 
expression levels 
To investigate whether cellular senescence influences the expression of the RAD9B variants, 
cellular senescence was triggered in the HEK293, HeLa and Kelly cell lines. Non-
proliferating enlarged, vacuolated cells are two markers for cellular senescence. Therefore, 
the capability of oxidative stress to induce cellular senescence was examined in these cell 
lines by exposing them to a sublethal dose of hydrogen peroxide (200 µM H2O2, 1 hr). Out of 
the three cell lines, neuroblastoma Kelly cells were extremely sensitive to H2O2 with all cells 
dead at 24 hr after addition of hydrogen peroxide. The senescence markers were visibly 
induced in HEK293 and HeLa cells 48 hr after addition of the hydrogen peroxide (Figure 
3.10-A).  
 
In addition to these markers, the effect of oxidative stress was examined on the main 
regulatory proteins of cellular senescence: p21 and p16 (Campisi, 2013). Protein samples 
were extracted from both normal HEK293 and HeLa cell lines at 48 hr and 72 hr after 
treatment. Western blot analysis showed moderately elevated levels of p21 and p16 in 
HEK293 cells 48 hr after treatment. Contrarily, in HeLa cells under the same conditions, p21 
expression was down-regulated 48 hr after treatment and levels were back to normal after 72 
hr, but no changes were seen in p16 expression (Figure 3.10-B). Taken together, these 
findings indicate that cellular senescence was induced in HEK293 cells and possibly in HeLa 
by a different mechanism.   
 
To investigate whether the RAD9B variants are up-regulated or down-regulated under 
senescent conditions, mRNA levels were analysed using one step and two step RT-PCR. The 
analysis revealed the up-regulation of RAD9B-001 48 hr after treatment in HEK293 and HeLa 
cells. The smaller band appearing on the agarose gel did not change under senescent 
conditions in HEK293 cells, but was down-regulated at the 72 hr time point in HeLa cells 
(Figure 3.10-C). However, the DNA sequence of the smaller band (~750bp) revealed that it 
was an unrelated ribosomal gene (RPL3). Expression of RAD9B-002/005 and RAD9B-003 did 
not change under senescence conditions, but the short splice variant RAD9B-S003 increased 
72 hr after treatment in HEK cells. In Hela cells, RAD9B-002 was slightly down-regulated 48 
hr post treatment, mimicking the p21 protein expression levels, as seen in Figure 3.10-C.  
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The full-length RAD9B-009 variant was not expressed in either of the two cell lines under 
normal conditions nor under senescence. Two step RT-PCR amplifying the short region of 
RAD9B-009 revealed an up-regulation in HEK293 cells with a possible new splice variant 
that could have a specific role for inducing cellular senescence (Figure 3.10-D). 
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Figure 3.10 Upregulation of RAD9B variant in oxidative stress-induced senescent cells. Cellular 
senescence was induced in HEK293 and HeLa cells with 200 µM H2O2. Cells were treated for 1 hr 
and then allowed to recover for 48 and 72 hrs. (A) Cells were either grown under normal conditions 
for 72 hr (Control) or treated with H2O2 for 1 hr and proliferated for 48 and 72 hrs after treatment. 
Images were taken with a CMEX-5000 Camera (Euromex) placed on an Eclipse TS100 Microscope 
(Nikon). (B) Protein levels of p21 and p16 in HEK293 and HeLa senescent cells analysed by western 
blotting. (C) One-step RT-PCR analysis of RAD9B variants in HEK293 and HeLa normal and 
senescent cells. Primers to amplify the full length variant transcripts were used. (D) Total RNA 
extracted from HEK293 and HeLa normal and senescent cells was reverse transcribed, followed by 
PCR amplification of the RAD9B variants. Internal primers amplifying short regions of RAD9B-003 
and RAD9B-009 were used. ACTB was used as a control for RNA and cDNA quality. Name of gene 
and the expected size (bp) can be seen to the right. 
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3.2.10   RAD9B splice variants are highly expressed in G1 phase 
Overexpression of human RAD9B was found to cause a G1 cell arrest (Perez-Castro & Freire, 
2012). To investigate whether the different RAD9B splice variants are specifically expressed 
in the G1 phase, both HEK293 and HeLa cells were synchronised in G1 by serum starvation. 
The two cell lines were plated and allowed to attach for a few hours. Then the cells were 
grown in FBS-free medium for 24 hr, followed by release in rich medium for 6 hr. The cells, 
including the control cells grown in complete medium, were fixed immediately after the 24 hr 
starvation period and 6 hr after release. Total RNA was extracted at these times as well.  
 
The fixed cells were analysed by flow cytometry, revealing the success of G1 arrest in both 
HEK293 and HeLa cells, as the G1 DNA content increased after the 24 hr starvation period. 
However, HeLa cells showed a stronger increase compared to HEK293 cells (Figure 3.11). 
 
The RAD9B-001 expression levels increased slightly in G1-synchronised HEK293 cells 
though the expression returned to normal 6 hr after release. Based on the histogram, the cells 
started entering the normal cell cycle at this point. The signal for RAD9B-002/RAD9B-005 
also increased slightly in G1, but the expression dropped significantly when the cells entered 
the cell cycle. The RAD9B-003 and RAD9B-S003 expression increased in G1 and remained 
high when cells entered the cell cycle. No change in the expression of RAD9B-009 was 
observed. These results indicate that especially expression of RAD9B-002/005 may change 
throughout the cell cycle with an expression peak in the G1 phase. 
 
Starved HeLa cells showed a similar change in RAD9B-001 expression as HEK293 cells. 
Expression of RAD9B-001 peaked in G1 enriched cells. Interestingly, expression of RAD9B-
002/005 strongly increased in serum starved HeLa cells and remained high 6 hr after release 
(Figure 3.12-A). RAD9B-003 and RAD9B-009 also showed an increase in their expression in 
G1 and after the release. These results strongly indicate a role of RAD9B-001 and RAD9B-
002/005 in the G1 phase of the cell cycle in both HEK293 and Hela cells.  
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Figure 3.11 Serum starvation-induced G1 cell cycle arrest in HEK293 and HeLa cells. Cells were 
grown in FBS-free medium for 24 hr, followed by release into rich medium. Cells were fixed with 
methanol at 0 h and 6 hr after release in addition to normal control cells and analysed by the flow 
cytometry. G1 arrest can be seen clearly with the 0 hr sample immediately after the end of the serum-
starvation period whereas cell started entering the normal cell cycle 6 hr after release. The histogram 
of the cell cycle phases was done after gating on propidium iodide-stained cells with the Flowing 
software 2.5.1.   
 
 
 
 
 90 
 
 
 
Figure 3.12 Up-regulation of RAD9B variant in G1-arrested cells by serum starvation. RT-PCR 
analysis of the of RAD9B splice variants in G1 cell cycle arrested cells. Total RNA was extracted from 
normal cells and G1-arrested cells immediately after the end of the arrest period and at 6 hr post 
release. (A) One-step RT-PCR analysis of RAD9B splice variants in HEK293 and HeLa normal and 
G1-arrested cells. Primers to amplify full-length variant transcripts were used. (B) Total RNA 
extracted from HEK293 and HeLa normal and G1-synchronised cells was reverse transcribed followed 
by PCR amplification. Internal primers amplifying short regions of RAD9B-003 and RAD9B-009 were 
used. ACTB was used as a control for RNA and cDNA quality. Name of gene and the expected size 
(bp) can be seen to the right.    
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 Discussion 
The key findings of this chapter are: (1) all five RAD9B are expressed at the mRNA level in 
HEK293 human embryonic kidney cells, HeLa cervical cancer cells and Kelly neuroblastoma 
cancer cells as well as in wide range of different human fetal and adult tissues. (2) The 5’ end 
region of RAD9B encodes for a short novel splice variant (RAD9B-S003) which is only 
expressed in a limited number of tissues. (3) Unlike the reported specific expression of the 
RAD9-HUS1-RAD1 interacting nuclear orphan 1 (C12ORF32/RHINO) in breast cancer cell 
lines, here its expression is detected in almost all normal human tissues that have been tested. 
(4)  RAD9B-001 and RAD9B-002/005 expression is down-regulated in non-dividing cells but 
not RAD9B-003 or RAD9B-009 indicating their role in the regulation of the ongoing cell cycle 
(5) The serum starvation response of RAD9B splice variants suggests a possible involvement 
in the regulation of G1 phase by RAD9B splice variants in HEK293 and HeLa cells. (6) Since 
RAD9B splice variants were up-regulated during senescence, and given their high expression 
in fetal tissues, this indicates a possible new role of RAD9B splice variants in the reported 
senescent stages during embryonic development.    
 
Cloning of human RAD9B in 2003 revealed the existence of a second RAD9 gene in the 
human genome which is closely related to RAD9A. The cloned RAD9B cDNA turned later out 
to be identical to RAD9B-002 although the first three amino acids (MAA) are absent from the 
published sequence. In addition to the RAD9B-002 transcript, the human RAD9B gene 
encodes four protein coding variants of which RAD9B-001 has been studied here (Dufault et 
al., 2003) .  
 
Table 3.4 Human RAD9B splice variants analysed in this study 
hRad9B Variant Specific Amplification Amino Acids Comment 
RAD9B-001 yes 345 - 
RAD9B-002 no (jointly with 005) 417 Full-length RAD9B 
RAD9B-003 yes 429 - 
RAD9B-005 no (jointly with 002) 345 ORF identical to 001 
RAD9B-009 yes 341 - 
 
 
The amplification of the RAD9B splice variants using the two RT-PCR techniques            
(one-step and two-step RT-PCR) showed the higher efficiency of using the one-step RT-PCR 
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in a situation where very low expressed genes were amplified. Among most databases of gene 
expression, at both the mRNA and protein levels, expression of RAD9B was reported in a 
very limited number of tissues. The results obtained at the beginning of this project were 
indeed consistent with these databases as RAD9B could not be amplified from a large number 
of the cell lines that were tested. However, several attempts at amplification of the low 
expressed RAD9B splice variants revealed possible alternative RT PCR conditions that could 
be used for the successful amplification of such low expressed genes. Therefore, it cannot be 
concluded that a certain gene is not expressed in a certain tissue, as shown in the results 
chapter regarding the amplification of the RAD9B splice variants and the amplification of the 
C12ORF32, as these showed that low expressed genes require special amplification 
conditions.  
 
A significant difference in efficiency between the one-step and two-step RT PCRs was 
evident in the amplification of the RAD9B splice variants. The amplification of the full coding 
sequence of the splice variants was either negative or almost undetectable when amplified by 
the two-step RT-PCR, while in comparison, the one-step RT-PCR revealed a decent 
amplification signal for the RAD9B splice variants. This is a result of all the cDNA from the 
RT reaction being used in the PCR reaction providing sensitive detection.  However, when 
applying the one-step method, the quality of the RNA must be taken into account. The 
extracted RNA must be free of any contaminants such as buffer salts and phenol that would 
affect the sensitivity of the RT reaction. In addition, the temperature of the primers should be 
taken into account when designing primers for the one-step PCR to avoid primer dimer 
formation during the PCR procedure as the primers are present during the RT reaction step at 
low temperatures. 
          
The two-step RT PCR revealed less sensitivity for the amplification of low expressed genes 
than the one-step method. However, some alterations in the two-step RT-PCR can enhance 
the amplification of such genes. Generally, in the RT-PCR reaction, oligo dT primers or 
random hexamers are used. The oligo dT primers prime at the 3’ tail of the mRNA, initiating 
reverse transcription until the reverse transcriptase enzyme efficiency drops, and are therefore 
not ideal for the amplification of long mRNA transcripts.  
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The random hexamer primers prime randomly along the mRNA, producing small, unequally 
amplified cDNA fragments. The choice of usage between the two primers depends on the 
specific primer binding regions on the mRNA transcript. The specific primers that were used 
for the detection of the RAD9B splice variants differ in their binding sites. Therefore, to 
ensure an efficient amplification of the RAD9B splice variants, a mixture of oligo dT and 
random hexamer primers were used for the RT reaction, which resulted in positive outcomes 
for the amplification of the RAD9B splice variants. Moreover, the dilution of the cDNA plays 
an important role in the amplification of low expressed genes. Minimising the cDNA dilution 
can contribute to the enhancement of the PCR detection of low expressed genes. Most 
published RT-PCR results use a cDNA dilution factor greater than 1:5. As a consequence, 
some genes can be reported to be expressed in only a few tissues, which is a false 
interpretation of the results due to the cDNA concentration that was used in the analyses. 
However, in this project, when a low dilution of 1:2 of cDNA was used, RAD9B and 
C12ORF32 were detected in a large number of tissues.  
 
The similarity between RAD9A and RAD9B is higher in their N-terminal sections, which 
both form the 9-1-1 ring, whereas their C-terminal tails are much more diverse. Interestingly, 
only one phosphorylation site of RAD9A, Ser-387, is conserved in RAD9B (Ser-409). 
Northern blot analysis showed three RAD9B transcripts (4.4, 3.0, and 2.2 kb) in testis and 
skeletal muscle, two transcripts in heart (4.4, 2.2 kb) and one larger transcript in brain         
(5.0 kb). RAD9B expression was also detected in K562, HeLa, OVCAR5, and HEK293 cell 
lines (Dufault et al., 2003). Using a more sensitive one-step RT PCR test with specific 
flanking primers, expression of RAD9B could be detected in more tissues as originally known 
(Figure 3.7). 
 
While full-length RAD9B-002/005 was expressed in all tested tissues with the exception of 
the placenta, the highest levels were detected in brain, kidney, lung and testis, fetal brain and 
liver (Figure 3.7). All variants except RAD9B-009 were present in testis. The N-terminally 
truncated variant RAD9B-001 was also present in most tissues with the exception of placenta. 
It highest levels were found in the brain and estis. The longest variant RAD9B-003 was 
weakly expressed in the salivary gland, brain, fetal brain and lung. Taken together, the 
RAD9B variants do have a tissue specific expression pattern although the two variants 
analysed here, RAD9B-001 and RAD9B-002 are found in most tissues. 
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The C12ORF32/RHINO gene has previously been shown to be involved in mammary 
carcinogenesis. Very high expression was detected in 11 breast cancer cell lines by two-step 
RT-PCR and northern blot compared to extremely weak detected expression in only few 
normal tissues (Kim et al., 2010). Interestingly, depletion of C12ORF32 significantly 
supressed the growth of breast cancer cell lines by cells accumulating in sub-G1 population 
indicating cell death. Despite reported weak expression of C12ORF32 in normal tissues, here, 
its expression was detected in 19 out of 20 normal tissues that were tested. The inconsistency 
with the published results is due to using a high template concentration that has been shown to 
be effective in the case of low expressed genes (Figure 3.3). The expression of C12ORF32 
was highly abundant in brain (whole), fetal brain, fetal liver and testis similarly to the 
expression of RAD9B but also showed different expression specificity in other tissues. It is 
unclear from this RNA panel experiment whether an expression relation exist between 
RAD9B and C12ORF32, however, a possible role between the two may exist in the brain and 
fetal tissues.   
   
The high expression levels of RAD9B-001, RAD9B-002/005 and RAD9B-003 in the devolving 
and mature brain are in line with a study by Leloup et al. who showed that mouse RAD9B 
plays an important role in brain development (Leloup et al., 2010). Interestingly, full length 
RAD9B-003 was found only in the testis and the fetal brain, and it was barely detectable in the 
salivary gland, the whole brain and the lung. This suggests that this splice variant may play a 
role in brain development. However, when small internal primers were used for the detection 
of the RAD9B-003 splice variant, it was found expressed only in testis and colon indicating 
that a new splice variants may exist in these tissues. 
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              10        20        30        40        50        60 
RAD9B-003 MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 
          :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-002 MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 
               10        20        30        40        50        60 
 
               70        80        90       100       110       120 
RAD9B-003 FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 
          :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-002 FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 
               70        80        90       100       110       120 
 
              130       140       150       160       170       180 
RAD9B-003 VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 
          :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-002 VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 
              130       140       150       160       170       180 
 
              190       200       210       220       230       240 
RAD9B-003 LAVTPLNFCLKSSNEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 
          :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-002 LAVTPLNFCLKSSNEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 
              190       200       210       220       230       240 
 
              250       260       270       280       290       300 
RAD9B-003 EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 
           :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-002 EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 
              250       260       270       280       290       300 
 
              310       320       330       340       350       360 
RAD9B-003 IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 
           :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-002 IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 
              310       320       330       340       350       360 
 
              370       380       390       400       410       420 
RAD9B-003 VSNTEEVPGSLCLRKFSCMFFGAVSSDQQEHFNHPFDSLARASDSEEDMNNVCCRKEFNG 
          :::::::::::::::::::::::::::::::::::::::::::::::::::        : 
RAD9B-002 VSNTEEVPGSLCLRKFSCMFFGAVSSDQQEHFNHPFDSLARASDSEEDMNN--------G 
              370       380       390       400       410           
 
                 
RAD9B-003 SDAKYFCII 
          :    : :. 
RAD9B-002 S----FSIF 
 
Figure 3.14 Alignment of RAD9B-002 and RAD9B-003. The alignment was created using ALIGN 
tool (http://xylian.igh.cnrs.fr/bin/align-guess.cgi. Accessed 20 August 2016). The two splice variants 
differ only at the very end of the C-terminus. 
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It is worth noting that the variant RAD9B-003 differs only by 13 amino acids at its very end 
from the full-length RAD9B protein RAD9B-002 (Figure 3.14). This implies that the           
C-terminus, which is highly charged in the case of RAD9B-003, plays an important role in 
brain development. 
 
The expression analysis reported here identified a shorter version of the RAD9B-003 
transcript, RAD9B-S003, in which its expression starts at the ATG start code of the ORF of 
RAD9B-003 but terminates approximately half way through the full length sequence. This 
suggests that RAD9B-S003 is a new RAD9B splice variant. The RAD9B-S003 is highly 
expressed in testis tissue, moderately expressed in the HEK293 and HeLa cells, and hardly 
detectable in the salivary gland, fetal brain, fetal liver and lung tissues. Its size appears to be 
smaller in the fetal brain (Appendix 1) while its expression follows the expression of the full-
length RAD9B-003, it is absent in adult brain (Figure 3.7). Being detected in the two and only 
fetal tissues in the RNA tissue array, this short RAD9B splice variant may play a similar role 
to the RAD9B-003 that is involved in the early developmental stages. In recent studies, a large 
number of short open reading frames (sORF) of between 15 and 138 amino acids have been 
identified in human tissues. These small ORFs were reported to play a role in the cell 
signalling and DNA repair. RAD9B-S003 may belong to this novel class of short peptides and 
proteins although it was not reported in these publications (Ma et al., 2014; Slavoff et al., 
2013).   
 
Since it was reported that over-expression of RAD9B results in a G1 cell cycle arrest (Perez-
Castro & Freire, 2012), the possible involvement of RAD9B in a G1 arrest was tested in 
HEK293 and HeLa cells by serum starvation. The two cell lines revealed interesting 
differences regarding the expression of the RAD9B splice variants. In HEK293 (non-
malignant cells) and HeLa (cervical cancer cells), RAD9B-001, RAD9B-005/002 and RAD9B-
003 showed elevated expression levels when cells were starved (Figure 3.12-A). This 
indicates a role of these variants in G1 or in the response to starvation. HeLa cells were 
different from HEK293 cells in that they showed also elevated expression of RAD9B-009 
(Figure 3.12-B). The latter is interesting as full-length RAD9B-009 was not detected in any 
tested tissue (Figure 3.7) suggesting a possible involvement in the regulation of the G1 phase.  
 
The accurate transition of the cell cycle from the G1 to S phase is crucial for cell proliferation, 
and its misregulation can lead to oncogenesis (Bertoli, Skotheim & de Bruin, 2013). RAD9B-
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002 levels may have a crucial impact on the G1-S transition in HEK293 cells. This was 
concluded after the reduction in RAD9B-002/005 expression during this cell cycle transition 
in HEK293 cells (Figure 3.12-A). In contrast, RAD9B-002/005 levels increased during G1 in 
malignant HeLa cells during the transition to the S phase suggesting that G1-S transition is 
independent of RAD9B-002/005 in this cell line (Figure 3.12-A). In addition, analysis of 
RAD9B-003 and RAD9B-009 also revealed high expression levels during G1-S transition in 
the HeLa cells while RAD9B-001 did not (Figure 3.11-A & B).  Although cells grown to the 
confluent stage generally reveal a G1 cell cycle arrest (Hayes et al., 2005), the analysis of 
RAD9B splice variants in these contact inhibited cells revealed a different expression profile 
from  that obtained in G1 cells arrested by serum starvation. Both splice variants RAD9B-001 
and RAD9B-002/005 expression levels were reduced (Figure 3.9), suggesting a different role 
of RAD9B-001 and RAD9B-002/005 in the permanent G1 block as in contact inhibited cells.  
  
As mentioned previously, mouse Rad9b is crucial for embryonic development and is mainly 
expressed in the embryonic tissues at week 7.5 and particularly in brain tissue at weeks 8.5 
and 9.5, whereas depletion of mouse Rad9b in embryos results in their early death (Leloup et 
al., 2010). The analysis of the RNA tissue samples supports this finding as all human RAD9B 
splice variants were expressed in fetal brain tissue. Given that senescence plays an important 
role in embryogenesis in a p21 dependent manner independently of DNA damage (Muñoz-
Espín et al., 2013; Storer et al., 2013),  it is interesting that RAD9B-001, RAD9B-009 and 
RAD9B-S003 were upregulated at the mRNA level in senescent HEK293 cells (Figure 3.10-
C). Also RAD9B-009 revealed an additional band in senescent HEK293 cells indicating a 
possible new role of RAD9B splice variants during embryonic development (Figure 3.10-D). 
This conclusion is supported by the co-compartmentalisation of over-expressed RAD9B and 
p21 in nucleoli (Perez-Castro & Freire, 2012).          
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Chapter 4: CONSTRUCTION OF STABLE HUMAN 
CELL LINES EXPRESSING RAD9B-001, RAD9B-
002 AND YEAST RAD9-M50 
 
 Introduction 
S. pombe Rad9-M50 is a heat-inducible protein variant of the DNA damage checkpoint 
protein Rad9 which regulates a heat induced G2 arrest and is linked with the de-
phosphorylation of Chk1 kinase at elevated temperature (Janes et al., 2012). So far, human 
RAD9B has not been found to have a similar role as a heat-inducible protein. However, the 
RAD9B variant 001 shares  similar features with yeast Rad9-M50 as both proteins lack 
extended sections of the N-terminus (49 aa SpRad9-M50; 72 aa RAD9B-001). While 
RAD9B-001 is produced by alternative splicing, yeast Rad9-M50 is an alternative translation 
product initiated from the cryptic start site AUG-50.  
 
The expression of the full-length RAD9B-001 splice variant was highest in brain, heart, 
skeletal muscle and testis, and up-regulated in serum starved G1 cells (Figure 3.7 & Figure 
3.11). The second RAD9B splice variant, RAD9B-002, resembles RAD9A.  It is identical to 
RAD9B-001, except that it contains an additional 72 aa at the N-terminus. The corresponding 
mRNA follows a similar expression pattern as RAD9B-001 but with higher expression levels 
in lung, liver and kidney (Figure 3.7). It is quite intriguing that the RAD9B-002 and RAD9B-
001 proteins resemble the S. pombe full-length RAD9 and Rad9-M50 proteins as this implies 
a conserved requirement for a N-terminally shortened RAD9 variant. As shown in Figure 4.1, 
both shorter RAD9 proteins may adopt in a similar structure consisting of two domains.  
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Figure 4.1 Models of human RAD9B-001 and S. pombe Rad9-M50. Both models were generated 
using the Swiss Model server (https://swissmodel.expasy.org. Accessed 30 August 2016). Both 
models are based on the crystal structure of human RAD9A (ID:3ggr.1), (Xu et al., 2009).  The 
identity scores are 37.8% for human RAD9B-001 and 27.2% for yeast Rad9-M50. The first and last 
amino acids are indicated. The sequence coverage for RAD9B-001 is T9 - L204 and for Rad9-M50 
V2-V251. Both proteins adopt a similar fold with two domains, domain A and domain B, linked by an 
extended beta-sheet. In the case of the yeast variant, the N-terminal part of the protein may make 
contact with domain B.   
 
 As mentioned before, the human RAD9B gene expresses 9 splice variants of which only 5 
are protein coding (RAD9B-001, 002, 003, 005 and 009). These five splice variants were all 
analysed at the mRNA level in normal and carcinoma cell lines under different conditions 
(Chapter 3). Since the commercially available anti-RAD9B antibodies (antibodies-online 
(AA150-258), Abcam (ab72873)) failed to detect endogenous RAD9B proteins, it was 
decided not to order custom-made antibodies. This approach was also hampered by the high 
similarity of the different protein splice variants (Figure 3.1).  Therefore, two RAD9B splice 
variants (RAD9B-001 and RAD9B-002) were studied at the protein level using an inducible 
protein expression system. Both variants were chosen because of their homology with 
RAD9A and the yeast Rad9M-50 protein, respectively. In addition, a third cell line, 
expressing the yeast Rad9-M50 protein, was constructed to investigate whether human cells 
would be able to utilise the yeast protein in comparison with the related human variant 
RAD9B-001. Moreover, human RAD9A and the yeast Rad9 full length were not included in 
the experiments due to time limitations of the project and also because concentrating on a 
small number of cell lines made it possible to investigate the roles of RAD9B in greater 
depth.  To construct stable cell lines expressing RAD9B-002 (417 aa), RAD9B-001 (345 aa) 
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or S. pombe Rad9-M50 (377 aa), the HEK293 Flp-In integration system from Invitrogen was 
used.  
 
The Flp-In system allows for the integration of any cDNA into the genome of the Flp-In T-
REx HEK293 cell line, taking advantage of the DNA recombination system from 
Saccharomyces cerevisiae (S. cerevisiae) (Sauer, 1994; Craig, 1988). The Flp-In T-REx 
HEK293 cell line has been generated by the insertion of the pFRT/lacZeo vector into its 
genome, as this vector provides the recombination FRT target site for the recombinase 
enzyme expressed from the pOG44 plasmid into the host cell line. Successful integration 
results in a switch from zeocin resistance coming from the laz/Zeocin expression gene under 
the control of the SV40 promotor to hygromycin resistance which is on the integration 
plasmid pcDNA5/FRT/TO.  
 
To insert RAD9B or yeast Rad9M-50 into the genome of the Flp-In T-REx HEK293 cell line, 
the corresponding cDNAs must first be cloned into the pcDNA5/FRT/TO plasmid. This 
vector contains two major components of the Flp-in system: one FRT site serving as a second 
target for the Flp recombinase enzyme and the hygromycin selective gene. Co-transfection of 
the recombinant pcDNA5/FRT/TO plasmid with the pOG44 plasmid expressing the Flp 
recombinase under the control of the CMV promotor (Buchholz et al., 1996) will allow the 
enzyme to initiate recombination between the two FRT sites (one in the genome and one on 
the recombinant plasmid) resulting in the stable integration. The recombinant cell line will 
then show resistance to hygromycin and sensitivity to zeocin. The Flp-In T-REx HEK293 cell 
line contains also the pcDNA6/TR plasmid which expresses high levels of the tetracycline 
suppressor that binds to the CMV promotor upstream of the recombinant cDNA resulting in 
its induction upon addition of doxycycline (Figure 4.2). 
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Figure 4.2 Integration of RAD9B and Rad9M-50 into the Flp-In T-REx HEK293 cells. Co-
transfecting the pcDNA5/FRT/To plasmid carrying RAD9B-001, RAD9B-002 or Rad9-M50 with the 
POG44 plasmid into the Flp-In TrEx HEK293 cells. The POG44 plasmid expresses the Flp enzyme, 
allowing for Flp recombination events between the two FRT sites in the pcDNA5/FRT/To plasmid and 
in the host HEK293 genome. The inserted genes are expressed under the control of the pCMV 
promotor following induction by doxycycline. The stable cell line confers sensitivity to zeocin and 
resistance to hygromycin. 
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 Results 
4.2.1 Construction and amplification of RAD9B-001, RAD9B-002 and 
SpRad9-M50. 
Since the initial attempts to clone the full-length RAD9B-001 cDNA failed (this was before 
the RT-PCR conditions were optimised), overlapping primers were designed to construct the 
cDNA by fusion PCR. To this end, the nine coding exons of RAD9B-001 with complementary 
sequence extension at either primer end were individually amplified and later fused using the 
flanking primers which also contained the restriction sites (Figure 4.3-A & B).  
 
The fusion PCR displayed an amplified fragment with the expected size of this variant (1038 
bp). Subsequent DNA sequencing confirmed the successful construction of the RAD9B-001 
cDNA. However, the DNA sequencing also revealed a four-nucleotide deletion in the 3’ end 
region of the variant and this deletion was repaired by designing new fixing primers as 
summarised in the next section. 
 
Since the RAD9B-002 cDNA could also not be amplified at the beginning of the project, its 
cDNA was purchased  and re-amplified from the acquired plasmid. The amplicon of RAD9B-
002 had the expected size (1254 bp, Figure 4.3-C). Subsequent sequencing confirmed that the 
amplicon is 100% identical to RAD9B-002. The S. pombe Rad9-M50 cDNA (1134 bp) was 
amplified from a yeast cDNA library and sequenced.  As in the case of RAD9B-001, the 
sequence showed three mismatches in the 3’ end section which were also repaired. 
 
As a first step to construct the stable cell lines, the amplified and repaired cDNAs were cloned 
into the plasmid pcDNA5/FRT/TO. The primers for the amplification of the inserts were 
designed to have an additional sequence motif for the restriction enzymes XhoI at the 5’ end 
and NotI at the 3’ end. All three genes were cloned into the pcDNA5/FRT/TO vector 
restricted with XhoI and NotI. Figure 4.4 shows the successful cloning of the cDNAs.  
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Figure 4.3 Construction of RAD9B-001 and the amplification of RAD9B-002 and yeast Rad9-
M50. (A) Diagram showing the primers designed to amplify the 9 exons of RAD9B-001 from the 
HEK293 cell genome. (B) Agarose gel showing the 9 amplified coding exons of the RAD9B-001 
and the successful fusion of these exons by fusion PCR. (C) PCRs for the amplification of RAD9B-
002 and yeast RAD9-M50 were subjected to agarose gel revealing their corresponding transcript 
sizes (1254 bp and 1134 bp, respectively).      
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Figure 4.4 Confirmation of successfully cloning inserts into the pcDNA5/FRT/TO vector. The 
RAD9B-001, RAD9B-002 and Rad9-M50 inserts were cloned into the pcDNA5/FRT/TO plasmid. The 
plasmid was digested with XhoI and NotI restriction enzymes to confirm the cloning. The cut plasmid 
appears on the top of the agarose gel with a size of 6514 bp (pcDNA5/FRT/To 5800 bp and GFP 714 
bp). The bottom bands represent the inserts RAD9B-001 (1038 bp), RAD9B-002 (1254 bp) and Rad9-
M50 (1134 bp). The empty pcDNA5/FRT/To plasmid was also digested with the same enzyme as a 
negative control.  
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Figure 4.5 Diagram of the empty pcDNA5/FRT/TO plasmid and the plasmid after insertion of 
RAD9B-001, RAD9B-002 and Rad9-M50. An overview of the pcDNA5/FRT/TO plasmid inserted 
with RAD9B-001, RAD9B-002 or Rad9-M50 between the NotI and XhoI restriction sites or left without 
insertion as a control. All plasmids contain an identical EGFP tag, except for the EGFP tag in the 
empty pcDNA5/FRT/TO, which is extended by a 28 aa until the first stop codon. 
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4.2.2 Repair of RAD9B-001 and Rad9-M50 
As shown in Figure 4.6, the RAD9B-001 cDNA contained a four-base-pair deletion close to 
the 3’ end which was the binding site of the forward primer number 6 used for the 
construction of the cDNA. The four-base-pair deletion was corrected by designing new 
primers with complementary extensions overlapping the opposite strand. These primers bind a 
few base pairs at either site of the deletion  resulting in two fused overlapping fragments 
amplified by PCR (Figure 4.6). The sequence of the repaired RAD9B-001 was 100% identical 
to the sequence curated at the NCBI data base.   
 
The sequence for the cloned yeast Rad9-M50 cDNA revealed three mismatches in the 3’ end 
region. One of the mismatches was silent while the other two resulted in an amino acid 
substitution (alanine with valine, and arginine with tryptophan). The mismatches were 
corrected with the Q5 Mutagenesis Kit (New England Biolabs), which allows for the 
replacement of one or multiple base pairs in a sequence. Two pairs of primers were designed 
to repair the two mismatches. The forward primer contained the altered codon approximately 
10 nucleotides away from the 3’ end of the primer to allow for the correct binding. The 
reverse primer started at the 5’ end with one base pair next to the beginning of the forward 
primer. This allowed for the correction of the first mismatch. The plasmid having the 
corrected first mismatch was used as a template to correct the second mismatch in the same 
way (Figure 4.7). The DNA sequence of Rad9-M50 revealed a successful repair.   
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Figure 4.6 Repair of RAD9B-001 by fusion PCR. The four missing base pairs in the RAD9B-001 
sequence are shown in green at the top of the figure. The deletion was fixed by using primers that bind 
to a few base pairs before the deletion (forward repair primer) with the original reverse primer, and 
bind to a few base pairs after the deletion (reverse repair primer) with the original forward primer. 
Both fixing primers have an extension of the opposite strand’s complementary sequence. The 
amplified fixed fragments were fused together and re-amplified with fusion PCR. The fusion PCR 
revealed the correct full sequence of RAD9B-001. 
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Figure 4.7 Repair of Rad9-M50 substitutions with the Q5 Mutagenesis Kit. Two mismatches 
within the sequence of Rad9-M50 were fixed using the Q5 Mutagenesis Kit (New England Biolabs). 
The forward primer (black) contains the correct altered base pair (green). The reverse primer (red) 
binds to the base pair next to the start binding region of the forward primer, allowing for the 
amplification of Rad9-M50 with the corrected mismatch. The same corrected plasmid was used as a 
template for the correction of the second substitution using new designed primers containing the right 
sequence. 
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4.2.3 Construction of stable RAD9B and SpRad9-M50 cell lines 
The stable cell lines expressing the two human RAD9B splice variants or the yeast Rad9-M50  
were established by transfecting the EGFP-pcDNA5/FRT/TO plasmid carrying either 
RAD9B-001, RAD9B-002, SpRad9-M50 gene or the empty plasmid (negative control) into 
human Flp-in T-REx HEK293 cells. The plasmids were co-transfected with the pOG44 
plasmid to mediate the homologous recombination event between the two FRT sites, allowing 
the integration of RAD9B or Rad9-M50 into a specific genomic FRT site. It is important to 
emphasise that all engineered cell lines still express the endogenous RAD9A and RAD9B 
proteins. Due to time restriction, the endogenous RAD9 genes were no deleted. 
 
Following the transfection, the cells were allowed to grow for two days. Then the cell-
growing medium was supplemented with hygromycin instead of the zeocin to select for 
integrants.  
 
4.2.4 Confirmation of integrants into the Flb-In T-REx HEK293 cell line 
The successful integration of the two RAD9B splice variants and the yeast Rad9-M50 into the 
Flp-in T-REx HEK293 cell genome was investigated by three methods. First, the whole 
genomic DNA was extracted from the transfected cells. The primers used to analyse the 
integrants were the same primers used for the cloning of the variants (L-001-002-005, L002-
005 and Rad9-M50 primers, Figure 3.2). In an additional test, a forward primer designed to 
bind at the CMV promotor upstream of the EGFP-Rad9 genes was used in combination with 
the reverse cloning primer. The PCR analysis confirmed the integration of all cDNAs (Figure 
4.8-A).   
 
The second method used to confirm the integration was performed at the protein level. Whole 
protein was extracted from the recombinant cell lines in the presence and absence of the 
inductor doxycycline (tetracycline family). All induced cells displayed a positive signal as 
detected with an anti-GFP antibody. The GFP signal in the EGFP-Control cell line appeared 
larger in size, 30 kD instead of 27 kD. This difference in size is a result of the EGFP tag in the 
EGFP-pcDNA5/FRT/TO plasmid. The plasmid does not contain a stop codon as it was 
designed for the integration of cDNAs down-stream of the EGFP tag resulting in an extra 28 
amino acids in the empty plasmid.  
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The non-induced cells showed no GFP signals on the western blot (Figure 4.8-B) Both results 
of the PCRs and western blots confirmed the successful integration of the three cDNAs and 
the empty control plasmid into the genome of the Flp-in TREx HEK293 cells.  
 
Confocal microscopy analysis was the third method used for the confirmation of stable cell 
lines. The cells were induced overnight, followed by fixation with paraformaldehyde, and 
then stained with the anti-GFP antibody. The results were consistent with those obtained from 
the PCRs and western blots (Figure 4.9). Untransfected HEK293 cells were used as a negative 
control and no GFP signal was obtained.  Interestingly all EGFP-Rad9 proteins localised 
predominantly to the cytoplasm in untreated but induced cells. 
 
 
 
Figure 4.8 Confirmation of the integration of EGFP-RAD9B-001, EGFP-RAD9B-002, Rad9-
M50 and EGFP-Control into the cell lines. (A) Genomic DNA was extracted from the integrated 
cell lines and successful integration was confirmed by PCR. Lane 1: Using the forward and reverse 
specific primers of the integrant. Lane 2: Using a forward primer that binds to the CMV promoter in 
combination with the reverse specific primer of the integrants. Lane 3: Using the forward and reverse 
specific primers for the integrant on genomic DNA extracted from the EGFP-Control cell line. 
Amplicon sizes (bp) are indicated on top of the bands. (B) Western blot analysis of the EGFP-
recombinant proteins. Cell lines were either induced with doxycycline or left without induction as a 
negative control. PCNA protein was used as a positive control.     
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Figure 4.9 Immunostaining of the overexpressed EGFP tagged proteins. The cells were grown 
overnight on coverslips in medium containing doxycycline, followed by fixation with 4% 
paraformaldehyde. Then the cells were stained with GFP antibody in combination with the secondary 
Alexa Fluor 568 antibody (red). Images were taken using the LSM710 confocal microscope. Images 
were taken with the 40x objective and processed using the Zen lite software. The HEK293 cell line 
was used as a negative control. 
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4.2.5 Induction kinetics of the Flp-FRT system 
As the integrated proteins were artificially expressed, it was important to test the induction 
conditions before starting the experiments. The time of induction after the addition of 
doxycycline was tested to obtain the optimal time with the highest levels of the expressed 
protein. The EGFP-RAD9B-001 cell line was induced with doxycycline and RNA as well as 
protein were extracted at different times after induction. As shown in Figure 4.10, expression 
of the EGFP-RAD9B-001 mRNA was induced within 2 hr and expression was highest 12 hr 
post induction. The corresponding protein was weakly expressed at the 2 hr time point and 
continued to accumulate reaching its highest level 18 hr post-induction.  
 
To investigate the stability of the integrated protein after the removal of doxycycline, all the 
cell lines were induced for 18 hr, followed by the removal of doxycycline. Proteins were 
extracted at different times up to 72 hr after the removal of the inducer. Surprisingly, the 
experiment revealed the presence of all recombinant proteins up to 72 hr in the absence of the 
inducer. This result indicates a high stability of the expressed proteins in untreated HEK293 
cells (Figure 4.11).   
 
Another feature of this system worth noting is that it has a low basal activity in the absence of 
doxycycline. As can be seen in Figure 4.11, Rad9-M50 was expressed in the absence of 
doxycycline (Non-induced cells) at a quite high level, while lower levels of EGFP-RAD9B-
001 were detected. This background activity may arise from antibiotics in the fetal bovine 
serum. It is however interesting that the levels of the yeast Rad9 variant are so high compared 
to the other constructs.  
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Figure 4.10 Time course induction of the Flp-FRT system. The EGFP-RAD9B-001 cells were 
either treated with doxycycline (1 μg/ml) or left without induction (control). (A) RT-PCR analysis of 
the control and induced RAD9B-001. Samples were extracted at different points post induction, as 
indicated at the top of the figure. ACTB was used as a positive control. Amplicon size is indicated on 
the right side. (B) SDS-PAGE of EGFP-RAD9B-001 in samples prepared from either non-induced 
cells or induced cells for different times post induction, as indicated in numbers at the top of the 
figure. PCNA protein was used as a positive control. Protein sizes are shown in kD to the right.   
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Figure 4.11 Induced protein stability following removal of doxycycline. The transfected cell lines 
were induced with doxycycline (1 μg/ml) for 18 hr, followed by the removal of the inducer. Protein 
was extracted from the four constructed cell lines (EGFP-RAD9B-001, EGFP-RAD9B-002, EGFP-
Rad9-M50 and EGFP-Control) at the indicated times. Samples were analysed on SDS-PAGE and 
immunoblotted with the GFP antibody. Protein extracts were also probed with PCNA antibody used as 
appositive control.             
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4.2.6 A possible cleavage event affects the RAD9B-002 protein 
While conducting the induction experiments, cleavage of the recombinant RAD9B-002 
protein was detected. This cleavage was observed in all RAD9B-002 lysates. The cleavage 
event produced two small forms with molecular weights of 40 kD and 27 kD, suggesting a 
cleavage site with the N-terminal of RAD9B-002, as the EGFP tag which is used for the 
detection of RAD9B-002 on western blot is designed on the N-terminal of RAD9B-002 
(Figure 4.12-A).  
 
Interestingly, a second cleavage event was also detected which produced a fragment similar in 
size to EGFP-RAD9B-001. No cleavage was detected when RAD9B-001 or Rad9-M50 were 
over-expressed (Figure 4.12-A). The cleavage happened regardless of the cells’ passage 
number, being detected in both low and high passage numbers. A possible explanation for this 
cleavage is that expression of the full-length EGFP-hRAD9B-002 protein has a negative 
impact on the host cell and that the cleavage reduces this. As mentioned in section 4.2.7, the 
over-expression of EGFP-RAD9B-002 leads to an accumulation in the sub G1 cell 
population, strongly indicating that this variant induces apoptosis that may force cells to 
cleave this variant to prevent cell death. It is also worth mentioning that a complete loss of the 
integrated EGFP-hRad9B-002 gene was observed, making it possible that the cells somehow 
removed this recombinant gene from their genome. 
 
To investigate the induced RAD9B-002 at the mRNA level, RNA was extracted from the 
induced and non-induced EGFP-RAD9B-002 and from the cleaved EGFP-Rad9B-002 cells. 
RT-PCR revealed the presence of RAD9B-002 mRNA from the cleaved cell line but at a 
lower level than in the intact EGFP-RAD9B-002 cell line. Hence, affected cells may also 
reduce the transcription of the recombinant gene or cells which have lost the recombinant 
gene accumulate in the culture.  
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Figure 4.12 Cleavage of RAD9B-002 protein. (A) Western blot analysis of overexpressed EGFP-
RAD9B-001, EGFP-RAD9B-002, EGFP-Rad9-M50 and EGFP-Control cell lines. The cell lines were 
induced with doxycycline (1 μg/ml) and the protein was extracted at the indicated times. In 
comparison to other cell lines, EGFP-RAD9B-002 revealed two cleaved bands on SDS-PAGE with 
size of 27 and 40 kD. (B) Cleavage of RAD9B-002 revealing a band of 65 kD compared to the full-
length size of 74 kD. (C) The RAD9B-002 protein before and after cleavage in comparison to the size 
of RAD9B-001 and Rad9-M50. (D) Total RNA was extracted from non-induced and induced EGFP-
RAD9B-002 cell lines (Normal and cleaved), followed by amplification of RAD9B-002 with the One-
step RT-PCR Kit in which ACTB was used as a positive PCR control. (E) Diagram showing the 
possible cleavage sites within the RAD9B-002 protein. 
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4.2.7 Analysis of the cell cycle progression in over-expressing cell lines 
The over-expression of RAD9B forces the cells to accumulate in the G1 phase (Perez-Castro 
& Freire, 2012). It should be pointed out here that it is unclear which full-length RAD9B 
variant was used in this experiment. It was therefore investigated whether RAD9B-001 or 
RAD9B-002 proteins have a similar impact on the cell cycle. Both cell lines were induced 
with doxycycline and the cell cycle was analysed by flow cytometry. The cell cycle 
progression was analysed at different times after induction. As shown in Figure 4.13, the 
over-expression of RAD9B-001 increased slightly the amount of G1 cells 24 hr post-
induction from 55% to 62%. However, this transient arrest only lasted for a short period of 
time as the percentage of G1 cells returned to normal after 36 hr. These results suggest that 
RAD9B-001 might be the splice variant used in the Perez-Castro & Freire’s (2012) study. 
 
The FACS analysis for RAD9B-002 expressing cells was very different. Its up-regulation 
resulted in the accumulation of a sub-G1 population, which was also observed at a lower level 
in non-induced cells as a result of the low background expression of RAD9B-002.  Nearly 
12% of the cell population were in the sub-G1 phase 24 hr after induction and this number 
increased a further to 23% after 48hr. The sub-G1 peak suggests that over-expression of 
RAD9B-002 may drive cells into apoptosis. However, this apoptotic induction was specific to 
this splice variant and was not observed for RAD9B-001. The over-expression of these two 
RAD9B splice variants have therefore different outcomes on the cell cycle, suggesting 
different roles for the two variants.  
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Figure 4.13 Different patterns of cell cycle progression caused by the overexpression of the two 
RAD9B splice variants HEK293 cells. Histograms of flow cytometry showing DNA content in 
overexpressed EGFP-RAD9B-001 and EGFP-RAD9B-002 cell lines. The two cell lines were induced 
with 1 µg/ml doxycycline, and cells were fixed with ice-cold 100% methanol after different induction 
points. The histogram of the cell cycle phases was obtained after gating on propidium iodide-stained 
cells using the Flowing software 2.5.1. 
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4.2.8 Overexpression of RAD9B-001 and RAD9B-002 has a negative 
impact on cell proliferation 
The flow cytometry indicated that cells over-expressing RAD9B-001 or RAD9B-002 arrest in 
G1 and sub G1, respectively. Therefore, the effect of their expression on cell proliferation was 
analysed by measuring the cell count of induced and non-induced cells at different times after 
seeding.  
 
The results were consistent with the flow cytometry findings. Both the EGFP-RAD9B-001 
and EGFP-RAD9B-002 cell lines showed significant inhibition of cell proliferation compared 
to the EGFP-Control cell line. (Figure 4.14). The EGFP-Rad9-M50 and the EGFP-Control 
cell lines showed a similar growth rate in the presence and absence of doxycycline. However, 
over-expression of EGFP-RAD9B-002 had a very strong negative impact on cell growth 
consistent with the accumulation of sub-G1 cells. The cell proliferation experiment results 
were also consistent with the transient G1 arrest of EGFP-RAD9B-001 expressing cells from 
the flow cytometry analysis, as growth of the induced cell population was retarded although 
not to the same extend at in the case of EGFP-RAD9B-002. Both cell lines grew also more 
slowly in the absence of doxycycline which is due to the low basal expression level of the 
variants.  
 
Expression of the yeast protein had no impact on cell growth. This answered the question 
regarding the possible impact of adding the doxycycline on cell growth, as it seems that it had 
no influence on cell proliferation for at least the 4 days of incubation. 
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Figure 4.14 Cell growth graph showing the impact of RAD9B-001 and RAD9B-002 
overexpression on cellular proliferation. Proliferation of either induced or non-induced RAD9B-
001, RAD9B-002, Rad9-M50 and control cell lines. Cells were plated at 3 x 105 density in medium 
with and without doxycycline, and they were collected and counted every 24 hr for 4 days using the 
Bio-Rad TC20 Automated Cell Counter.  Graphs were created using Excel 2013 software. The (I) 
symbol on the growth curve indicates the standard deviation of three repeats.    
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4.2.9 Analysis of apoptosis-related protein markers in the overexpressing 
EGFP-RAD9B-002 cell line 
To further investigate the possible role of RAD9B-002 in inducing apoptosis, proteins 
involved in the activation of the apoptotic pathway were analysed in the over-expressing 
EGFP-RAD9B-002 cell line. The apoptotic proteins analysed in this experiment are known 
apoptotic markers, showing in the case of apoptosis a decrease in the expression of BCL-2, an 
increase in the expression of BAK and p53, and a cleavage of the PARP  by caspase 3 (Wu et 
al., 2015; Wang et al., 2013).  
 
The EGFP-RAD9B-002 cell line was induced for 8, 12, 24 and 48 hr and whole protein was 
extracted at these times. All extracts were subjected to western blot and immunoblotted for 
the apoptotic marker proteins. As mentioned in Section 4.2.6, RAD9B-002 is cleaved 
resulting in two forms (27 kD and 40 kD). This cleavage happened in an induction time-
dependent matter. The amount of the cleaved forms were barely detectable after 8 hr of 
induction but cleavage increased significantly 24 and 48 hr post-induction (Figure 4.15).  
 
Interestingly, as a result of RAD9B-002 over-expression, the cleaved PARP product increased 
slightly compared to the non-induced control cells. This cleavage reached its highest peak at 
24 hr of RAD9B-002 induction. To test whether RAD9B-002 is a cleavage target for caspase 
3 like the PARP protein, the protease sites within RAD9B-002 were analysed using the 
Peptide Cutter-ExPASy tool. RAD9B-002 contained multiple possible target sites for many 
proteases; however, it did not have any target sites for Caspase 3 or any of the other caspases 
involved in the apoptotic pathway, suggesting a different cleavage role than that of the 
apoptotic PARP protein. No expression alterations were observed amongst the other apoptotic 
markers, indicating that over-expression of RAD9B-002 induces apoptosis in a p53-
independent  manner. 
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Figure 4.15 Overexpression of RAD9B-002 does not show a major influence on the apoptosis 
pathway. The human RAD9B-002 variant was overexpressed in the HEK293 cell line for different 
lengths of time (hr), as indicated at the top of the figure. Whole protein was extracted at the indicated 
time points, subjected to SDS-PAGE and immunoblotted with GFP antibody for the detection of 
EGFP-RAD9B-002, in addition to different antibodies against apoptotic proteins (PARP, p53, BAK 
and BCL-2). The GAPDH was used as a loading control. 
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4.2.10  Investigating the post-translational modification of human RAD9B 
and yeast Rad9-M50 
RAD9B-001, RAD9B-002 and Rad9-M50 have multiple phosphorylation sites in their protein 
sequences. Here, the post-translational modification of the recombinant proteins was analysed 
using two methods. Isoelectric focusing (2D electrophoresis) and phos-tag SDS page (Caspari 
& Hilditch, 2015). To test whether any post-translational modifications would affect the 
EGFP domain of the fusion proteins, EGFP expression was induced in the control cell line. 
Although isoelectric focusing indicated the presence of between 3 and 4 forms of the Rad9 
fusion proteins in undamaged cells,  the EGFP-Control cell line revealed a similar pattern of 
three isoforms of the EGFP protein alone (Figure 4.16). This shows that the post-translational 
modifications are not specific to the Rad9 moiety of the fusion proteins but to the EGFP 
domain. It is therefore very likely that EGFP, either alone or fused to Rad9 becomes modified 
in HEK293 cells.   
 
When the same cell lines were analysed by phos-tag electrophoresis to determine their 
phosphorylation status; phosphorylated proteins migrate more slowly in this assay, only 
EGFP-RAD9B-002 and the yeast EGFP-Rad9-M50 protein displayed slower migrating bands 
indicative of phosphorylation (Figure 4.16-C).  Interestingly, EGFP-Control did not display 
any additional bands which indicates that the modifications detected by isoelectric focusing, 
which detects any modification that changes the overall charge of the protein, are not 
phosphorylation events. Taken together this implies that EGFP-RAD9B-002 and the yeast 
Rad9-M50 protein are phosphorylated in undamaged HEK293 cells. 
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Figure 4.16 Analysis of post-translational modification of recombinant proteins. (A) 2D 
isoelectric focusing of the EGFP-RAD9B-001, EGFP-RAD9B-002, EGFP-Rad9-M50 and EGFP-
Control induced proteins. Approximately 20 μg of protein was loaded on a nonlinear 7-cm strip (pH 
3–10) and focused using the 2D isoelectric focusing machine followed by SDS-PAGE analysis. All 
membranes were immunoblotted with GFP antibody. (B) Whole protein extracted from the induced 
constructed cell lines were run on normal SDS-PAGE and immunoblotted with GFP antibody. (C) 
Whole protein extracted from the induced constructed cell lines were run on phos-tag gels and 
immunoblotted with GFP antibody. 
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4.2.11   Heat stress does not regulate the expression of RAD9B 
According to the Human Protein Atlas database (http://www.proteinatlas.org. Accessed 15 
June 2016) RAD9B was only expressed at the protein level in two tissues: skeletal muscle and 
testis. Therefore, a number of commercial RAD9B antibodies were not efficient in detecting 
RAD9B splice variants in cell lines, such as HEK293, HeLa, MCF7 (breast cancer) and Kelly  
as no expression was detected on western blot even with as high as 50 µg of whole protein. 
This might be due to low protein expression, as was shown with the splice variants mRNA 
expression (Chapter 3). However, at late stages of this project, we kindly received a RAD9B 
antibody created in Perez-Castro & Freire’s (2012) study. This antibody was validated by the 
detection of the over-expressed recombinant EGFP-RAD9B-002 protein (Figure 4.17).  
 
The Perez-Castro & Freire’s RAD9B antibody was used to test whether the expression of 
RAD9B is elevated similarly to Rad-M50 in response to heat stress. HEK293 cells were heat 
treated for 1 hr and the cells were allowed to recover up to 2 hr after treatment, the time in 
which checkpoint pathways are activated. 
 
The immunoblot results showed elevated phosphorylation of the CHK1 protein, reflecting the 
activation of the ATR-CHK1 checkpoint as a result of the heat-stress treatment. The 
expression of RAD9B was not detected with the commercial antibody in normal cells or heat-
stressed cells. In addition, the RAD9B antibody from Perez-Castro & Freire’s group appeared 
to detect a protein with a ~ 46 kD molecular weight corresponding to the size of RAD9B-002 
and RAD9B-003 with no expression changes to RAD9B under heat stress. However, other 
smaller bands (22 kD, 26 kD and 32 kD) were also detected in both normal and treated 
samples (Figure 4.17). The smallest band could reflect RAD9B-S003 described in Section 
3.5.2 as the size of the PCR fragment corresponds to the size of the band on the SDS-PAGE 
gel. However, this small band did not show any changes in response to heat stress. Taking 
these results together, RAD9B is not heat inducible as in the case of the yeast Rad9M-50.     
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Figure 4.17 Analysis of RAD9B response to heat stress. (A) HEK293 cells were heat treated at 
43°C for 1 hr and then the cells were allowed to recover for up to 2 hr after treatment. Whole protein 
was extracted from normal and heat-treated cells at the indicated times. Protein samples were analysed 
by western blotting with two different antibodies against RAD9B. Only one antibody revealed the 
expression of RAD9B at 46 kD and three smaller bands at 32 kD, 26 kD and 22 kD. The CHK1 
phosphorylation confirmed the success of the heat treatment. RAD9B expression was normalised to 
the expression of the control PCNA protein . (B) Validation of RAD9B antibody from Perez-Castro & 
Freire’s study. Whole protein was extracted from a constructed cell line expressing the RAD9B-002 
tagged with GFP (27 kD) before and after induction. The engineered RAD9B-002 was displayed with 
a size of 74 kD indicating the validation of the RAD9B antibody.           
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4.2.12   RAD9B-001, RAD9B-002 and Rad9M-50 do not influence the                                                                                                                                                                                                      
phosphorylation of CHK1 in HEK293 cells under heat stress  
The 2012 study by Janes et al. showed that the yeast Rad9 variant Rad9M-50 can reprogram 
the DNA damage response in S. pombe cells at elevated temperatures. The study also showed 
that Chk1 becomes dephosphorylated at Ser-345 when S. pombe cells are shifted to 40°C, 
which correlates with the induction of the variant (Janes et al., 2012). In human cells, CHK1 
is rapidly phosphorylated at Ser-345 by ATR kinase at elevated temperatures (Turner & 
Caspari, 2014). Moreover, recent work by our group (unpublished data) showed that while the 
induction of Rad9M-50 and the dephosphorylation of Chk1 are two correlative events  they 
are not causatively linked. 
 
To test whether the presence of RAD9B splice variants or the yeast Rad9-M50 variant has 
any effect on the human cell response under heat stress conditions, the EGFP-RAD9B-001, 
EGFP-RAD9B-002 and EGFP-Rad9-M50 cell lines were shifted to the elevated temperature 
of 43°C for 1 hour and the cells were allowed to recover at 37°C for various durations, 
followed by protein extraction. First, the phosphorylation status of CHK1 was investigated by 
normal SDS-PAGE using a phospho-specific antibody against the CHK1 Ser-345 site. 
Consistent with published work (Tuul et al., 2013), CHK1 was highly phosphorylated at Ser-
435 in response to heat stress. This phosphorylation was detected immediately after the heat 
shock treatment and increased rapidly for up to 4 hours in recovery at 37°C. As seen in Figure 
4.18, over-expression of RAD9B splice variants or of the yeast Rad9 does not correlate with a 
decrease in CHK1 phosphorylation at S345, as was found in S. pombe, indicating a different 
mechanism for human cells in response to heat stress.  
 
Other proteins that are activated by heat stress, such as ATM, ATR and CHK2, were also 
analysed in constructed cell lines under heat stress. No changes in the protein expression 
levels or in their phosphorylation statuses were observed as a consequence of the over-
expression of either RAD9B or yeast Rad9-M50 (Figure 4.19). 
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Figure 4.18 Analysis of CHK1 phosphorylation under heat stress in the constructed cell lines.  
RAD9B-001, RAD9B-002 and Rad9M-50 cell lines were heat shocked at 43°C for 1 hr. The cells 
were allowed to recover and then whole protein was extracted from the recovered cells at the indicated 
times. The extracts were subjected to SDS-PAGE and immunoblotted with CHK1, p-CHK1 (Ser-345), 
GFP and GAPDH antibodies. 
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Figure 4.19 Analysis of major checkpoint proteins under heat stress in the constructed cell lines.  
The constructed cell lines were heat shocked at 43°C for 1 hr. The cells were allowed to recover and 
then whole protein was extracted from normal and treated cells 1 hr post treatment. The extracts were 
subjected to SDS-PAGE and immunoblotted with the indicated antibodies. The expression of the 
analysed proteins was normalised to the expression of GAPDH. 
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4.2.13   Effects of RAD9B-001 and RAD9B-002 over-expression on the cell    
cycle regulator p21Cip1/WAF1 
The CDK regulator and DNA repair factor p21Cip1/WAF1 (p21) interacts with a large number of 
kinases including the cyclin-dependent kinases and CHK1 as well as with DNA repair 
proteins like PARP. The protein contains multiple phosphorylation sites and over-expression 
studies suggest the possibility that p21 interacts with RAD9B (Perez-Castro & Freire, 2012; 
Child & Mann, 2006). To determine the relation between these two proteins and whether the 
over-expression of RAD9B has an impact on p21, the protein levels of p21 were analysed in 
cells with elevated levels of RAD9B. A time course of RAD9B-001 and RAD9B-002 
induction revealed no impact on the expression of p21, as its levels remained stable up to 24 
hr post induction. However, when extracts from the same time points were run on phos-tag 
SDS page, p21 became highly phosphorylated in both cell lines resulting in an additional p21 
band at approximately 30 kD. This phosphorylation was induced from 2 hr onwards after the 
induction of RAD9B and lasted for at least 24 hr (Figure 4.20). However, RAD9B-001 
seemed to have a slightly higher impact on p21 phosphorylation than RAD9B-002. Although 
PCNA is a target of p21, PCNA expression remained stable through the time course of both 
RAD9B splice variants. 
 
 
Figure 4.20 Increased p21 phosphorylation upon overexpression of either RAD9B-001 or 
RAD9B-002. Whole protein was extracted from induced EGFP-RAD9B-001 and EGFP-RAD9B-002 
at different times (hr) post induction as indicated. The protein lysate was analysed on SDS-PAGE and 
immunoblotted with GFP antibody to detect tagged RAD9B-001 and RAD9B-002. Protein from non-
induced cell lines was used as a control. The same protein extractions were subjected to either normal 
SDS-PAGE gels or on phospho-tag electrophoretic separation gels and immunoblotted for p21 protein. 
The integrated hRad9B and p21 expressions were normalised to the PCNA control.   
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4.2.14   Over-expression of RAD9B-001 and RAD9B-002 have no influence 
on   the expression of the 9-1-1 complex proteins 
The 9-1-1 complex proteins (RAD9, RAD1 and HUS1) are known to activate the checkpoint 
signalling pathway after being loaded onto damaged DNA (Ohashi et al., 2014; Wu, Shell & 
Zou, 2005). RAD9B was also found to interact directly with the RAD9A-interacting proteins 
HUS1 and RAD1 to form a complex similar to the 9-1-1 ring (Perez-Castro & Freire, 2012). 
However, the functional relationships between RAD9B and the other two 9-1-1 complex 
subunits is poorly understood. RAD9B over-expression has not yet been reported to influence 
the expression of any of the other ring proteins. To understand the link between RAD9B and 
these proteins better, the expression levels of these proteins were analysed in the presence of 
elevated levels of RAD9B-001 or RAD9B-002 under normal and genotoxic stress conditions. 
In addition, the localisation of the 9-1-1 complex proteins were also tested in these over-
expressed cell lines. 
 
If RAD9B interacts with HUS1 and RAD1 to form a 9-1-1-like complex, this should reduce 
the expression levels of Rad9A and possibly increase the expression levels of HUS1 and 
RAD1 upon the over-expression of either RAD9B-001 or RAD9B-002. To utilize this, 
RAD9, HUS1 and RAD1 expression levels were checked in the induced cell lines under 
normal and genotoxic conditions. Both the mRNA and protein levels were analysed. 
  
The protein expression of RAD9A, RAD1 and HUS1 were stable and did not change in the 
over-expression cell lines neither under normal conditions nor when cells were heat treated or 
exposed to UV light. However, when p21 was used as a control for the UV treatment, it 
revealed an interesting result as its degradation was reduced in the EGFP-RAD9B-001 and 
EGFP-Rad9-M50 cell lines, but not in the EGFP-RAD9B-002 cell line. This indicates that 
RAD9B-001 and Rad9M-50 protect p21 from degradation in the response to UV light.  In 
addition, heat stress resulted in a slight up-regulation of p21 in EGFP-Control and EGFP-
Read9-M50 cell lines but not in the RAD9B-001 and RAD9B-002 cell lines (Figure 4.21 & 
Figure 4.22-A).    
 
After DNA damage, components of the 9-1-1 complex are located in the nucleus where the 
complex is being loaded onto DNA damaged sites. Here, the localisation of the complex 
proteins was analysed in over-expressing EGFP-RAD9B-001, EGFP-RAD9B-002, EGFP-
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Rad9-M50 and the EGFP-Control cell lines under genotoxic stress. Surprisingly, all three 
proteins localised to the cytoplasm in normal and genotoxic stress conditions (Figure 4.22-B). 
Only a faint presence was detected in the nuclear fraction when the western blot films were 
exposed for a long time. This indicates that only small amounts of these proteins actually 
form the complex and locate to the nucleus after DNA damage or that the complex is released 
from chromatin during the extraction. In conclusion, no alteration in the localisation of the 9-
1-1 proteins were observed when RAD9B-001, RAD9B-002 or Rad9-M50 was over-
expressed.    
 
To check whether the two RAD9B splice variants have an impact at the mRNA levels of the 
9-1-1 complex components, q-RT PCR analysis was performed. The results showed that all 
three components of the 9-1-1 complex had stable expression when RAD9B-001 and 
RAD9B-002 levels were elevated. The expression of all the targets in the two induced cell 
lines compared to the expression in the non-induced cells (Control) were almost the same 
with difference of no more than 0.55 expression fold change, indicating no significant 
expression changes within the 9-1-1 complex components. The mRNA levels of p21 were 
also analysed revealing stable expression in the presence of RAD9B-001 and RAD9B-002 
elevated mRNA levels (Figure 4.23 & Figure 4.24). 
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Figure 4.21 9-1-1 complex proteins show stable expression in the presence of high expression 
levels of RAD9B-001 and RAD9B-002. The EGFP-Rad9B-001 and EGFP-RAD9B-002 cell lines 
were induced and whole protein was extracted at the indicated times post transfection. The protein 
extracts were immunoblotted with GFP, RAD9A, HUS1, RAD1 and p21 antibodies. The expression of 
these proteins was normalised to the expression of the PCNA protein. 
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Figure 4.22 Overexpression of RAD9B splice variants or yeast Rad9-M50 do not influence the 
expression nor the localisation of the 9-1-1 complex protein in response to genotoxic stress.  (A) 
Western blot analysis of RAD9A, HUS1, RAD1 and p21 in response to heat stress and  UV light in 
the constructed over-expressed cell lines. Cells were either heat treated for 1 hr at 43°C or were UV 
treated (40 J/m2). Whole protein was extracted from treated cells 1 hr after treatment. (B) Localisation 
analysis of RAD9A, HUS1 and RAD1 proteins in protein fractionation (cytoplasmic and nuclear) 
extracted from overexpressed cell lines under normal conditions and after exposure to UV light (40 
J/m2, 1 hr recovery). The GAPDH was used as a quality control for the cytoplasmic fraction whereas 
the histone H3 was used as a quality control for the nuclear fraction. 
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Figure 4.23 qPCR analysis of RAD9A, HUS1, RAD1 and p21 expression in EGFP-RAD9B-001 
overexpressed cell line. (A) Total RNA was extracted from the overexpressed EGFP-RAD9B-001 
cell line at the indicated times. 200 ng of the RNA was used as a template for the amplification of 
RAD9B-001 splice variants using the specific flanking primers. ACTB was used as a positive control. 
(B) 1 μg of total RNA was reversed transcribed and the cDNA was used as a template in the qPCR 
analysis to detect the expression levels of RAD9A, HUS1, RAD1 and p21. The expression of these 
genes was normalised to the expression of the TBP and TUBA. 
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Figure 4.24 qPCR analysis of RAD9A, HUS1, RAD1 and p21 expression in EGFP-RAD9B-002 
overexpressed cell line. (A) Total RNA was extracted from the overexpressed EGFP-RAD9B-002 
cell line at the indicated times. 200 ng of the RNA was used as a template for the amplification of 
RAD9B-002 splice variants using the specific flanking primers. ACTB was used as a positive control. 
(B) 1 μg of total RNA was reversed transcribed and the cDNA was used as a template in the qPCR 
analysis to detect the expression levels of RAD9A, HUS1, RAD1 and p21. The expression of these 
genes was normalised to the expression of the TBP and TUBA. 
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4.2.15   RAD9A knockdown by shRNA in HEK293 cells  
To further investigate the functional relationship between RAD9A protein and its paralog 
RAD9B, it was of interest to analyse RAD9B expression in the absence of RAD9A. This 
would address whether RAD9B can complement the loss of RAD9A to form a similar 9-1-1 
complex by interacting with HUS1 and RAD1 proteins.    
 
To down-regulate RAD9A, four shRNA cassettes constructed in puromycin plasmids 
containing a sequence that targets RAD9A were transfected into HEK293 cells. All plasmids 
were RFP-tagged for the transfection control. As most shRNAs sequences are 25–30% 
successful, four shRNAs sequences were transiently transfected to investigate the most 
effective shRNA. To assure a maximum knockdown, a mix of the four shRNAs were also 
transfected into the same cell line. This particular shRNA system was selected because it uses 
longer shRNA (29 bp), which is more effective in the down-regulation in addition to its 
hairpin constructs that allows for long-lasting down-regulation compared to short siRNAs. 
 
The transfection of the individual shRNA plasmids and the four shRNA mixture was done 
using the Lipofectamine transfection reagent (Invitrogen). Since no validated antibody exists 
for the detection of RAD9B, the influence of RAD9A knockdown on the expression of 
RAD9B was tested at the mRNA level. Whole protein and total RNA were extracted 72 hr 
post-transfection with the shRNAs. Transfected cells displayed puromycin resistance and 
expressed the red RFP signal only 24 hr post transfection (Figure 4.25-A).  
 
The RT-PCR and Western blot showed that RAD9A was not down-regulated by any of the 
four transfected shRNA plasmids nor by the mix of plasmids. Assuming the shRNA plasmids 
are functional, the results indicate that RAD9A inhibition could lead to a cell response against 
the reduction of RAD9A forcing them to induce more copies of RAD9A to overcome the 
reduction.   
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Figure 4.25 RAD9A is not downregulated when using the HuSH shRNA system. The four shRNA 
plasmids A, B, C and D were transfected into HEK293 cell separately or in conjunction. Total RNA 
and whole protein were extracted from the HEK293 cells 72 hr post transfection. (A) Expression of 
the RFP-tag from the shRNA plasmid reflecting the red colour under the microscope only 24 post 
transfection. (B) Amplification of RAD9A by two-step RT-PCR from normal and shRNA-transfected 
cells. ACTB was used as a positive control. (C) Western blot analysis of protein extracted from normal 
and shRNA-transfected cell immunoblotted with RAD9A antibody. The expression of RAD9A was 
normalised to the expression of the PCNA protein.      
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4.2.16    RAD9B-001 and RAD9B-002 do not translocate to the nucleolus in    
response to UV light  
To investigate the functional role of the RAD9B variants and yeast Rad9-M50, their cellular 
localisation was investigated in HEK293 cells by either protein fractionation analysed by 
western blot or immuno-localisation using confocal microscopy. In previous studies, over-
expressed RAD9B localised to the nucleus under normal conditions (Dufault et al., 2003). 
RAD9B also was reported to translocate to the nucleolus in the response to DNA damage 
(Perez-Castro & Freire, 2012). To test whether RAD9B-001 or RAD9B-002 shared a similar 
cellular location, all engineered cell lines were induced for at least 12 hr, followed by the 
extraction of the cytoplasmic and nuclear protein fractions.  
 
For the confocal imaging, cells were grown on Poly-D-Lysine glass cover slips and fixed with 
para-formaldehyde and stained with an anti-GFP antibody.  
 
Unlike the reported localisation of RAD9B, neither RAD9B-001 nor RAD9B-002 localised to 
the nucleus as they were only found in the cytoplasm when the fractions were analysed on 
SDS-PAGE. The quality of the protein fractions and the accuracy of the protein fractionation 
was determined by immunoblotting for cytoplasmic and nuclear specific marker proteins, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Lamin B (LMNB), respectively. 
These control proteins confirmed the quality of the fractionation. However, the GFP-tag can 
influence the sub-cellular localisation of the recombinant proteins and over-expression can 
lead to artefacts that cause misleading results, as discussed later. 
 
In Perez-Castro & Freire’s study (2012), RAD9B was reported to translocate to the nucleolus 
in a co-compartmentalisation pattern with p21 after UV irradiation. Therefore, the localisation 
of this protein was analysed in normal conditions and under UV damage stress. Other proteins 
in the p21 pathway such as CHK2 or p53, were also analysed. In line with the localisation of 
RAD9B, p21 was found to localise to the cytoplasm in normal and UV-treated cells (Figure 
4.26). The expression of p21 decreased in a time-dependent manner post-treatment as a result 
of its degradation in response to UV. CHK2 was present in the cytoplasm, but p53 was highly 
expressed in the cytoplasm and nucleus under normal conditions and in response to UV light. 
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Immunofluorescence with the confocal microscope was performed to confirm the RAD9B 
and Rad9-M50 localisation obtained by western blotting and also to verify that their 
localisation is not an error that occurred during the cytoplasmic and nuclear fraction 
procedure. The immuno-localisation results were consistent with the results obtained from the 
protein fractionation analysis. The RAD9B splice variants and Rad9-M50 were detected 
mainly in the cytoplasm (Figure 4.27). The empty plasmid control also had similar results to 
the other engineered proteins. Untransfected HEK293 cells were used as a negative control, as 
they should not induce any GFP signal, hence, the negative cell line did not reflect any GFP 
fluorescence signal, indicating the validation of florescence staining. 
 
 
Figure 4.26 Localisation of EGFP-recombinant proteins and cell cycle regulator proteins in 
normal cells and in response to DNA damage. Two protein fractions (cytoplasmic (C) and nuclear 
(N)) were extracted from EGFP-RAD9B-001, EGFP-RAD9B-002, EGFP-Rad9-M50 and EGFP-
Control cell lines under normal conditions and at different times post DNA damage by UV treatment. 
The fraction extracts were subjected to SDS-PAGE and immunoblotted with EGFP, CHK2, p53 and 
p21 antibodies. GAPDH and LMNB were used as positive controls for the cytoplasmic and nuclear 
fractions, respectively.   
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Figure 4.27 RAD9B-001 and RAD9B-002 do not localise to the nucleolus in response to UV light. 
Cells from the constructed cell lines were grown on coverslips in medium containing doxycycline for 
at least 12 hr. The cells then were either left untreated (normal) or were UV treated (40 J/m2) followed 
by fixation with 4% paraformaldehyde. The cells then were stained with GFP and nucleolus (Anti-
Fibrillarin) antibodies in combination with Alexa Fluor (red) and Alexa Fluor 488 (green), 
respectively, in addition to the nucleus stain DAPI (blue). HEK293 cells were used as a negative 
control. Images were taken by a Zeiss LSM710 confocal microscope with a 40x objective. Images 
were processed using Zen lite software. 
 144 
 
 Discussion 
The key findings of this chapter are: (1) All GFP recombinant proteins reside mainly to the 
cytoplasm in normal and treated cells. (2) Exposure of the EGFP-RAD9B-001 and EGFP-
Rad9B-M50 constructed cell lines to UV light revealed a delay in the degradation of the CDK 
inhibitor p21 which is not observed for the control or the EGFP-RAD9B-002 constructed cell 
lines. (3) Over-expression of RAD9B-002 have a negative impact on cell proliferation 
indicated by the accumulation of sub G1 cell population which may have undergone 
apoptosis. (4) The reported RAD9B in Perez-Castro Freire’s (2012) study is likely to be the 
RAD9B-001 splice variant since its over-expression results in the reported G1 transient arrest. 
(5) Elevated levels of RAD9B-001 or RAD9B-002 increase the phosphorylation of p21 kinase 
inhibitor but do not show any impact on its transcription levels. (6) RAD9B may have a 
distinct role than RAD9A or the 9-1-1 complex since no alteration in the expression of 
RAD9A, HUS1 or RAD1 was observed at their mRNA or the protein levels when RAD9B 
was over-expressed. (7) RAD9B does not seem to be induced by heat stress or neither have an 
influence on the phosphorylation of CHK1 at elevated temperature. 
 
Like RAD9B, HUS1B, a paralog of the human cell cycle checkpoint gene HUS1, is highly 
expressed in testis which led to the model that the `B` forms of these proteins are involved in 
the processing of the programmed DNA breaks during meiosis (Lyndaker et al., 2013). 
HUS1B plays a distinct role as its over-expression induces clonogenic cell death (Hang et al., 
2002). Interestingly, over-expression of RAD9B-002 may have a similar impact on cells as 
indicated by the accumulation of sub G1 cell population which may have undergone apoptosis 
(Figure 4.13). Only RAD9A but not HUS1 was reported to cause an effect on cell survival 
when over-expressed (Broustas & Lieberman, 2012; Hang et al., 2002). It is likely that the 
expression of RAD9B and HUS1B is required only under certain conditions or during a 
specific cell cycle phase. The toxicity and cleavage of RAD9B-002 when over-expressed 
(Figure 4.12) supports this hypothesis. This toxic effect is very like caused by RAD9B-002 as 
high levels of EGFP are nontoxic to cells (Okabe et al., 1997), and only a few reports on the 
side effects of EGFP expression exist (Koike, Yutoku & Koike, 2013; Baens et al., 2006). 
Moreover, only the RAD9B-002 fusion partner and neither RAD9B-001 nor yeast Rad9-M50 
triggers protein cleavage and a sub G1 population.   
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Since RAD9B-002 and RAD9B-001 only differ in their N-terminal sequence (Figure 4.28), 
and because this part of the protein is required for the formation of the 9-1-1 ring, it is 
reasonable to assume that high levels of RAD9B-002 in the 9-1-1 ring may be responsible for 
the toxic effect. 
 
                   10        20        30        40        50        60 
RAD9B-002 MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 
          :                                                            
RAD9B-001 M----------------------------------------------------------- 
                                                                   
 
                    70        80        90       100       110       120 
RAD9B-002 FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 
                       ::::::::::::::::::::::::::::::::::::::::::::::: 
RAD9B-001 -------------SENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 
                           10        20        30        40         
 
Figure 4.28 Alignment of RAD9B-001 and RAD9B-002. The alignment was created using ALIGN 
tool (http://xylian.igh.cnrs.fr/bin/align-guess.cgi. Accessed 28 August 2016). The two splice variants 
differ only at the first 72 amino acids. 
 
  
Since RAD9A and RAD9B can both assemble with RAD1 and HUS1 in the ring (Perez-
Castro & Freire, 2012; Dufault et al., 2003), elevated RAD9B-002 levels may out compete 
RAD9A and thereby cause cell death. Moreover, it was reported that RAD9A can be cleaved 
by caspase 3 where its N-terminal localises to the cytosol and binds to BCL-XL to neutralises 
its anti-apoptotic activity, thus promoting cell death (Broustas & Lieberman, 2012; Komatsu 
et al., 2000). Therefore, it is possible that the interaction of RAD9B-002 with HUS1 and 
RAD1 allows the accumulation of a large amount of RAD9A protein outside of the 9-1-1 
complex leading to its apoptotic activity, hence the sub-G1 population. In addition, since 
RAD9B-002 N-terminal shares more homology with RAD9A than its C-terminal, it is also 
possible that RAD9B-002 interacts directly with BCL-XL and induces cell death in a similar 
manner to RAD9A.   
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Figure 4.29 Possible induction of apoptosis by the RAD9B-002. (A) Over-expression of RAD9B-
002 results in the substitution of RAD9A in the 9-1-1 complex ring leading to the accumulation of 
RAD9 molecules. The free RAD9A molecules are being cleaved by caspase 3 and the N-terminal of 
RAD9A translocate to the cytosol where it binds and neutralises the anti-apoptotic activity of BCL-XL 
and promoting cell death. (B) High elevated levels of RAD9B lead to its interaction with BCL-XL by 
its N-terminal domain (resembles the N-terminal of RAD9A) and inducing cell death.   
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Although RAD9B shares an extensive amino acid homology with RAD9A (36% identity, 
48% similarity), the two proteins may have different properties. One striking difference 
between RAD9A and RAD9B is the inability of RAD9B to interact with TOPBP1 in the ATR 
pathway (Perez-Castro & Freire, 2012). Interestingly, only one of the key phosphorylation 
sites in the RAD9A tail domain, Ser-387 (Ser-409 in RAD9B-002), is conserved (Dufault et 
al., 2003). This could be significant since in S. pombe, the phosphorylation sites are crucial 
for the association with TOPBP1 (Rad4/Cut5) (Furuya et al., 2004). When the structure of 
full-length RAD9B-002 was modelled using the Swiss Model tool and the crystal structure of 
the N-terminal section (the tail domain is absent) of human RAD9A as a template, RAD9B-
002 appears to differ in one domain which is located above the second beta sheets (Figure 
4.30). While this section adopts a loop structure in RAD9A, it is significantly larger in 
RAD9B and adopts some beta sheet elements. In summary, the toxic impact of high RAD9B-
002 protein levels could be explained by a competition between RAD9A and RAD9B for the 
9-1-1 ring and a negative impact of RAD9B-002 due to its structural changes on DNA 
damage checkpoint activation. The latter could lead to the accumulation of a sub-G1 cell 
population and a cleavage event in an attempt of the cells to minimise the negative impact.  
 
 
 
 
Figure 4.30  RAD9B-001, RAD9B-002 and RAD9A crystal structure. The structure was created 
using SWISS-MODEL server (https://swissmodel.expasy.org.  Accessed 20 July 2016). 
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Although  RAD9B and RAD9A were both previously reported to localise to the nucleus under 
normal conditions (Perez-Castro & Freire, 2012; Hopkins et al., 2003), in this project RAD9B 
and RAD9A were primarily localised to cytoplasm under normal conditions as well as in 
response to UV damage (Figure 4.26). The differences between this study and the published 
studies may be linked with the affinity tag. While RAD9B and RAD9A were FLAG-tagged 
and over-expressed in the HeLa or U2OS cell lines in the previous studies, RAD9B was N-
terminally EGFP-tagged and over-expressed in the HEK293 cells.  It has been reported that 
GFP can affect the localisation of proteins regardless of whether the GFP tag was attached to 
the N-terminus or the C-terminus. A study on EB1 (microtubule plus-end tracking protein) 
localisation found that GFP-EB1 had a different localisation to its untagged counterpart 
indicating that the GFP-tag can indeed result in misinterpretation (Skube, Chaverri & 
Goodson, 2010). Regardless of whether the EGFP tag did alter the localisation of the over-
expressed RAD9B splice variants, this is unlikely to be the cause of the inconsistency for 
untagged RAD9A, HUS1 and RAD1 that were also found to localise to the cytoplasm in the 
cellular fractionation experiments (Figure 4.21). This could however be an artefact of the 
fractionation method as the 9-1-1 ring may slip off the chromatin during sample preparation. 
In confocal microscopy studies when the proteins were fixed with para-formaldehyde, 
RAD9A was confined to the nucleus in HEK293 and in K526 normal and treated cells. 
Surprisingly, in the same study, protein fractionation analysis of the K526 cells showed that 
RAD9A was not associated with the nucleus, as RAD9A was released from the chromatin 
(Burtelow, Kaufmann & Karnitz, 2000).   
                
In this project, over-expression of RAD9B-001 and RAD9B-002 resulted in the increased 
phosphorylation of p21 when analysed on a phos-tag gel (Figure 4.20). It is unclear whether 
RAD9B-001 and RAD9B-002 mediated the reported phosphorylation of p21 by AKT kinase 
which prevents the association of p21 and PCNA to block DNA replication (Rossig et al., 
2001).  A close link between RAD9B and p21 is further supported by the finding that the UV-
induced degradation of p21 is delayed by high protein levels of RAD9B-001 or the yeast 
Rad9-M50 variant (Figure 4.22-A).  
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As shown in the next chapter, UV irradiation resulted in the reduction of RAD9B mRNA 
expression (Figure 5.6) indicating that low levels of RAD9B are required for the degradation 
of p21 in the response to UV induced DNA damage. The E3-ligase CRL4 (CDT2) (CUL4-
DDB1-CDT2) promotes p21 proteolysis after UV irradiation to enable the translesion DNA  
eta (POL η) to be recruitment to DNA lesions (Soria et al., 2008) .  
 
The N-terminally truncated variant, RAD9B-001, may adopted a distinct structure when 
compared to full-length RAD9B-002 (Figure 4.30). Given the absence of the first 72 amino 
acids, it is unlikely that the shorter protein forms the 9-1-1 ring. It may however be able to 
assemble with PCNA, which is required for the degradation of p21 (Soria & Gottifredi, 2010) 
or with the E3 ligase CUL4-DDB1-CDT2 which is involved in p21 degradation. In any case, 
a delay in p21 degradation in the presence of high RAD9B-001 protein levels would result in 
UV sensitivity due to the retarded recruitment of DNA lesion bypass polymerases of the Y 
family (Mansilla et al., 2013). A close link between RAD9B and p21 may also explain the G1 
arrest observed upon over-expression of RAD9B-001 (Figure 4.13) as p21 blocks the cyclin-
dependent kinases required for G1-S transition (Harper et al., 1993). 
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Chapter 5: HUMAN RAD9B SPLICE VARIANTS IN 
RESPONSE TO DNA DAMAGE AND THEIR 
RELATION TO CHK2 PROTEIN KINASE  
 
 Introduction  
So far, the hypothesis that the RAD9B splice variants regulate the dephosphorylation of the 
CHK1 kinase has not been shown to be true. However, while conducting experiments 
analysing different checkpoint proteins known for their involvement in the DNA damage 
response pathways, some alterations have been noted in the phosphorylation of the CHK2 
protein but not in the phosphorylation of CHK1, in addition to the changes observed for the 
CHK2 downstream p21 protein. This chapter summarises the relationship between RAD9B, 
yeast Rad9 and the proteins of the ATM-CHK2 pathway. As mentioned previously, the ATM 
protein kinase targets and phosphorylates a number of proteins in response to DSBs including 
the CHK2 protein kinase. ATM phosphorylates CHK2 at Thr-68 in its N-terminal serine-
threonine-glutamine (SQ-TQ) rich motif which triggers the dimerisation of the kinase and its 
auto-phosphorylation (Smith et al., 2010). Approximately 24 substrates have been identified 
so far for CHK2 protein kinase in human cells, all of which have been phosphorylated at one 
or more serine or threonine sites. A number of CHK2 substrates, such as p53, BRCA1, 
BRCA2 and KAP-1 are also phosphorylated directly by ATM suggesting that CHK2 might 
play a role in fine tuning ATM  kinase (Zannini, Delia & Buscemi, 2014).  
 
Recently, a novel interaction has been reported between CHK2  and the mitotic kinase MPS1. 
MPS1 was first discovered in yeast and the phenotypic analysis of mutant strains revealed key 
functions of this kinase in the duplication of the spindle pole body (SPB) (centrosome in 
humans) (Rose & Fink, 1987). Later, MPS1 was reported to play an important role in the 
spindle checkpoint. Its over-expression results in the activation of the spindle checkpoint 
pathway leading to a mitotic cell cycle arrest (Hardwick et al., 1996; Weiss & Winey, 1996) . 
MPS1 is found in many eukaryotic cells and 11 splice variants of this kinase are recorded in 
human cells, of which code 8 encode a protein (Ensemble data base). MPS1 has also been 
found to function in other signalling pathways including the genotoxic stress response. 
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DNA damage forces the cell cycle to arrest either in G1 or at the G2/M boundary or it directs 
the cell into apoptosis. In HeLa cells, UV irradiation causes these cervical cancer cells to 
arrest at the G2/M transition. Interestingly this arrest is completely dependent on the MPS1 
protein kinase leading to a direct association between MPS1 and CHK2 resulting in the 
phosphorylation of CHK2 at Thr-68, the same site targeted by ATM. Phosphorylation of 
CHK2 requires the N-terminal domain of MPS1 (Yeh et al., 2009; Wei et al., 2005). 
Activated CHK2 increases MPS1 stability by directly phosphorylating MPS1 at Thr-288, 
whereby creating a feedback loop required for the G2/M arrest. The phosphorylation of MPS1 
is dependent on the FHA and kinase domains of CHK2. Moreover, over-expression of CHK2 
kinase increases the expression levels and phosphorylation of MPS1, whereas mutations 
within its FHA or kinase domain were not capable of inducing the MPS1 kinase (Yeh et al., 
2009). 
  
The CHK2 is considered to be a good target for cancer treatment. The main idea is to 
inactivate pro-survival activities after the DNA damaging treatment, such as cell cycle arrest 
and DNA repair, or activation of senescence and apoptosis. However, it has been reported that 
inhibition of CHK2 can increase the resistance of cells to chemotherapy as well as to 
radiotherapy. This is probably because CHK2 plays a role in the induction of the p53 
apoptosis pathway. However, the absence of CHK2 and p53 result in failure to arrest in either 
the G1/S or G2/M phase after treatment that damages the DNA. Hence, inhibition of only 
CHK2 protein in p53 deficient tumour cells can sensitise these cells to genotoxic treatments 
(Jiang et al., 2009). Moreover, CHK2 inhibition has been reported to be beneficial for the 
treatment of some tumour types, such as pancreatic cancers. Inhibition of CHK2 in four 
pancreatic cancer cell lines (PaCa-2, Panc-1, BxPC-3 and CFPAC-1) enhanced the anti-
tumour effect of gemcitabine (GEM) by significantly increasing the levels of intracellular 
reactive oxygen species (ROS) (Duong et al., 2013). 
  
This chapter focuses on the response of CHK2 in cells over-expressing RAD9B-001, 
RAD9B-002 or yeast Rad9-M50 to two important types of DNA damaging agents, namely 
UV irradiation and H2O2. These experiments are informed by the role of human RAD9B and 
p21 in the response to UV light in the nucleolus (Perez-Castro & Freire, 2012). Also the 
findings from chapter 4 suggest a UV-specific function of both proteins. Moreover, the focus 
on oxidative DNA damage was because it is the dominating source of endogenous damage 
and is a strong stimulator of checkpoint proteins as was reported in multiple studies (Wei et 
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al., 2005; Yeh et al., 2009; Perez-Castro & Freire, 2012; Yu, Huang & Shieh, 2016; Tubbs & 
Nussenzweig, 2017). The analysis included two steps: first,  the expression of the two splice 
variants RAD9B-001 and RAD9B-002 is tested at the mRNA level using the one-step RT-
PCR assay to understand their expression in the response to the treatments. The same 
treatments are then applied to the EGFP-RAD9B-001 and EGFP-RAD9B-002 cell lines to 
analyse CHK2, MPS1, p53 and p21 in the presence of elevated levels of RAD9B-001 and 
RAD9B-002.      
 
5.2 Results 
5.2.1 Analysis of the apoptotic pathway in EGFP-RAD9B-001 and EGFP-
RAD9B-002 over-expressing cell lines 
The UV radiation dosage that has been used so far (40 J/m2) does not seem to drive cells into 
apoptosis. As shown in Figure 5.1-A, cleavage of the PARP protein, which is generally 
regarded as a sign of apoptosis, does not occur in HEK293 cells under these conditions even 
48 hr post-treatment. In line with this interpretation, no changes were observed in the other 
apoptotic marker BCL-2, with only a slight upregulation of the BAK protein, the expression 
of which is known to increase in apoptotic cells. The p53 transcription factor is 
phosphorylated at (Ser-15) up to 48 hr post UV radiation. Interestingly, 24 hours post 
treatment, almost 30-40% of cells were dead, which corresponds to the high dosage of UV 
light, and this percentage increased to nearly 60% 48 hr post-treatment. This is reflected in a 
drop in the phosphorylation of p53 as the cells can no longer recover from the damage. These 
results suggest that high dosages of UV light causes major damage killing the HEK293 cells 
independently of the apoptotic pathway. 
 
Therefore, a lower dosage of UV radiation was used (15 J/m2) to test whether this dosage is 
able to induce apoptosis in HEK293 cells as this would provide an insight into the possible 
role of the hRad9B splice variants in apoptosis.  
 
A clear difference between the two doses can be seen in the apoptotic and checkpoint 
responses (Figure 5.1-B). At the lower dose, HEK293 entered apoptosis 24 hr post-UV 
irradiation as indicated by the smaller band of the PARP protein which indicates its cleavage. 
PARP cleavage increases 24hr and 48hr post-treatment. This apoptosis marker was observed 
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in all four cell lines indicating that this is a response to UV damage rather than a specific 
outcome of RAD9B-001 or RAD9B-002 over-expression. However, no changes were 
observed with the other two apoptosis markers BCL-2 and BAK. Unlike the high doses 
experiment, the p21 protein levels declined at the 12 hr and 24 hr time points and recovered 
after 48 hr post-treatment.  
 
This drop in p21 correlated well with the phosphorylation of CHK2 at Thr-68 and indicated 
an ATM-CHK2 checkpoint response. As mentioned previously, p21 is degraded after UV 
irradiation to free up PCNA for DNA repair and translesion synthesis (Soria & Gottifredi, 
2010).  
 
The recovery of p21 expression levels after 48hr signals that cells have completed the UV 
response as 15 J/m2 is a sub-lethal UV dose. While these responses were similar in all four 
cell lines, the p21 expression levels did not seem to recover to the same extent in the presence 
of high levels of EGFP-RAD9B-002 and yeast Rad9-M50. This suggests a role for the full-
length RAD9B-002 and the yeast variant in inhibiting the exit from the UV-induced cell cycle 
effect. 
 
The cell lines in this experiment were induced for approximately 18 hrs before the treatment. 
They were also grown in a medium containing doxycycline during the recovery time, in total 
66 hrs. It can be seen that all four cell lines showed a drop in EGFP-Rad9 expression 
including the control cells, even though they were induced for a longer period of time. This 
may suggest that the UV treatment reduces their expression or results in their removal. The 
latter is clearly the case for RAD9B-002 which undergoes UV-induced cleavage (Figure 5.1-
B).  
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Figure 5.1 Western blot analysis of apoptosis-related proteins after UV damage in the 
constructed cell lines. (A) The EGFP-Control cell was induced for 18 hr then cells were exposed to a 
high dose of UV light (40 J/m2) and whole protein was extracted 12, 24 and 48 hr post treatment. 
Protein extracts were analysed on the normal SDS-PAGE and immunoblotted for apoptosis-related 
proteins p53, p-p53, p21, PARP, BCL-2 and BAK and the protein loading control, GAPDH. (B) The 
four constructed cell lines EGFP-RAD9B-001, EGFP-RAD9B-002, EGFP-Rad9-M50 and the EGFP-
Control were induced for 18 hr then were treated with a moderate UV radiation dose (15 J/m2). Whole 
protein was extracted from treated cells 12, 24, 48 hr post treatment. Protein extracts were analysed on 
the normal SDS-PAGE immunoblotted for GFP and for apoptosis-related proteins p53, p-p53, p-
CHK2, p21, PARP BCL-2 and BAK and for the GAPDH loading control. (*) indicates the cleaved 
EGFP-RAD9B-002 (40 kD), (**) indicates the second EGFP-RAD9B-002 cleaved band (27 kD). 
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5.2.2 Over-expression of RAD9B-001 and RAD9B-002 promotes high 
phosphorylation of CHK2 kinase. 
So far no major differences in the expression of ATM, ATR, CHK1, CHK2 and p53 and p21 
have been found as a result of the over-expression of any of the constructed cell lines. To find 
out whether over-expression of the variants over a longer period triggers a change in the 
phosphorylation of these checkpoint proteins, samples were taken 8 hr, 12 hr, 24 hr and 48 hr 
after addition of doxycycline. 
  
As shown in Figure 5.2-A, no changes in the phosphorylation of ATR (Ser-428), ATM (Ser-
1981) or CHK1 (Ser-345) were observed.  Interestingly, prolonged over-expression of both 
human RAD9B variants resulted in an increase in CHK2 phosphorylation at Thr-68  
(Figure 5.2-A). It is worth noting that the phosphorylation levels of the up-stream kinase 
ATM did not change indicating that CHK2 is phosphorylated by an alternative kinase which 
could be MPS1. It is also possible that the CHK2 phosphorylation is linked with the G1 
arrests and sub-G1 cell population observed after over-expression of RAD9B-001 or RAD9B-
002, respectively (Figure 4.13). 
 
Analysis of p53, revealed an interesting result for RAD9B-001 as its over-expression 
increased p53 phosphorylation at (Ser-15). This phosphorylation was specific for the RAD9B-
001 variant and was not observed upon over-expression of EGFP-RAD9B-002 (Figure 5.2-
A). The latter could be linked with the accumulation of a sub-G1 cell population in the 
induced cell line (Figure 4.13). Finally, no phosphorylation of the CHK1 at Ser-345 was 
observed in either of the cell lines. These results indicate the possibility that over-expression 
of RAD9B affects the ATM-CHK2 pathway but not the ATR-CHK1 pathway. 
  
To further investigate the phosphorylation status of CHK2 changes in untreated cells over-
expressing the Rad9 variants, their expression was induced for 24hr and soluble protein 
extracts were loaded onto a 6% phos-tag SDS page. As shown in Figure 5.2-B, Over-
expression of EGFP-RAD9B-001 resulted in a strongly reduced mobility of CHK2 indicating 
an increase in its phosphorylation status.  
 
Over-expression of EGFP-RAD9B-002 caused only a partial over-phosphorylation of CHK2, 
whereas over-expression of the yeast variant had no impact on CHK2 mobility. Taken 
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together, these data suggest that elevated levels of the human RAD9B proteins affect CHK2 
phosphorylation in untreated cells (Figure 5.2-B). 
 
Based on the increase in CHK2 phosphorylation upon over-expression of the RAD9B-001 
and RAD9B-002 and the increase in phosphorylation of p53 as a result of the RAD9B-001 
over-expression, a possible physical interaction of the variants with either CHK2 or p53 was 
examined. To achieve this, immunoprecipitation of the GFP-tagged proteins was performed. 
Several immunoprecipitation kits were used for the pull down of the over-expressed GFP-
tagged proteins, such as GFP magnetic beads, magnetic beads and GFP agarose beads. 
However, most attempts failed to pull down the RAD9B variants. These negative outcomes 
might indicate that the RAD9B-001 and RAD9B-002 have interaction partners forming a 
larger complex making it difficult for the GFP tagged proteins to bind to the beads. Only 
EGFP-RAD9B-001 was successfully pulled down using the anti-GFP agarose beads. Probing 
with antibodies for CHK2 and p53 revealed that neither protein binds to this variant indicating 
that RAD9B-001 causes phosphorylation changes indirectly (Figure 5.2-C). 
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Figure 5.2 High phosphorylation of CHK2 kinase in over-expressed EGFP-RAD9B-001 and 
EGFP-RAD9B-002 cell lines. (A) The EGFP-RAD9B-001 and EGFP-RAD9B-002 were induced by 
doxycycline (1µg/ml), and whole protein was extracted from the induced cell lines at the points 
indicated. Protein extracts were analysed on normal SDS-PAGE and immunoblotted for the 
checkpoint proteins using phospho-specific antibodies against ATM, ATR, p53, CHK2 and CHK1. 
The GAPDH was used as the negative control. (B) CHK2 is aberrantly phosphorylated in untreated 
cells over-expressing human RAD9 variants. Whole protein extracts of untreated cells 24hr after the 
addition of doxycycline were loaded on a phos-tag gel (6% acrylamide 29:1) and stained with an anti-
CHK2 antibody.  (C) The EGFP-RAD9B-001 was over-expressed or left non-induced followed by 
whole protein extraction. The EGFP-RAD9B-001 was immunoprecipitated from the protein extract 
using the EGFP agarose beads before analysing on western blot for the indicated proteins. (IP): 
immunoprecipitate, (Ext): total extract. 
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5.2.3 Possible mediation for CHK2 interaction by the human RAD9B splice 
variants and the yeast Rad9M-50 
To gain more insight into the relationship between the RAD9B splice variants and the 
phosphorylation of CHK2, protein extracted from UV treated cells was analysed on native 
polyacrylamide gels. This allows the detection of differences in the native conformation or 
complex formation of proteins (Nowakowski, Wobig & Petering, 2014). Under native 
conditions CHK2 migrated in at least 3 forms in untreated EGFP-Control cells while p53 
produced 2 bands (Figure 5.3). After UV treatment with 40 J/m2, p53 increased in EGFP 
control cells. A similar band pattern was observed in UV treated cells expressing EGFP-
RAD9B-001, EGFP-RAD9B-002 or EGFP-Rad9-M50. Therefore, there were no variant 
specific changes to p53 (Figure 5.3). Interestingly, there was one important difference in the 
amount of the CHK2 middle form (form 2 in Figure 5.3) which increased very strongly in the 
presence of all three variants whereas form 3 did not increase as found in the control cell line. 
The other interesting observation was a faster migrating form of CHK2 in UV treated control 
cells which was absent in the presence of either RAD9 variant. Taken together this supports 
the conclusion that over-expression of the Rad9 variants has a specific impact on CHK2 
kinase. Unfortunately it is as yet unknown which post-translational modifications contribute 
to the observed changes in CHK2 mobility.   
 
 
 
Figure 5.3 Native-PAGE analysis of CHK2 and p53 response to UV radiation in the 
constructed cell lines. Whole protein was extracted from UV treated (40 J/m2, 1 hr recovery) over-
expressed EGFP-RAD9B-001, EGFP-RAD9B-002 and EGFP-Rad9-M50 and the EGFP-Control 
cell lines. Extracts were analysed on native-PAGE and probed with antibodies for the CHK2 and 
p53. The numbers indicate the isoforms.      
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5.2.4  RAD9B mRNA expression in response to UV light 
 
Based on published observations that RAD9B responds to UV light (Perez-Castro & Freire, 
2012), the mRNA levels were tested at different time points after UV treatment with 40J/m2. 
The expression of RAD9B was analysed using the quantitative PCR (qPCR) assay where its 
levels are normalised to two reference genes (TUBA and PB1).  
 
The effectiveness of the UV treatment was validated by the degradation of p21. Interestingly, 
the expression of RAD9B dropped immediately after the UV irradiation by 1.80 fold relative 
to  untreated cells, and this decline reached its maximum with a 2.94 fold decline 3 hrs post-
treatment (Figure  5.5-A). It is worth mentioning that the primers used for this qPCR are not 
specific to any of the RAD9B splice variants as the primers binds to exon 3 and exon 4 which 
are conserved in all 5 RAD9B splice variants. 
 
Since this qPCR test can not distinguish between the variants, the same RNA samples were 
analysed by one-step RT-PCR using more specific primers for the full-length mRNA 
molecules of RAD9B-001 and RAD9B-002 (the same two splice variants studied on the 
protein level in the constructed cell lines). Here the primers used previously for the cloning of 
RAD9B-001 and RAD9B-002 were used.  However, the primers that amplified the coding 
region of the RAD9B-001, as shown previously, also bind to RAD9B-002 and RAD9B-005, 
whereas the primers that amplified the coding region of the RAD9B-002 bind to RAD9B-002 
and RAD9B-005 (Figure 5.4).  
 
The RT-PCR test revealed a slight lower expression of both amplified RAD9B fragments 
RAD9B-001/002/005 and RAD9B-002/005 in UV-treated samples although the difference in 
expression was almost undetectable (Figure 5.5-B). This could be because of the small fold 
changes that are detected in the qPCR analysis arose from primers which detect all RAD9B 
variants. From the same cells, whole protein was extracted and run on a SDS-PAGE to test 
p21 protein levels. As expected, they dropped in the response to the UV treatment 
(Figure 5.5-C).  
 
To test whether this response was specific to the non-malignant HEK293 cells, the same 
treatment was applied to the HeLa (cervical cancer) and Kelly (neuroblastoma) cell lines. The 
Kelly cell line showed a high sensitivity to UV light as all cells died 24 hrs post-treatment. 
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This time point could therefore not be included in the analysis. Interestingly, HeLa cells 
appeared to be more resistant to UV light than either HEK293 or Kelly cells, as almost 90% 
of cells were alive 24 hrs post-treatment. However, for unknown reasons and in repeat tests 
no RNA could be obtained for this time point. It appears that mainly RAD9B-002/005 is 
down-regulated in both tumour cell lines with an additional decline in the Neuroblastoma cell 
line (Kelly) (Figure 5.6 & Figure 5.7). These results suggests that RAD9B remains expressed 
after UV damage but at a lower levels compared to untreated cells. 
 
 
Figure 5.4 Primer design to amplify RAD9B-001 and RAD9B-002 CDS. Sites of primer binding 
across RAD9B splice variants amplifying the CDS of RAD9B-001 and RAD9B-002. 
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Figure 5.5  Figure RAD9B mRNA expression levels drops in response to UV light in HEK293 
cells. (A) A bar chart demonstrating the expression of RAD9B in response to UV radiation in HEK293 
cells as analysed by qPCR. The primers that are used for this qPCR are not specific to any of the 
RAD9B splice variants as the primers bind to exon 3 and exon 4 which are conserved in all 5 RAD9B 
splice variants. The expression of RAD9B was normalised to TUBA and PB1 reference genes. The 
numbers on the top of columns represent the expression fold change compared to expression in the 
control (untreated cells). (B) RT-PCR of RAD9B-001/002/005 and RAD9B-002/005 in response to UV 
light in HEK293 cells. Cells were treated with UV light (40 J/m2) and total RNA was extracted at the 
indicated points. The expression of the RAD9B was normalised to the expression of ACTB. (C) Whole 
protein extracted from UV treated cells at the indicated points and immunoblotted for the p21 protein 
used for the UV treatment control. The GAPDH was used as the protein loading control. 
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Figure 5.6 Analysis of RAD9B mRNA expression in response to UV light in HeLa cells. (A) RT-
PCR of RAD9B-001/002/005 and RAD9B-002/005 in response to UV light in HeLa cells. Cells were 
treated with UV light (40 J/m2) and total RNA was extracted at the indicated points. The expression of 
the RAD9B was normalised to the expression of ACTB. (B) Whole protein extracted from UV treated 
cells at the indicated points and immunoblotted for the p21 protein used for the UV treatment control. 
The GAPDH was used as the protein loading control. 
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Figure 5.7 Analysis of RAD9B mRNA expression in response to UV light in Kelly cells. (A) RT-
PCR of RAD9B-001/002/005 and RAD9B-002/005 in response to UV light in Kelly cells. Cells were 
treated with UV light (40 J/m2) and total RNA was extracted at the indicated points. The expression of 
RAD9B was normalised to the expression of ACTB. (B) Whole protein extracted from UV treated cells 
at the indicated points and immunoblotted for the p21 protein used for the UV treatment control. The 
GAPDH was used as the protein loading control. 
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5.2.5 Dephosphorylation of Chk2 protein kinase upon RAD9B-002 over-
expression in response to UV radiation.  
Based on the results obtained for the aberrant CHK2 phosphorylation as a result of the over-
expression of RAD9B-001 and RAD9B-002 (Figure 5.2), the response of the ATM-CHK2 
pathway was analysed in the four cell lines: EGFP-Control, EGFP-RAD9B-001, EGFP-
RAD9B-002 and EGFP-Rad9-M50. The cell lines were exposed to UV light (40 J/m2) and 
whole protein was extracted at 30 min and 2 hr post-treatment. 
 
Analysis of CHK2 revealed two interesting observations. A faster migrating band was 
observed in most cell lines which increased in abundance during the recovery period with the 
exception of EGFP-RAD9B-002. The phosphorylation of CHK2 at Thr-68 which increased 
during the recovery period in the EGFP control cells and in EGFP-RAD9B-001 cells, did not 
accumulate to the same extend in the remaining to cell lines expressing either EGFP-RAD9B-
002 or the yeast variant  (Figure 5.8). The identity of the faster migrating CHK2 band is not 
known, but it could be a splice variant of the kinase (Berge et al., 2010), or CHK2-cleaved 
band (Golan et al., 2010). In summary, the data confirm a close link between the RAD9B 
variants and CHK2 and suggest that the UV-induced modification of CHK2 is normal in 
EGFP-RAD9B-001. In contrast, expression of EGFP-RAD9B-002 or the yeast variant seems 
to suppress CHK2 modification at Thr-68 in the presence of UV damage.   
 
The analysis of MPS1 revealed additional smaller bands in all cell lines. One of these bands, 
which appears at a size of 45 kD, is the most intense band and is down-regulated in the 
EGFP-RAD9B-002 and yeast Rad9 cell lines (Figure 5.8). This down-regulation correlates 
with the decrease in the faster migrating CHK2 band suggesting that both Rad9 variants may 
have an impact of the induction of these MPS1 and CHK2 smaller forms. 
  
As observed in the earlier experiments (Figure 4.21), p21 degradation is delayed when 
RAD9B-001 and RAD9-M50 are over-expressed. These results suggest that RAD9B-001 
delays the cellular response to UV damage, which coincides with the degradation of p21 
(Soria et al., 2006). 
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Figure 5.8 Over-expression of EGFP-RAD9B-002 dephosphorylates the CHK2 protein in 
response to UV light. The four constructed cell lines, EGFP-Control, EGFP-RAD9B-001, EGFP-
RAD9B-002 and EGFP-Rad9M50, were over-expressed over-night, followed by UV exposure (40 
J/m2), then cells were left to recover for 30 min and 2 hr. Whole protein was extracted from the 
recovered cells and subjected to normal SDS-PAGE and immunoblotted with the indicated 
antibodies. GAPDH was used as a loading control. 
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5.2.6 RAD9B mRNA expression in response to heat stress 
In the previous chapter, over-expression of the RAD9B-001 or RAD9B-002 did not show any 
negative influence on the phosphorylation of CHK1 protein kinase in response to heat stress. 
This indicated that they play a different role than that of the yeast Rad9-M50. Here, the 
expression levels of RAD9B in the response to heat stress was analysed in HEK293, HeLa and 
Kelly cells. Heat stress was applied by incubating cells at 43°C for 1 hr followed by a 
recovery period of up to 24 hr (Figure 5.9). Analysis was performed on the total RNA 
extracted from the recovered cells by using the one-step RT-PCR.  
 
When HEK293 cells were heat treated, the expression levels of RAD9B-001/002/005 and 
RAD9B-002/005 were reduced 3 hr after the heat treatment, and the expression remained low 
for up to 24 hr. As shown previously (Figure 4.22-B), p21 expression levels increased in the 
response to heat stress in HEK293 cells (Figure 5.9-B). The expression of RAD9B in response 
to heat stress was also analysed in the two cancer cell lines, HeLa and Kelly, but with samples 
taken after shorter recovery times. In HeLa cells, RAD9B-002/005 expression dropped already 
30 min after the end of the heat stress period. The expression remained low up to 24 hr post-
treatment. As the primers used detect RAD9B-002 and RAD9B-005 it is unclear which of the 
two genes is down-regulated (Figure 5.10-A). As found in HEK293 cells, p21 expression also 
increased in the HeLa cells to an even greater extent (Figure 5.10-B). In Kelly cells the 
expression levels of RAD9B-001/002/005 and RAD9B-002/005 remained stable in response to 
heat stress. Also the expression of p21 remained stable, suggesting that the neuroblastoma 
cells have a different response to elevated temperatures (Figure 5.11-A & B).   
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Figure 5.9 Analysis of RAD9B response to heat stress in HEK293 cell line. (A) RT-PCR of 
RAD9B-001/002/005 and RAD9B-002/005 in response to heat stress. Cells were incubated at elevated 
temperature (43°C) for 1 hr and total RNA was extracted at the indicated points. The expression of the 
RAD9B was normalised to the expression ACTB. (B) Whole protein was extracted from the heat 
treated cells at the indicated points and immunoblotted for the p21 protein used as the heat treatment 
control. The GAPDH was used as a protein loading control. 
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Figure 5.10 Analysis of RAD9B response to heat stress in HeLa cell line. RT-PCR of RAD9B-
001/002/005 and RAD9B-002/005 in response to heat stress. Cells were incubated at an elevated 
temperature (43°C) for 1 hr and total RNA was extracted at the indicated points. The expression of 
RAD9B was normalised to the expression ACTB. (B) Whole protein was extracted from heat treated 
cells at the indicated points and immunoblotted for the p21 protein used for as the heat treatment 
control. The GAPDH was used as a protein loading control. 
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Figure 5.11 Analysis of RAD9B response to heat stress in Kelly cell line. (A) RT-PCR of RAD9B-
001/002/005 and RAD9B-002/005 in response to heat stress. Cells were incubated at elevated 
temperature (43°C) for 1 hr and total RNA was extracted at the indicated points. The expression of 
RAD9B was normalised to the expression of ACTB. (B) Whole protein was extracted from the heat 
treated cells at the indicated points and immunoblotted for the p21 protein used as the heat treatment 
control. The GAPDH was used as a protein loading control. 
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5.2.7 Over-expression of EGFP-RAD9B-001 results in high phosphorylation 
of CHK2 in the response to heat stress 
To test whether expression of the human RAD9B variants has an impact on the modification 
of CHK2 under heat stress conditions, ATM, CHK2, MPS1, p53 and p21 were analysed after 
incubation at 43°C for 1 hr. Samples were collected 30 min and 2 hr post-treatment. Since, the 
CHK2 protein was not found to be phosphorylated in response to heat stress in previous 
chapter (Figure 4.19), here the concentration of the antibody was doubled to allow for the 
detection of CHK2 phosphorylation in case it occurred. As shown in Figure 5.12, CHK2 
phosphorylation at Thr-68, which was only very slightly induced in the EGFP control cells, 
was strongly upregulated in cells expressing EGFP-RAD9-001 and to a lesser degree in 
EGFP-RAD9B-002 expressing cells. This is in line with the hyper-phosphorylation of CHK2 
in untreated EGFP-RAD9B-001 cells and to the partial hyper-phosphorylation in EGFP-
RAD9B-002 cells (Figure 5.2). Interestingly up to three phosphorylated CHK2 bands were 
observed. As in the previous experiment (Figure 5.8) the levels of the faster migrating CHK2 
band and the 45 kD Mps1 band were decreased in heat-treated EGFP-RAD9B-002 cells 
(Figure 5.12).  
 
Taken together these findings strengthen the conclusion that over-expression of the shorter 
001 variant of human RAD9B has a specific impact on CHK2 phosphorylation especially in 
untreated or heat treated cells. A similar function is not provided by the related yeast variant. 
Full-length RAD9B-002 has also an impact on CHK2 modification which is however much 
reduced compared to its shorter variant. It should be pointed out that the amino acid sequence 
is identical between RAD9B-001 and RAD9B-002, and that the only difference between the 
variants is the absence of the N-terminal 72 aa. 
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Figure 5.12 Analysis of CHK2 phosphorylation in response to heat stress in the 
constructed cell lines. The four constructed cell lines, EGFP-Control, EGFP-RAD9B-001, 
EGFP-RAD9B-002 and EGFP-Rad9-M50, were induced with doxycycline over-night followed by 
heat treatment (43°C) for 1 hr and cells were then left to recover for 30 min and 2 hr. Whole protein 
was extracted from the recovered cells and was subject to normal SDS-PAGE immunoblotted with 
the indicated antibodies. GAPDH was used as a loading control.   
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5.2.8 RAD9B-001 and RAD9B-002 are required after oxidative DNA 
damage. 
Oxidative stress can lead to both DNA single and double strand breaks (Driessens et al., 
2009). Therefore, the expression of RAD9B-001 and RAD9B-002 was analysed in cells treated 
with moderate doses of H2O2 (500 µM). As in the previous treatments, the transcriptional 
RAD9B response was analysed in the normal cell line (HEK293) and the cancer cell lines 
(HeLa and Kelly). Of the three cell lines, and similar to the UV treatment, the Kelly cells 
revealed a high sensitivity to H2O2, as the treatment was 100% lethal after  less than 24 of 
incubation with H2O2, therefore the response of RAD9B was analysed only up 4 hr after 
addition of the drug. 
 
The RAD9B-002/005 mRNA expression was found to be mostly stable for up to 24 hr after 
the addition of H2O2 in HEK293 cells (Figure 5.13). Surprisingly, the RAD9B-001/002/005 
expression increased significantly after 1 hr of incubation with H2O2 and remained high 
throughout the rest of the experiment. 24 hr after incubation with H2O2 almost 100% of 
HEK293 cells were alive despite morphological alterations due to the oxidative stress. This 
suggests that 500 µM H2O2 is a sub-lethal dose for HEK293 cells. 
  
In HeLa cells, the RAD9B-001/002/005 mRNA expression peaked between 2hr and 4hr with a 
transient drop at the 30min time point. The levels of RAD9B-002/005 did not change (Figure 
5.14).  
 
Kelly cells did not reveal a change of any mRNA levels. There was only a drop after 4 hr 
which could be linked with their high sensitivity to oxidative stress (Figure 5.15). 
  
 In both the HeLa and Kelly cell lines, p21 was quickly degraded after the addition of H2O2. 
The degradation of p21 in both cell lines was irreversible indicating that these cancer cell 
lines might have had an instant response to oxidative stress. However, different results for p21 
were observed in the HEK293 cell line. Here, the p21 protein was degraded after the start of 
the treatment, as in HeLa and Kelly cells, but the levels recovered significantly 24 hr after 
incubation with H2O2.  
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These results indicate that the RAD9B splice variants are required for the response to 
oxidative stress in HEK293 and HeLa cells. In addition, these results show clearly how 
different cells can respond the same type of cellular stress.    
 
 
 
 
 
Figure 5.13 RAD9B-001 mRNA expression levels increase in response to H2O2 in HEK293 cells. 
(A) Expression levels of RAD9B-001/002/005 and RAD9B-002/005 in response to H2O2. Cells were 
incubated with 500 µM and total RNA was extracted from normal (control) and treated cells at the 
indicated time points. The expression levels of RAD9B-001/002/005 and RAD9B-002/005 were 
detected in normal and treated cells using the one step RT-PCR. The expression of the RAD9B splice 
variants was normalised to the expression ACTB. (B) Whole protein was extracted from H2O2 treated 
cells at the indicated time points and immunoblotted for the p21 protein used as the H2O2 treatment 
control. The GAPDH was used as a protein loading control. 
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Figure 5.14 RAD9B-001 mRNA expression level increases in response to H2O2 in HeLa cells.  
(A) Expression levels of RAD9B-001/002/005 and RAD9B-002/005 in response to H2O2. Cells were 
incubated with 500 µM H2O2 and total RNA was extracted from normal (control) and treated cells at 
the indicated time points. The expression levels of RAD9B-001/002/005 and RAD9B-002/005 were 
detected in normal and treated cells using the one step RT-PCR. The expression of the RAD9B splice 
variants was normalised to the expression of ACTB. (B) Whole protein was extracted from H2O2 
treated cells at the indicated time points and immunoblotted for the p21 protein used as H2O2 treatment 
control. The GAPDH was used as a protein loading control. 
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Figure 5.15 Analysis of RAD9B splice variants in response to H2O2 in the Kelly cell line. (A) 
Expression levels of RAD9B-001/002/005 and RAD9B-002/005 in response to H2O2. Cells were 
incubated with 500 µM H2O2 and total RNA was extracted from normal (control) and treated cells at 
the indicated time points. The expression levels of RAD9B splice variants were detected in normal and 
treated cells using the one step RT-PCR. The expression of the RAD9B splice variants was normalised 
to the expression of ACTB. (B) Whole protein was extracted from H2O2 treated cells at the indicated 
time points and immunoblotted for the p21 protein used as H2O2 treatment control. The GAPDH was 
used as a protein loading control. 
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5.2.9 Over-expression of EGFP-RAD9B-001 results in increased 
phosphorylation of Chk2 in response to H2O2.  
On the basis of the results described previously (Figure 5.13), H2O2 appears to be an inducer 
of the RAD9B-001 splice variant, therefore, the role of this variant in response to H2O2 was 
investigated further in the EGFP-RAD9B-001 constructed cell line. The analysis of CHK2 
phosphorylation at Thr-68 revealed a strong response to oxidative stress in cells over-
expressing EGFP-RAD9B-001 (Figure 5.16). While CHK2 was phosphorylated after 2 hr and 
4 hr in the presence of hydrogen peroxide in the EGFP control cell line, the levels were 
strongly increased in the presence of EGFP-RAD9B-001 and to a lesser extent in the presence 
of the yeast variant (Figure 5.3). Interestingly, the high phosphorylation of CHK2 in the 
EGFP-RAD9B-001 cell line correlates with increased RAD9B-001 mRNA levels in response 
to H2O2 (Figure 5.13). The other interesting observation was the very low CHK2 
phosphorylation levels in the presence of EGFP-RAD9B-002 which could indicate that this 
variant suppresses CHK2 modification as observed in  
Figure 5.8. 
 
As shown previously, the p21 protein levels dropped in the response to H2O2. Surprisingly, 
expression of EGFP-RAD9B-002 at the 2 hr time point showed unusually high p21 levels 
(Figure 5.16).  
 
When the H2O2 treated samples were analysed on a phos-tag SDS page, neither RAD9B-001 
nor RAD9B-002 revealed any changes in their phosphorylation status after 2 hr and 4 hr of 
incubation with H2O2. However, the yeast Rad9-M50 variant became phosphorylated in  
response to H2O2 (Figure 5.17). This indicates that human cells recognise the yeast variant 
during the response to oxidative stress. 
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Figure 5.16 Exposure of EGPF-RAD9B-001 and EGFP-RAD9B-002 to H2O2 reveals different 
status in the phosphorylation of CHK2. Representative western blot shows levels of ATM, p-ATM, 
CHK2, p-CHK2, MPS1, p-p53 and p21 obtained from the over-expressed constructed cell lines 
exposed to H2O2 (500 µM) for 2 hr and 4 hr. GAPDH was used as a positive control. 
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Figure 5.17 Separation of EGFP-RAD9B-001, RAD9B-002 and EGFP-Rad9-M50 H2O2 treated 
samples on phos-tag SDS-PAGE. Cell lines were incubated with H2O2 (500 µM) for 2 and 4 hr. 
Whole protein extracted from normal and treated cells was analysed on phos-tag SDS-PAGE. Only the 
Rad9-M50 revealed an additional top band in response to H2O2, reflecting the phosphorylation 
isoform. 
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5.2.10   Dephosphorylation of CHK2 by hRad9B-002 in response to H2O2  
may be dependent on MPS1 protein. 
To investigate the possible role of RAD9B-002 in dephosphorylating the CHK2 kinase in  
response to H2O2 and to find out whether the dephosphorylation is dependent on MPS1 
kinase, the phosphorylation status of CHK2 kinase was analysed in the presence and absence 
of the MPS1 inhibitor (AZ 3146, Selleck Chemicals) in response to H2O2 in the over-
expressing RAD9B-002 cell line. To inhibit the Mps1, cells were incubated with 2µM of AZ 
3146 for 72 hr. Cells were then exposed to 500μM H2O2 for 2 hr. 
  
Western blot analysis revealed that CHK2 is indeed a target of MPS1 kinase as its 
phosphorylation was reduced upon inhibition of MPS1 under oxidative stress conditions. As 
observed previously, induction of EGFP-RAD9B-002 reduced CHK2 phosphorylation in the 
presence of hydrogen peroxide. Interestingly, the reduction was partly released upon 
inhibition of MPS1 (Figure 5.18). These results indicate that CHK2 kinase is de-
phosphorylated in EGFP-RAD9B cells in a manner partly dependent on MPS1 kinase. 
Moreover, CHK2 protein levels also seemed to be reduced when MPS1 protein was blocked 
in both the induced and non-induced EGFP-RAD9B-002 cell line.  
 
The main band of the MPS1 (95 kD) was not affected by either its inhibition or the over-
expression of EGFP-RAD9B-002. However, the 45 kD band, which increased in intensity 
upon induction of the RAD9B variant, was affected by Mps1 inhibition (Figure 5.18). This 
implies that the induction of RAD9B-002 increases this 45 kD band in a manner dependent on 
MPS1 kinase. If this smaller band is a cleavage product of MPS1, RAD9B-002 may affect 
this cleavage but only when MPS1 is active (Figure 5.18). Taking this together, RAD9B-002 
may function in relationship with MPS1 in the regulation of CHK2 phosphorylation.  
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Figure 5.18 Analysis of CHK2 phosphorylation in response to H2O2 after inhibition of MPS1 
kinase in over-expressed EGFP-RAD9B-002 cell line. EGFP-RAD9B-002 cells were either 
incubated with MPS1 inhibitor (2µM) for 72 hr or were left untreated. The EGFP-RAD9B-002 cell 
line then was either induced with doxycycline (1 µg/ml) or left without induction. The cells then  were 
incubated with H2O2 (500 µM) for 2 hr and whole protein was extracted and subjected to SDS-PAGE, 
immunoblotted with GFP, MPS1, CHK2 and p-CHK2 antibodies. GAPDH was used as a loading 
control. 
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 Discussion 
The key findings of this chapter are as: (1) elevated levels of RAD9B-001 and to a lesser 
extent RAD9B-002 result in high phosphorylation of CHK2 kinase in untreated cells. (2) 
Over-expression of RAD9B-002 inhibit the phosphorylation of CHK2 at Thr-68 in the 
response to UV light and oxidative stress caused by H2O2 in an ATM-independent manner. 
This influence on the phosphorylation of CHK2 seems to be dependent on the mitotic MPS1 
kinase. (3) An opposite role was detected for the RAD9B-001 variant in controlling the 
phosphorylation of CHK2 in the response to H2O2. CHK2 appeared highly phosphorylated 
compared to the treated control cell line. This increased phosphorylation at Thr-68 is in line 
with the increased mRNA expression of RAD9B-001 in response to H2O2. 
 
Over-expression of RAD9B-001 or RAD9B-002 results in the elevated phosphorylation of 
CHK2 kinase under normal conditions in a manner which appears independent of ATM 
(Figure 5.2). Similar results were obtained in the previous chapter with p21 phosphorylation. 
Moreover, over-expression of RAD9B-001 caused a transient G1 arrest which has also been 
reported upon over-expression of p21 (Mansilla et al., 2013).  
 
CHK2 kinase is phosphorylated at Thr-68 by ATM in the response to DNA damage. ATM 
activation depends on the type of DNA lesion. When DNA breaks occur, ATM is recruited to 
the break by NBS1 in the RAD50-MRE11-NBS1 complex and undergoes 
autophosphorylation at Ser-367, Ser-1893, Ser-1981 and Ser-2996 and TIP60-dependent 
acetylation at K3016 (Stracker et al., 2013). However, in the response to oxidative stress, 
ATM forms an active homodimer upon oxidation of cysteine residues. Both conditions result 
in the phosphorylation of CHK2 kinase. Interestingly, over-expression of RAD9B-001 and to 
a lesser extend RAD9B-002 results in the hyper-phosphorylation of CHK2 in untreated 
HEK293 cells (Figure 5.2). This indicates that the phosphorylation of CHK2 is a result of 
either the presence of DNA damage caused by the over-expression or the recruitment of a 
kinase to CHK2. 
 
The partial hyper-phosphorylation of CHK2 in untreated RAD9B-002 cells could be linked 
with the appearance of the sub-G1 cell population which may have undergone cell death in 
the response to chromatin abnormalities. 
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It is however interesting that ATM phosphorylation was not elevated at Ser-1981 (Figure 5.2) 
which indicates that another kinase targets CHK2 under these conditions. Over-expression of 
RAD9B-001, the shorter variant, did only transiently arrest cells in G1 but caused high CHK2 
phosphorylation in untreated cells (Figure 5.2). This implies that the shorter variant also 
targets another kinase to CHK2 as no changes to ATM phosphorylation at Ser-1981 were 
observed (Figure 5.2). 
 
Interestingly, when RAD9B-002 was over-expressed in response to UV radiation, the CHK2 
Thr-68 phosphorylation was significantly reduced compared to the high phosphorylation in 
the control cell line (Figure 5.8). UV-irradiated cells have increased levels of the tumour 
suppresser p53, but over expression of RAD9B-002 had no impact on p53 under these 
conditions (Figure 5.8) suggesting that the changes to CHK2 modification are not channelled 
into the p53 pathway. The delay of p21 degradation by high RAD9B-001 and yeast Rad9-
M50 protein levels (Figure 5.8) do however not correlate with the hyper-phosphorylation of 
CHK2 as this is absent in cells with high levels of the yeast variant . This shows that the 
impact on p21 degradation in the response to UV is independent of the changes to CHK2 Thr-
68 phosphorylation.  
 
The experiments this chapter revealed a possible functional link between the RAD9B and  
MPS1 kinase.  MPS1 kinase plays a role in the cell response to UV radiation, oxidative stress 
and during mitosis at the centrosome (Marquardt et al., 2016). Cells with down-regulated 
MPS1 showed a reduction in the phosphorylation of CHK2 at Thr-68 and a G2/M arrest 
defect after UV radiation with a population of sub-G1 cells (Wei et al., 2005). Interestingly, 
MPS1 levels in addition to its smaller forms were reduced upon over-expression of EGFP-
RAD9B-002 in response to UV radiation, while this reduction correlated with a reduction in 
the phosphorylation of CHK2 (Figure 5.8). It is therefore likely that elevated levels of 
RAD9B-002 affect MPS1 kinase in response to UV damage which consequently results in a 
reduction in CHK2 Thr-68 phosphorylation. This is in line with the ability of MPS1 to target 
Thr-68 (Wei et al., 2005) and its activation in response to DNA damage caused by UV light 
(Huang & Shieh, 2016; Zhang et al., 2013).  
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In response to the oxidative stress caused by H2O2, both kinases, ATM and CHK2, in addition 
to histone H2AX serine-139 modification are activated. The phosphorylation of these proteins 
was detected mostly in S phase (Zhao et al., 2008). When oxidative stress was triggered in the 
RAD9B cell lines, the CHK2 phosphorylation at Thr-68 was significantly reduced upon 
RAD9B-002 over-expression, but increased phosphorylation was detected in the RAD9B-001 
over-expressing cell line (Figure 5.16). As summarised in the chapter 3, RAD9B-002 mRNA 
expression levels were reduced when cells underwent the G1-S transition which indicates that 
RAD9B-002 interferes with this cell cycle stage. Alternatively, it may also indicate that 
RAD9B-002 is not expressed during S phase. Taking this together, it may be possible that 
forced elevated levels of RAD9B-002 result in a drop in the CHK2 phosphorylation during S 
phase. 
 
The MPS1 inhibitor experiment (Figure 5.18) is in line with this suggestion as CHK2 Thr-68 
phosphorylation levels are reduced upon the down-regulation of MPS1 activity. Interestingly, 
the negative impact of RAD9B-002 over-expression on CHK2-Thr-68 modification is 
mitigated upon inhibition of MPS1 which implies that the variant depends on high MPS1 
activity to block or dephosphorylate CHK2-Thr-68. Given that MPS1 activity is essential for 
the spindle attachment checkpoint at the kinetochore during mitosis (Isokane et al., 2016), it 
could be that elevated RAD9B-002 levels affect CHK2-Thr-68 modification during mitosis. 
Thr-68 phosphorylated CHK2 is localised to the centrosome where it can be phosphorylated 
by Polo like kinase 1 (PLK1) (Tsvetkov et al., 2003). Human MPS1 kinase is required for 
centrosome duplication during S phase through regulation by CDK2 which phosphorylates 
MPS1 directly and this phosphorylation suppresses the protostome-mediated degradation of 
MPS1 (Cui et al., 2010; Kasbek, Yang & Fisk, 2009). Since CHK2 phosphorylates MPS1 at 
Thr-288 in the response to IR which leads to G2/M arrest (Yeh et al., 2009; Wei et al., 2005), 
it is possible that RAD9B-002 interferes with a kinase system at the centrosome and/or the 
kinetochore during mitosis which consists of CHK2, MPS1 and PLK1. Since the data for the 
different treatments revealed that over-expression of RAD9B-002 reduced the amount of a 
smaller, 45 kD band of MPS1, the variant may also suppress the proteasome-mediated 
degradation of MPS1 during G1 and S phase and thereby indirectly affect the centrosome. As 
shown in the model (Figure 5.19), the best explanation of the results is provided by a negative 
impact of RAD9B-002 on PLK1 kinase.  
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The key observation is that inhibition of MPS1 kinase partly restores CHK2-Thr-68 
phosphorylation by reducing the ability of RAD9B-002 to negatively impact on it         
(Figure 5.18). This strongly indicates that MPS1 is not blocked by the variant but that MPS1 
is required to stimulate a protein which is the target of RAD9B-002. If RAD9B-002 were to 
directly block MPS1, its over-expression and the inhibition of MPS1 should have an additive 
impact on CHK2-Thr-68 phosphorylation causing a much stronger reduction which is not the 
case. It is therefore more likely that RAD9B-002 blocks CHK2-Thr-68 modification by 
down-regulating PLK1 kinase or another kinase which can target CHK2-Thr-68. This view is 
supported by a close functional relationship between MPS1 and PLK1 kinase (von Schubert 
et al., 2015).  
 
 
 
Figure 5.19 Possible down-regulation of polo like kinase (PLK1) by RAD9B-002. Over-expression 
of RAD9B-002 may reduce CHK2-T68 phosphorylation in the presence of UV light and oxidative 
DNA damage by down-regulating PLK1. This down-regulation may require the activity of MPS1 at 
the kinetochore or centromere. 
 
 
A role of RAD9B-002 at the centromere may also explain the accumulation of sub-G1 cells 
and the strong growth reduction upon its over expression. It would be interesting to test 
whether mitotic markers are accumulated in these cells and whether the biology of PLK1 is 
affected. 
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Chapter 6:  GENERAL DISCUSSION 
 
The current study focused on the role of the RAD9B splice variants in human cells. The study 
analysed the endogenous RAD9B expression at the mRNA level, since no commercial product 
is currently available to detect the RAD9B protein. In addition, the study analysed the effects 
of the over-expression of RAD9B-001 variant and full-length RAD9B-002 on the progression 
of the cell cycle and on the checkpoint pathways in the response to different types of DNA 
damage. The study discovered a number of interesting findings for each of the two RAD9B 
splice variants and revealed a possible relation between them. Table 6.1 summarises the over-
expression effects of the RAD9B splice variants on cell proliferation and checkpoint proteins. 
Table 6.1 Summary of the over-expression phenotypes 
Rad9 
Variant 
Cell Cycle 
Effect 
CHK2- 
Phosph 
CHK2- 
Phosph 
UV 
Light 
Cleavage 
of Rad9 
variant 
p21 Deg 
UV 
Light 
p21- 
Phosph 
CHK2- 
Phosph 
H2O2 
p21 Deg 
Oxidative 
stress 
 
 
RAD9B 
001 
(345aa) 
 
G1 arrest 
Hyper Normal None Delayed Yes Hyper Not 
delayed 
RAD9B
002 
(417aa) 
Sub-G1 
population 
Partially 
hyper 
Reduced Cleaved Not 
delayed 
Yes Reduced Delayed 
Yeast 
Rad9 
(377aa) 
None None Reduced None Delayed None Normal Not 
delayed 
*deg: degradation.*phosph: phosphorylation. 
 
 Low expression of RAD9A and RAD9B         
Previous studies on RAD9B expression were mainly based on the northern blot technique 
rather than the RT-PCR assay which is more sensitive (Hopkins et al., 2003, Dufault et al., 
2003). The northern blot has great specificity and allows for the detection of potential spliced 
transcripts of a gene in addition to giving a clear indication of the abundance of the particular 
gene. The disadvantage of using the northern blot assay is that it is not sufficiently accurate 
for the detection of weakly expressed genes. In such a situation, RT-PCR is the better option. 
In this project, RT-PCR analysis revealed contrary results for the expression of RAD9B splice 
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variants compared to previous published works. While earlier work identified three RAD9B 
transcripts in testis, skeletal muscle and heart, the more sensitive RT-PCR test revealed 
expression in most tested human tissues. However, RAD9B expression was extremely weak 
and the full length transcripts were only detected when the high sensitivity RT-PCR kits were 
used. The presence of RAD9B transcription across a wide range of human tissues indicates 
that the protein plays an essential role in different cell types in the body.  
 
Interestingly, a study on Rad9 expression in S. pombe cells found that Rad9 is expressed at a 
very low level and it was difficult to clone the cDNA (Murray et al., 1991). Work in budding 
yeast (S. cerevisiae) revealed that most genes involved in DNA repair have low expression     
(Friedberg, 1988). During evolution, low expression levels may have protected cells from the 
aberrant activation of the DDR genes. For example, high levels of RAD9A could induce 
apoptosis like elevated levels of HUS1B (Lee, Hirai & Wang, 2003; Hang et al., 2002). 
Expression of RAD9B seems to oscillate throughout the cell cycle as shown by the specific 
increase in RAD9B mRNA during the G1 phase (Figure 3.11). It should however be noted that 
high mRNA levels do not automatically translate into high protein levels as additional 
regulations are in place in the cell to control protein synthesis. It is also possible that the 
transcribed mRNA fulfils structural or regulatory functions independently from its role in 
translation (Kloc, Foreman & Reddy, 2011).  
 
Many DDR genes are up-regulated in the presence of DNA lesions. For example, expression 
of p21 upon ionising radiation promotes a G1 cell cycle arrest (Abbas & Dutta, 2009). These 
conditions may also increase the levels of alternative transcripts of DNA repair or checkpoint 
genes (Forrester et al., 2012). This is consistent with the findings in this work that oxidative 
damage increases the expression of RAD9B-001 (Figure 5.13).  
 
Compared to RAD9B, expression of RAD9A is higher but still at a low level compared to 
many other genes, Rad9A is expressed in a wide variety of tissues and cell lines. A northern 
blot analysis using 16 different normal tissues showed expression of RAD9A in all tissues, 
whereas expression of RAD9B was only detected in testis, skeletal muscle and heart. The 
mouse Rad9b gene revealed a similar very low expression pattern to the human RAD9B 
(Hopkins et al., 2003). This difference suggests that cells tolerate only very low levels of 
RAD9B and that RAD9B may be responsible for infrequent events or events which occur 
only in a sub-compartment of the cell. This notion is in line with the role of RAD9B in the 
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nucleolus after UV irradiation (Perez-CastroFreire, 2012) and the observation in this work 
that over-expression of RAD9B-001 delays cells in G1 (Figure 4.13 & 4.14). It is noteworthy 
that RAD9A is well known for its role in the activation of the ATR-CHK1 pathway at DNA 
lesions with single-stranded DNA but has no direct impact on the ATM-CHK2 system at 
broken chromosomes which did not undergo end resection (Ohashi et al., 2014). The results 
presented here suggest that RAD9B impacts on the modification of CHK2 kinase but not of 
CHK1. This would place RAD9B in the context of the ATM-CHK2 pathway and may explain 
why gene duplication was necessary during the evolution of multicellular organisms. In single 
cell organisms like the fission yeast ATR (Rad3) activates both Chk1 and Chk2 which would 
make a second Rad9 protein dedicated to the ATM (Tel1)-Chk2 system obsolete. 
  
 
 The role of RAD9A and RAD9B in tumorigenesis 
To find out whether changes in the RAD9B gene are associated with cancer development, the 
148 cancer studies curated in the cBioPortal database were searched for RAD9B alterations 
(http://www.cbioportal.org. Accessed 11 February 2017). As shown in Figure 6.1, 59 studies 
reported changes in this gene, which were on average less frequent when compared with other 
cancer promoting genes. It was however interesting to see that the majority of changes are 
amplifications of the RAD9B gene. In line with the earlier discussion on the low expression 
level of RAD9B, this implies that cancer cells may benefit from higher levels of RAD9B. The 
highest number of cases (19) were reported in the Neuroendocrine Prostate Cancer (NEPC) 
(Trento/Cornell/Broad 2016) study (Beltran et al., 2016). It was very interesting to find that 
mutations in three genes, PSD1 (significance 3.2), FANCI (significance 2.3) and PDP1 
(significance 1.2) had a high co-occurrence rate with the amplification of the RAD9B gene 
(Figure 6-2). The PSD1 gene encodes a Pleckstrin homology and SEC7 domain-containing 
protein that functions as a guanine nucleotide exchange factor. It regulates signal transduction 
by activating ADP-ribosylation factor 6 (ARF6). ARF6 is involved in cell migration and the 
formation of metastasis (Sabe, 2003). 
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FANCI is a member of the Fanconi anemia protein complex. It is required for the repair of 
DNA double-strand breaks by homologous recombination and in the repair of interstrand 
DNA cross-links (Boisvert & Howlett, 2014). PDP1 encodes the Pyruvate Dehydrogenase 
Phosphatase Catalytic Subunit 1 which has phosphatase activity and locates to the matrix of 
the mitochondria (Vassylyev & Symersky, 2007). 
 
 
Figure 6.2 Genetic mutations which co-occur with the amplification of the RAD9B gene. 
Mutations in the three genes co-occur with RAD9B amplification (the three blue dotes at log 10 Ratio 
above the dotted line with high significance). The genes are PSD1 (significance 3.2), FANCI 
(significance 2.3) and PDP1 (significance 1.2). (http://www.cbioportal.org. Accessed 11 February 
2017). 
 
The gene with the highest probability of being co-amplified with RAD9B is EFNA5 (Figure 
6-3). The EFNA5 protein is a tyrosine kinase cell surface receptor which is involved in 
normal hematopoietic development and tumorigenesis (Kuang et al., 2010). 
 191 
 
 
Figure 6.3 Genetic amolifications which co-occur with the amplification of the RAD9B gene. The 
highest probability of co-amplification has the EFAN5 gene. (http://www.cbioportal.org. Accessed 11 
February 2017). 
 
Using the Catalogue of Somatic Mutations in Cancer (COSMIC) database 
(http://cancer.sanger.ac.uk/cosmic. Accessed 11 February 2017), the number of somatic point 
mutations in RAD9B was analysed. The database curates currently 36 somatic mutations in 
the N-terminal 260 amino acid long PCNA-like domain of RAD9B. The majority, 72% (26 
mutations), are missense mutations. The mutation D141N displays the highest frequency. 
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Figure 6.4 Somatic point mutations in human RAD9B. The COSMIC database currates currently 36 
somatic mutations in the N-terminal 260 amino acid long PCNA-like domain. 72% (26 mutations) are 
missense mutations shown in this diagram. The mutation D141N displays the highest frequency. 
(http://cancer.sanger.ac.uk/cosmic. Accessed 11 February 2017). 
 
The total number of somatic mutations in RAD9B are extremely low demonstrating a 
mutation frequency of less than 1% for all tested tissues. This suggests that these mutations 
are unlikely to be causatively linked with the development of cancer. It is more likely that 
they are passenger mutations that arise due to an increase in genomic instability in cancer 
tissues (Pon & Marra, 2015).   
 
While aberrant expression of human RAD9A has been linked to several cancers, including 
skin, lung, prostate, thyroid and breast tumorigenesis, there is very limited evidence that 
RAD9B is a driver of malignant growth. High expression levels of RAD9A were detected in 
breast tumours, where 52.1% of breast tumours over-expressed RAD9A mRNA, and knock-
down of RAD9A protein levels in the MCF-7 breast cancer cell line inhibited their 
proliferation. This suggests a link between high RAD9A abundance and growth control 
(Lieberman et al., 2011; Cheng et al., 2005). In a study on RAD9A expression in prostate 
cancer tissue, a strong correlation between RAD9A protein levels and the stage of prostate 
cancer was reported. Of all prostate cancer samples that were tested, 40.01% were positive for 
Rad9A expression. In contrast, only 3.8% of normal prostate tissues revealed weak expression 
of Rad9A. This aberrant expression of RAD9A has been linked to a methylation event of a 
transcription repressor located in the second intron of RAD9A, which is responsible for its 
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high abundance (Zhu, Zhang & Lieberman, 2008; Cheng et al., 2005). A high abundance of 
RAD9A was also reported in three prostate cancer cell lines, namely CWR22, DU145 and   
PC-3. Only one study has reported the expression of RAD9B in several cancer cell lines, such 
as K562 (myelogenous leukaemia), OVCAR5 (ovarian adenocarcinoma) and HeLa (human 
cervix epithelioid carcinoma) (Hopkins et al., 2003). The expression of RAD9B in HeLa cells 
in addition to brain neuroblastoma cells (Kelly) was also confirmed in this study.  
 
 
 The toxicity of RAD9B-002 over-expression 
As discussed previously (Figure 4.28), a possible explanation for the appearance of a sub-G1 
cell population in cells over-expressing RAD9B-002 is provided by the link between RAD9A 
and the apoptotic pathway. High protein levels of full-length RAD9B-002 may release 
RAD9A from the 9-1-1 complex resulting in its accumulation in the cytoplasm where it could 
induce apoptosis by interacting with the anti-apoptotic protein BCL-XL. In addition, RAD9B 
may directly interact with BCL-XL through its N-terminal domain, in a similar way as shown 
for the corresponding domain of RAD9A (Lee, Hirai & Wang, 2003). While the first 
possibility is supported by the high homology between the N-terminal section of RAD9A and 
RAD9B, the second possibility is in line with the presence of a BCL-2 homology 3 (BH3) 
domains in RAD9A and RAD9B. This is one of four domains (BH1, BH2. BH3 and BH4) 
which are conserved among BCL-2 family members and required for their interactions and 
functions in controlling cell death. While the BH1 and BH2 domains are conserved in anti-
apoptotic members, the BH3 domain is present in pro-apoptotic proteins. RAD9A is known to 
interact via its BH3 domain with the anti-apoptotic proteins BCL-2 and BCL-XL to inhibit 
their role and to initiate cell death. Since this region is also conserved in RAD9B, it is likely 
that RAD9B plays a similar role to RAD9A in initiating cell death, a conclusion which is 
supported by the toxicity of RAD9B-002 when over expressed (Hopkins et al., 2003; 
Komatsu et al., 2000). 
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 The role of RAD9B-001 and RAD9B-002 in cell cycle regulation, DNA 
damage response and cell death 
 
6.4.1 Is p21 modification by RAD9B-001 or RAD9B-002 direct? 
The role of p21 in binding to the G1-cyclin-CDK complexes and causing a G1 cell cycle 
arrest is well known (Harper et al., 1995). Moreover, low expression levels of p21 are 
required for CDK activity, although basal levels of p21 are insufficient in inhibiting CDK 
activity (Soria & Gottifredi, 2010; Dotto, 2000). 
 
The GTP-binding protein 1 (NGP-1), also known as guanine nucleotide-binding protein-like 2 
(GNL2), is a member of the HSR1-MMR1 family of GTPases, was reported to act as a 
regulator of the G1-S transition. NGP-1 is expressed in various cancers with up-regulation in 
certain cancers such as breast, colon and colorectal tumours. The over-expression of NGP-1 
increases cell proliferation and DNA replication (Datta et al., 2015). Over-expression of 
NGP-1 also increases the levels of p53 and p21. These findings were surprising since p53 and 
p21 are known to be suppressors of cell proliferation. The same study showed good evidence 
that NGP-1 mediates cell cycle progression through the p53 protein and its downstream target 
p21 and the interaction between p21 and the cyclin D1-CDK4 complex which results in the 
hyperphosphorylation of the retinoblastoma RB protein. This hyperphosphorylation leads to 
the up-regulation of the E2F1 transcription factors required for the G1-S transition (Datta et 
al., 2015). Despite the role of p21 in the inhibition of cyclin D1-CDK4 complex activity, p21 
can enhance the activity of this complex by acting as an adaptor protein to assemble and 
programme the complex to perform specific functions (La & Baer et al., 1997). The  research 
reported here shows that the expression levels of RAD9B-002/005 drop during the G1/S cell 
cycle transition in HEK293 cells (Figure 3.12). Furthermore, the results showed that the over-
expression of EGFP-RAD9B-002 slows cell growth (Figure 4.14), suggesting that elevated 
RAD9B protein levels negatively impact the G1-S transition in HEK293 cells. Such a 
misregulation of the G1-S transition can affect cell proliferation and lead to oncogenesis 
(Bertoli, Skotheim & de Bruin, 2013). This is in line with the reported over-expression of the 
NGP-1 protein in cancers, which leads to a faster G1-S transition. The drop in RAD9B-
002/005 mRNA levels required for the G1-S transition in normal cells could  be linked with 
the high phosphorylation of p21 upon the over-expression of EGFP-RAD9B-002. Elevated 
levels of full-length RAD9B-002 could stimulate a kinase that phosphorylates p21 during the 
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cell cycle G1/S transition. A poosible kinase is AKT kinase as it modifies p21 to prevent its 
association with PCNA which blocks DNA replication (Rossig et al., 2001). How RAD9B-
002 impacts on AKT is not known, but one possible link is provided by the functional link 
between TOPBP1 (Crb2), AKT and E2F1. Akt phosphorylates TOPBP1 thereby promoting 
the oligomerization of TOPBP1 and its association with E2F1 which initiates cell death at the 
G1/S transition (Liu et al., 2006). A stimulation of this AKT-TOPBP1-E2F1 pathway may 
also be an alternative explanation for the accumulation of a sub-G1 cell population upon over-
expression of RAD9B-002 (Figure 4.13). In summary, these results suggest a negative impact 
of RAD9B-002 on G1/S transition and cell survival that is linked with the phosphorylation of 
p21. Moreover, RAD9B-002/005 mRNA levels are significantly high in HeLa cancer cells 
(Figure 3.12); supporting a possible link between RAD9B and the NGP-1 G1/S escalator 
protein which also regulates p21 levels. 
 
The p21 protein is thought to have a dual function in oncogenesis depending on its cellular 
localisation. It acts as a tumour suppressor when it localises to the nucleus after DNA damage 
but is oncogenic when it localises to the cytoplasm. Further, p21 accumulates in the nucleus 
after DNA damage to induce cell cycle arrest (Abella et al., 2010). Interestingly, p21  
localises also to the nucleolus after DNA damage independently of p53 and ATM (Perez-
Castro & Freire, 2012; Abella et al., 2010). As aforementioned, RAD9B was also reported to 
localise to the nucleolus in special spherical structures in the response to UV light. However, 
the roles of RAD9B and p21 in this localisation remain unclear. Since the nucleolus provides 
the environment for the assembly of ribosomes, it is possible that the function of RAD9B is 
related to maintaining ribosomal rDNA integrity after UV damage (Calkins, Iglehart & 
Lazaro, 2013). This localisation of RAD9B requires its C-terminal domain and is dependent 
on ATR and JNK kinase signalling, as the inhibition of these signalling pathways results in 
the reduced migration of RAD9B to the disturbed nucleolus (Perez-Castro & Freire, 2012). 
As mentioned previously, the over-expression of RAD9B-001, but not RAD9B-002, results in 
a transient G1 cell cycle arrest as reported for the over-expression of RAD9B in the study by 
Perez-Castro and colleagues (Perez-CastroFreire, 2012). 
 
Since the authors did not clearly state which RAD9B variant was over-expressed, it is very 
likely that they studied the shorter RAD9B-001 and not the full-length RAD9B-002. 
Although the over-expression of both, RAD9B-001 and RAD9B-002, results in the 
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hyperphosphorylation of p21, it is clear that both variants perform distinct functions. For 
example, high levels of RAD9B-001 result in a profound hyper-phosphorylation of CHK2 in 
untreated cells and delay the UV-induced degradation of p21, whereas over-expression of 
RAD9B-002 only partly increases CHK2 phosphorylation and does not delay p21 degradation 
in response to UV light (Table 6.1). These differences could be explained by a specific role of 
RAD9B-001 in the maintenance of the ribosomal DNA in the nucleolus where p21 and 
RAD9B-001 may collaborate.  
 
In addition, p21 causes a G1 cell cycle arrest when over-expressed, similarly to RAD9B-001 
(Mansilla et al., 2013). Also RAD9B-001 is up-regulated in senescent cells (Figure 3.10-C) as 
it is the case for p21 (Park, Lim & Jang, 2011) where the activation of senescent p21 is p53 
tumour suppressor-dependent (Campisi, 2013). This could explain the increased 
phosphorylation of p53 when RAD9B-001 is over-expressed (Figure 5.2) which is not 
observed when RAD9B-002 is over expressed. Taken  together, these findings strongly 
indicate that both full-length RAD9B-002 and its shorter variant RAD9B-001 are functionally 
linked with the p21 pathways but possibly under different circumstances or in distinct cellular 
compartments. 
 
6.4.2 P21 degradation after exposure to UV light 
The p21 protein response to DNA damage depends on the extent of the damage. With low 
DNA damage, p21 expression levels increase resulting in the inhibition of CDK activation. 
This consequently leads to a cell cycle arrest allowing for anti-apoptotic activities and DNA 
repair. However, when DNA is extensively damaged, p21 expression levels decrease and the 
cells undergo apoptosis (Cmielova & Rezacova, 2011). 
 
p21 can be down-regulated by some types of DNA damage; for example, it is degraded in the 
response to UV irradiation. Degradation of p21 is dependent on the E3-ubiquitin ligase 
CRL4/CDT2 in the response to UV light (Nishitani et al., 2008).  
 
The E3 ubiquitin ligase couples protein degradation to DNA replication and recognises its 
substrate when bound to PCNA (Havens & Walter, 2011). Its activity is important to prevent 
re-replication within one cell cycle and to respond to DNA damage. The forced stabilisation 
of p21 after UV irradiation impairs DNA replication and genomic stability, resulting in the 
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accumulation of replication stress markers. The release of PCNA from the PCNA-p21 
complex in the response to UV light promotes PCNA-dependent DNA repair by allowing the 
recruitment of other PCNA partners, such as the Y-family DNA polymerases to bind 
(Mansilla et al., 2013). This polymerase switch defines DNA translesion synthesis (TLS). The 
TLS polymerases replicate damaged DNA templates to avoid the stalling of DNA replication 
forks as this would cause DNA double-strand breaks. Polymerases from the Y family show a 
critical, evolutionary role as they exist in all three kingdoms of life. However, it has been 
proposed that they perform tumour suppressive functions since higher organisms express a 
larger number of these TLS polymerases. One of the main disorders in patients with impaired 
TLS is xeroderma pigmentosum variant (XPV) syndrome which is characterised by a genetic 
predisposition to sunlight-induced skin cancer due to autosomal recessive mutation in TLS 
polymerases and associated factors (Knobel & Marti, 2011; Stallons & McGregor, 2010; 
Ohmori et al., 2001; Cordonnier, Lehmann & Fuchs, 1999).  
 
The results in Figure 5.5-A & B  shows that importance of regulating the levels of RAD9B in 
response to UV irradiation. Furthermore, the results in Figure 5.8 show that after UV 
radiation, p21 degradation is delayed by high levels of RAD9B-001, and interestingly, the S. 
pombe Rad9-M50 variant. Since both N-terminally truncated variants slow down p21 
degradation, they may bind either to PCNA or to p21 to block the formation of the PCNA-p21 
complex, which is essential for the CRL4CDT2 E3 ubiquitin ligase to recognise p21 (Figure 
6.5). Since RAD9B-001 is thought to physically interact with p21 (Perez-Castro & Freire, 
2012), it is likely that the physical interaction of RAD9B-001 and SpRad9-M50 with p21 
prevents the formation of the p21-PCNA complex. Alternatively, it is also possible that the 
Rad9 variants interact directly with the E3 ligase CRL4CDT2 to prevent p21 degradation (Soria 
et al., 2008). However, the possibility of a direct interaction between RAD9B-001 and p21 is 
the strongest (Figure 6.5). Since full-length RAD9B-002 does not delay the degradation of 
p21 after UV-light exposure, removal of the N-terminal domain by alternative splicing may 
be essential for RAD9B to regulate p21 degradation. The latter would also explain why the 
yeast Rad9 variant can slow down p21 degradation. Furthermore, it strongly indicates that the 
domain required for this regulation is conserved in the yeast protein. The PCNA binding 
domain resides in the last 22 C-terminal amino acids of human p21 (Gulbis et al., 1996), and 
since RAD9A and RAD9B share some similarity with PCNA (Xu et al., 2009), it may be the 
case that p21 binds to RAD9B-001 or SpRad9-M50 via the same domain. It is also worth 
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pointing out that the different effects of RAD9B-001 and RAD9B-002 on the p21 protein in 
response to UV light also indicate that the phosphorylation of p21 during the over-expression 
of either variant result in distinct roles for p21. At a minimum, the regulation of RAD9B-001 
levels in response to UV irradiation and possibly other reagents causing stalled replication 
forks is an essential mechanism for p21 degradation and TLS function.   
 
 
 
Figure 6.5 Inhibition of DNA translesion synthesis (TLS) by RAD9B-001 over-expression. 
Following UV irradiation, p21 binds to PCNA, which results in p21 ubiquitination by the CRL4CDT2 
E3 ligase complex; this, in turn, results in p21 degradation. The release of PCNA from the p21-PCNA 
complex allows for PCNA monoubiquitination, an important process in switching from normal 
replication polymerase binding to TLS polymerase 𝜂 (POL 𝜂). POL 𝜂 is then located at damaged sites 
by PCNA where the TLS mechanism is initiated. The TLS mechanism can be inhibited by impaired 
p21 degradation in the presence of high levels of RAD9B-001 via three possible mechanisms, as 
follows: (A) RAD9B-001 physically interacts with p21 and inhibits p21-PCNA coupling; (B) due to 
the high homology between RAD9B-001 and the interacting PCNA partner RAD9A, RAD9B-001 
interacts with PCNA and prevents PCNA-p21 coupling; or (C) RAD9B-001 interacts with the 
CRL4CDT2 E3 ligase complex and impairs p21 ubiquitination. The possibilities A or B or C result in 
preventing p21 degradation, and as a consequence, impaired TLS initiation. However, hypothesis A is 
the strongest, since RAD9B and p21 were reported to physically interact.         
 
 
This other intriguing observation is the inverse relationship between RAD9B-001 and 
RAD9B-002 on p21 degradation. While high levels of RAD9B-001 delay p21 degradation in 
the response to UV light, elevated RAD9B-002 levels block p21 degradation in the presence 
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of oxidative stress (Table 6.1). Only a few studies exist in the literature on the decline in p21 
expression in the response to oxidative stress. They suggest that p21 is targeted by an E3 
ubiquitin ligase which may be distinct from the PCNA-coupled process. Since MPS1 levels 
are reported to be regulated through the cell cycle by the anaphase-promoting complex (APC) 
E3 ligase (Palframan et al., 2006), it is possible that MPS1 and p21 are regulated in a similar 
manner in response to H2O2, Indeed, p21 is degraded during mitosis in a CDK2-dependent 
manner by the APC (Yamada et al., 2011). Moreover, since MPS1 and p21 proteolysis are 
affected by the high levels of hRad9B-002, it is highly likely that RAD9B-002 negatively 
interferes with the CDC2 pathway and consequently influences APC activity. Hence, 
RAD9B-001 and RAD9B-002 may affect p21 stability through the PCNA and APC 
pathways, respectively.  
 
6.4.3 CHK2 hyperphosphorylation by RAD9B-001 
In the response to DNA damage, CHK2 stabilises the p53 tumour-suppressor protein leading 
to a G1 cell cycle arrest (Chehab et al., 2000). CHK2 is also involved in the G2/M arrest 
(Zannini, Delia & Buscemi, 2014). During the G1/S cell cycle arrest, ATM and CHK2 
stabilise p53 which leads to the up-regulation of p21 expression, resulting in the inhibition of 
CDK complexes and consequent blocking of the G1/S transition (Chehab et al., 2000; Hirao 
et al., 2000). The over-expression of CHK2 was also reported to result in a G1/S arrest           
(Chehab et al., 2000). In this study, the over-expression of RAD9B-001 caused the strong 
hyperphosphorylation of CHK2 and increased p53 phosphorylation 12 hours after inducing 
the expression of RAD9B-001 in untreated cells (Figure 5.2). Up to 12 hours post RAD9B-
001 induction, no G1 arrest was observed when the samples were analysed in a fax machine 
(Figure 4.13) as the G1 arrest appeared only 24 hours after induction. This indicates that the 
increased phosphorylation of CHK2 and p53 is not a result of the G1 arrest but caused by the 
over-expression of RAD9B-001. Interestingly, over-expression of Rad9-M50 did not affect 
CHK2 phosphorylation (Figure 5.2) implying that this function is distinct from the delayed 
degradation of p21.  
 
These results strongly evidence that RAD9B-001 acts upstream of CHK2 and plays a role in  
activating the CHK2-p53 pathway, subsequently leading to G1 arrest. Since the accumulation 
of the p21 protein is essential for the inhibition of the CDK complexes to stop cell cycle 
progression, and since p21 levels did not increase upon over-expression of RAD9B-001 
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(Figure 4.20), an alternative G1/S arrest pathway may exist. One possible example is the 
binding of the active p53 protein to the 5’ region of CDK4 mRNA to inhibit its translation 
thereby leading to a G1 arrest (Miller et al., 2000). Further support for a close link between 
RAD9B-001 and the CHK2-p53 pathway is provided by the hyperphosphorylation of CHK2 
in the response to H2O2 in the RAD9B-001 cell line (Figure 5.16) along with the increased 
expression of endogenous RAD9B-001 in the response to H2O2. How high levels of RAD9B-
001 trigger the phosphorylation of CHK2 is not yet clear. Since the ATM-CHK2 pathway is 
typically activated when ATM is recruited to DNA double-strand breaks (Falck, Coates & 
Jackson, 2005), elevated levels of RAD9B-001 could cause such breaks maybe via its 
interaction with the PCNA-p21 system during DNA replication. 
 
6.4.4 CHK2 phosphorylation by RAD9B-002 in untreated cells 
While high levels of RAD9B-001 cause a strong hyper-phosphorylation of CHK2 in 
otherwise untreated cells, elevated levels of the full-length RAD9B-002 protein are much less 
effective (Figure 5.2-B). It is therefore likely that CHK2 phosphorylation caused by RAD9B-
002 occurs in a different manner to RAD9B-001. Since the over-expression of RAD9B-002 
results in the increased phosphorylation of CHK2 in an ATM-independent manner (Figure 
5.2-A), another kinase may be involved. As aforementioned, MPS1 is a mitotic kinase that is 
required for error-free mitotic progression in eukaryotes (Tyler et al., 2009). In human cells, 
MPS1 levels are regulated in a cell cycle-dependent manner by the ubiquitin 
ligase/proteasome pathway during late mitosis and in G1 (Cui et al., 2010). Interestingly, 
cleavage of MPS1 was observed in all protein samples analysed in this project (Figure 5.8). 
The MPS1 kinase is required for centrosome duplication during the S phase where it is 
phosphorylated by CDK2 as this phosphorylation suppresses the proteostome-mediated 
degradation of MPS1.  
 
The CDK2-regulated MSP1 degradation pathway is specific to the centrosome since the 
inhibition of the phosphorylation of MPS1 causes the loss of the kinase specifically from the 
centrosome but not from other locations (Kasbek et al., 2007). MPS1 activity is essential for 
the coordinated duplication of the centrosome as the suppression of MPS1 degradation results 
in centrosome re-duplication associated with the abnormal, multipolar mitotic cell division 
found in some cancers  (Kasbek, Yang & Fisk, 2009).   
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A few potential mechanisms for the suppression of MPS1 degradation exist in the literature, 
including an increase in CDK2 activity, which inhibits the degradation of MPS1 at the 
centrosomes, or the inhibition of degradation machinery itself, which inhibits the proteasome 
(Kasbek, Yang & Fisk, 2009). As mentioned previously, in all the experiments, MPS1 is less 
degraded upon over-expression of RAD9B-002 (Figure 5.8, Figure 5.12). These results 
suggest that RAD9B-002 has a negative impact on the degradation of MPS1 maybe at the 
centrosome as a result of its interference with the CDC2-MPS1 pathway. The effect of 
RAD9B-002 on the CDC2 pathway is supported by the high phosphorylation levels of CDC2 
main regulator p21 in the cell line over-expressing RAD9B-002. This could be a good 
explanation for the weak abundancy of RAD9B-002 in general and specifically during the 
time of centrosome duplication at the G1-S transition (Figure 3.12) to ensure an accurate 
centrosome duplication and cell cycle division. A centrosomal role of RAD9B-002 may also 
explain the increased phosphorylation of CHK2 upon the over-expression of the variant as 
CHK2 co-localises with MPS1 at the centrosome in a DNA damage independent manner 
(Golan et al., 2010).  CHK2 is required to stabilise MPS1 at the kinetochors during mitosis 
and MPS1 can phosphorylate Chk2 at Thr-68 in the response to DNA damage 
(PetsalakiZachos, 2014, Wei et al., 2005). 
 
6.4.5 Why is CHK2 phosphorylation reduced by RAD9B-002 in the 
response to DNA damage? 
Although high levels of RAD9B-002 cause an increase in CHK2 phosphorylation in 
undamaged cells (Figure 5.2), CHK2 phosphorylation at Thr-68 is inhibited in the response to 
UV and oxidative stress in the RAD9B-002 cell line (Figure 5.8 & Figure 5.18). This suggests 
that RAD9B-002 impacts on CHK2 phosphorylation is a rather specific manner. A study of 
CHK2 phosphorylation in response to oxidative stress showed that the phosphorylation signal 
was highest in S-phase cells, less in G1- phase cells and the least in G2/M-phase cells (Zhao 
et al., 2008). It is likely that the forced elevation of RAD9B-002 interferes and blocks the 
phosphorylation of CHK2 during the S phase under DNA conditions.  
 
It is also likely that the CHK2 phosphorylation events in undamaged cells could occur in 
different cellular compartments such as at the centrosomes or the kinetochore (Golan et al., 
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2010), whereas the DNA damage induced phosphorylation is expected to take place at the 
chromatin. The suppression of the smaller CHK2 band by the over-expression of RAD9B-002 
also could be linked with its centrosomal role, as this cleaved CHK2 form was also found to 
localise to the centrosome (Golan et al., 2010).  The data in (Figure 5.18) shows that the 
pharmacological down-regulation of MPS1 decrease CHK2 phosphorylation in the response 
to H2O2 which is in line with the ability of MPS1 to target CHK2-T68 in the presence of DNA 
damage. However, a combination of the down-regulation of MPS1 and the over-expression of 
RAD9B-002 shows a slight recovery of CHK2-T68 phosphorylation which supports the 
model that RAD9B-002 targets MPS1 by blocking Polo-like kinase PLK1 at the centrosome 
(Figure 5.19). In summary, RAD9B-002 may target CHK2 at the centrosome, at the 
kinetochore and/or at the chromatin as the kinase localises to all three structures (Yeh et al., 
2014; Li & Stern, 2005; Tsvetkov et al., 2003). More experimental work is however required 
to investigate the relationship between RAD9B-002 and CHK2 further.  
 
 Conclusion 
This project provides, for the first time, an insight into the diverse roles of the splice variants 
of the human RAD9B gene which regulate the CHK2-p53-p21 G1/S signalling module in 
quite different ways. While over-expression of the full-length protein RAD9B-002 induces 
cell death in G1 and delays p21 degradation in the response to oxidative stress, over-
expression of its N-terminally deleted variant RAD9B-001 only transiently arrests G1 
progression and only delays p21 degradation in the presence of UV induced DNA damage. 
Both proteins have an impact on CHK2 phosphorylation levels, probably through distinct 
mechanisms. Taken together, the results presented here suggest that RAD9B acts on CHK2 
kinase, whereas RAD9A regulates CHK1 kinase. Since the clear division between ATR-
CHK1 and ATM-CHK2 DNA damage signalling emerged after the development of 
multicellular organism, it is possible that RAD9B evolved from an early gene duplication 
event to enable multicellular organisms to regulate CHK1 and CHK2 independently. The 
work also provides evidence that RAD9B may regulate the modification of CHK2 by the 
mitotic kinase MPS1 which controls the spindle attachment checkpoint in mitosis and the 
duplication of the centrosome in G1/S. 
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 Future work 
The reliance on engineered EGFP-RAD9B fusion proteins which are over-expressed in the 
presence of the endogenous RAD9 proteins may limit the interpretation of this work.  Two 
strategies could be applied to resolve this issue. The endogenous RAD9B gene could be 
deleted using the Crispr/Cas9 technology as this would render cells dependent on the 
engineered proteins. This would allow to study RAD9B in the absence of the endogenous 
splice variants. This approach may however be limited if any of the RAD9B variants were to 
be essential for cell viability.  
 
The second approach could aim to raise variant specific antibodies or an antibody that 
recognises more RAD9B variants. Currently none of the commercially available antibodies 
recognises endogenous RAD9B, possibly because of the low expression levels. Also the high 
degree of identity at protein level may make it difficult to raise variant specific antibodies. 
Future work could focus on the functional relationships between RAD9B-002, PLK1, MPS1 
and CHK2, and their role at the centrosome. This could be achieved by using confocal 
microscopy to analyse RAD9B-002 localisation in G1, S and G2 in synchronised cells. It 
would also be interesting to search for possible interaction partners of RAD9B-002 through 
immunoprecipitation in these cell cycle phases.  
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Appendices 
Appendix 1 
 
RT-PCR analysis of human RAD9B splice variants in normal tissues 
 
RT-PCR analysis of the RAD9B mRNA across several normal human tissues. (A) 200 ng of total 
human RNA (Human Total RNA Master Panel II, Clontech Laboratories) was reverse transcribed and 
amplified by Bioline One-Step RT-PCR kit using specific primers for RAD9B-001, 002/005, 003 and 
009. Then 10 µl of the RT-PCR reactions were run on 0.8% agarose gels. (B) 1 µg of RNA from the 
Human Total RNA Master Panel II (Clontech Laboratories) was reverse transcribed into cDNA by a 
Bioline cDNA synthesis kit, followed by RT-PCR to amplify short regions of RAD9B-001, 002/005, 
003 and 009 using Bioline Red Mix polymerase. Then 20 µl of the RT-PCR reactions were loaded on 
1.5% agarose gels for all variants, except for 009. The 009 variant was run on 2% agarose gels. ACTB 
was used as a positive control for the one-step and two-step RT-PCRs. For ACTB, 10 µl of the reaction 
was run on 1.5% agarose gels. All images were taken by the Bio-Rad Documentation System. The 
name and expected amplicon size of each gene is shown to the right.   
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Appendix 2 
 
Alignment of the five RAD9B splice variants 001, 002, 003, 005 and 009 
 
 
RAD9B-001      AAAGCCGTTTGGGAACTTGTGGAGGCGGGGTGGTAGAGTGCAGAGACGAGATCGCGAAGC 60 
RAD9B-002      ------------------------------------------------------------ 0 
RAD9B-003      ---------------------------------------GCAGAGACGAGATCGCGAAGC 21 
RAD9B-005      ------------------------------------------------------------ 0 
RAD9B-009      ------------------------------------------------------------ 0 
                                                                            
 
RAD9B-001      TTTGAAAAGCGCGGGCAACATCCGGGCACCTGGGCCGTCGAGCTGAGGCGCGCCTTCCGA 120 
RAD9B-002      -------------------------------GGGCCGTCGAGCTGAGGCGCGCCTTCCGA 29 
RAD9B-003      TTTGAAAAGCGCGGGCAACATCCGGGCACCTGGGCCGTCGAGCTGAGGCGCGCCTTCCGA 81 
RAD9B-005      -------------------------------GGGCCGTCGAGCTGAGGCGCGCCTTCCGA 29 
RAD9B-009      ------------------------------------------------------TTCCGA 6 
                                                                     ****** 
 
RAD9B-001      GCCTGCTTTTTAGGGCGGATGGCAGCC-----------------------------ATGC 151 
RAD9B-002      GCCTGCTTTTTAGGGCGGATGGCAGCCATGCTGAAGTGCGTGATGAGCGGCAGTCAGGTG 89 
RAD9B-003      GCCTGCTTTTTAGGGCGGATGGCAGCCATGCTGAAGTGCGTGATGAGCGGCAGTCAGGTG 141 
RAD9B-005      GCCTGCTTTTTAGGGCGGATGGCAGCCATGCTGAAGTGCGTGATGAGCGGCAGTC----- 84 
RAD9B-009      GCCTGCTTTTTAGGGCGGATGGCAGCCATGCTGAAGTGCGTGATGAGCGGCAGTCAGGTG 66 
               ***************************                                  
 
RAD9B-001      TGAATATTTGGGAAAGCAGTTCAAGCTCTATCACGAATTAGTGACGAGTTCTGGCTAGAC 211 
RAD9B-002      AAAGTATTTGGGAAAGCAGTTCAAGCTCTATCACGAATTAGTGACGAGTTCTGGCTAGAC 149 
RAD9B-003      AAAGTATTTGGGAAAGCAGTTCAAGCTCTATCACGAATTAGTGACGAGTTCTGGCTAGAC 201 
RAD9B-005      --AGTATTTGGGAAAGCAGTTCAAGCTCTATCACGAATTAGTGACGAGTTCTGGCTAGAC 142 
RAD9B-009      AAAGTATTTGGGAAAGCAGTTCAAGCTCTATCACGAATTAGTGACGAGTTCTGGCTAGAC 126 
                 * ******************************************************** 
 
RAD9B-001      CCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCTTCTCGGTCAGCATATGGATGT 271 
RAD9B-002      CCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCTTCTCGGTCAGCATATGGATGT 209 
RAD9B-003      CCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCTTCTCGGTCAGCATATGGATGT 261 
RAD9B-005      CCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCTTCTCGGTCAGCATATGGATGT 202 
RAD9B-009      CCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCTTCTCGGTCAGCATATGGATGT 186 
               ************************************************************ 
 
RAD9B-001      GTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGGTCAGCTTTAGTGAAAATGAGT 331 
RAD9B-002      GTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGGTCAGCTTTAGTGAAAATGAGT 269 
RAD9B-003      GTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGGTCAGCTTTAGTGAAAATGAGT 321 
RAD9B-005      GTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGGTCAGCTTTAGTGAAAATGAGT 262 
RAD9B-009      GTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGGTCAGCTTTAGTGAAAATGAGT 246 
               ************************************************************ 
 
RAD9B-001      GAAAATGAACTTGACACAACACTGCATTTAAAATGCAAATTGGGAATGAAGTCAATTTTG 391 
RAD9B-002      GAAAATGAACTTGACACAACACTGCATTTAAAATGCAAATTGGGAATGAAGTCAATTTTG 329 
RAD9B-003      GAAAATGAACTTGACACAACACTGCATTTAAAATGCAAATTGGGAATGAAGTCAATTTTG 381 
RAD9B-005      GAAAATGAACTTGACACAACACTGCATTTAAAATGCAAATTGGGAATGAAGTCAATTTTG 322 
RAD9B-009      GAAAATGAACTTGACACAACACTGCATTTAAAATGCAAATTGGGAATGAAGTCAATTTTG 306 
               ************************************************************ 
 
RAD9B-001      CCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATAGAGAAGTGCAGAATATTCACC 451 
RAD9B-002      CCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATAGAGAAGTGCAGAATATTCACC 389 
RAD9B-003      CCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATAGAGAAGTGCAGAATATTCACC 441 
RAD9B-005      CCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATAGAGAAGTGCAGAATATTCACC 382 
RAD9B-009      CCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATAGAGAAGTGCAGAATATTCACC 366 
               ************************************************************ 
 
RAD9B-001      AGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTACAGACATGGTATTAAAAGAACT 511 
RAD9B-002      AGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTACAGACATGGTATTAAAAGAACT 449 
RAD9B-003      AGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTACAGACATGGTATTAAAAGAACT 501 
RAD9B-005      AGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTACAGACATGGTATTAAAAGAACT 442 
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RAD9B-009      AGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTACAGACATG-------------- 412 
               **********************************************               
 
RAD9B-001      CATAATATATGTTTTCAAGAAAGTCAGCCTTTGCAAGTTATTTTTGACAAGAATGTTTGT 571 
RAD9B-002      CATAATATATGTTTTCAAGAAAGTCAGCCTTTGCAAGTTATTTTTGACAAGAATGTTTGT 509 
RAD9B-003      CATAATATATGTTTTCAAGAAAGTCAGCCTTTGCAAGTTATTTTTGACAAGAATGTTTGT 561 
RAD9B-005      CATAATATATGTTTTCAAGAAAGTCAGCCTTTGCAAGTTATTTTTGACAAGAATGTTTGT 502 
RAD9B-009      ------------------------------------------------------------ 412 
                                                                            
 
RAD9B-001      ACTAATACGCTAATGATTCAACCAAGATTGCTTGCTGATGCCATTGTTCTTTTTACATCA 631 
RAD9B-002      ACTAATACGCTAATGATTCAACCAAGATTGCTTGCTGATGCCATTGTTCTTTTTACATCA 569 
RAD9B-003      ACTAATACGCTAATGATTCAACCAAGATTGCTTGCTGATGCCATTGTTCTTTTTACATCA 621 
RAD9B-005      ACTAATACGCTAATGATTCAACCAAGATTGCTTGCTGATGCCATTGTTCTTTTTACATCA 562 
RAD9B-009      ------------------------------------------------------------ 412 
                                                                            
 
RAD9B-001      AGTCAAGAGGAAGTTACTCTTGCTGTTACTCCACTGAATTTTTGCCTCAAGAGTTCTAAT 691 
RAD9B-002      AGTCAAGAGGAAGTTACTCTTGCTGTTACTCCACTGAATTTTTGCCTCAAGAGTTCTAAT 629 
RAD9B-003      AGTCAAGAGGAAGTTACTCTTGCTGTTACTCCACTGAATTTTTGCCTCAAGAGTTCTAAT 681 
RAD9B-005      AGTCAAGAGGAAGTTACTCTTGCTGTTACTCCACTGAATTTTTGCCTCAAGAGTTCTAAT 622 
RAD9B-009      ------------------------------------------------------------ 412 
                                                                            
 
RAD9B-001      GAGGAATCAATGGATTTGAGCAATGCTGTACACAGTGAGATGTTTGTTGGCTCAGATGAG 751 
RAD9B-002      GAGGAATCAATGGATTTGAGCAATGCTGTACACAGTGAGATGTTTGTTGGCTCAGATGAG 689 
RAD9B-003      GAGGAATCAATGGATTTGAGCAATGCTGTACACAGTGAGATGTTTGTTGGCTCAGATGAG 741 
RAD9B-005      GAGGAATCAATGGATTTGAGCAATGCTGTACACAGTGAGATGTTTGTTGGCTCAGATGAG 682 
RAD9B-009      -------------ATTTGAGCAATGCTGTACACAGTGAGATGTTTGTTGGCTCAGATGAG 459 
                            *********************************************** 
 
RAD9B-001      TTTGACTTCTTTCAAATTGGAATGGACACTGAGATAACATTTTGTTTCAAAGAATTGAAG 811 
RAD9B-002      TTTGACTTCTTTCAAATTGGAATGGACACTGAGATAACATTTTGTTTCAAAGAATTGAAG 749 
RAD9B-003      TTTGACTTCTTTCAAATTGGAATGGACACTGAGATAACATTTTGTTTCAAAGAATTGAAG 801 
RAD9B-005      TTTGACTTCTTTCAAATTGGAATGGACACTGAGATAACATTTTGTTTCAAAGAATTGAAG 742 
RAD9B-009      TTTGACTTCTTTCAAATTGGAATGGACACTGAGATAACATTTTGTTTCAAAGAATTGAAG 519 
               ************************************************************ 
 
RAD9B-001      GGAATACTGACATTTTCAGAAGCTACACATGCTCCTATATCCATTTATTTTGATTTCCCT 871 
RAD9B-002      GGAATACTGACATTTTCAGAAGCTACACATGCTCCTATATCCATTTATTTTGATTTCCCT 809 
RAD9B-003      GGAATACTGACATTTTCAGAAGCTACACATGCTCCTATATCCATTTATTTTGATTTCCCT 861 
RAD9B-005      GGAATACTGACATTTTCAGAAGCTACACATGCTCCTATATCCATTTATTTTGATTTCCCT 802 
RAD9B-009      GGAATACTGACATTTTCAGAAGCTACACATGCTCCTATATCCATTTATTTTGATTTCCCT 579 
               ************************************************************ 
 
RAD9B-001      GGGAAACCTCTGGCTTTGAGTATTGATGATATGTTAGTGGAAGCTAACTTTATTTTGGCC 931 
RAD9B-002      GGGAAACCTCTGGCTTTGAGTATTGATGATATGTTAGTGGAAGCTAACTTTATTTTGGCC 869 
RAD9B-003      GGGAAACCTCTGGCTTTGAGTATTGATGATATGTTAGTGGAAGCTAACTTTATTTTGGCC 921 
RAD9B-005      GGGAAACCTCTGGCTTTGAGTATTGATGATATGTTAGTGGAAGCTAACTTTATTTTGGCC 862 
RAD9B-009      GGGAAACCTCTGGCTTTGAGTATTGATGATATGTTAGTGGAAGCTAACTTTATTTTGGCC 639 
               ************************************************************ 
 
RAD9B-001      ACATTAGCTGATGAACAAAGTAGAGCATCTTCACCACAGTCACTGTGTCTTTCACAGAAA 991 
RAD9B-002      ACATTAGCTGATGAACAAAGTAGAGCATCTTCACCACAGTCACTGTGTCTTTCACAGAAA 929 
RAD9B-003      ACATTAGCTGATGAACAAAGTAGAGCATCTTCACCACAGTCACTGTGTCTTTCACAGAAA 981 
RAD9B-005      ACATTAGCTGATGAACAAAGTAGAGCATCTTCACCACAGTCACTGTGTCTTTCACAGAAA 922 
RAD9B-009      ACATTAGCTGATGAACAAAGTAGAGCATCTTCACCACAGTCACTGTGTCTTTCACAGAAA 699 
               ************************************************************ 
 
RAD9B-001      CGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGCAAAAATGTAACTGGCCAGGCCCTG 1051 
RAD9B-002      CGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGCAAAAATGTAACTGGCCAGGCCCTG 989 
RAD9B-003      CGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGCAAAAATGTAACTGGCCAGGCCCTG 1041 
RAD9B-005      CGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGCAAAAATGTAACTGGCCAGGCCCTG 982 
RAD9B-009      CGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGCAAAAATGTAACTGGCCAGGCCCTG 759 
               ************************************************************ 
 
RAD9B-001      GAATGTATTTCAAAAAAAGCAGCACCAAGAAGGCTTTATCCTAAGGAGACTCTCACAAAC 1111 
RAD9B-002      GAATGTATTTCAAAAAAAGCAGCACCAAGAAGGCTTTATCCTAAGGAGACTCTCACAAAC 1049 
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RAD9B-003      GAATGTATTTCAAAAAAAGCAGCACCAAGAAGGCTTTATCCTAAGGAGACTCTCACAAAC 1101 
RAD9B-005      GAATGTATTTCAAAAAAAGCAGCACCAAGAAGGCTTTATCCTAAGGAGACTCTCACAAAC 1042 
RAD9B-009      GAATGTATTTCAAAAAAAGCAGCACCAAGAAGGCTTTATCCTAAGGAGACTCTCACAAAC 819 
               ************************************************************ 
 
RAD9B-001      ATATCTGCATTGGAAAACTGTGGCAGCCCTGCAATGAAAAGAGTGGATGGAGATGTCAGT 1171 
RAD9B-002      ATATCTGCATTGGAAAACTGTGGCAGCCCTGCAATGAAAAGAGTGGATGGAGATGTCAGT 1109 
RAD9B-003      ATATCTGCATTGGAAAACTGTGGCAGCCCTGCAATGAAAAGAGTGGATGGAGATGTCAGT 1161 
RAD9B-005      ATATCTGCATTGGAAAACTGTGGCAGCCCTGCAATGAAAAGAGTGGATGGAGATGTCAGT 1102 
RAD9B-009      ATATCTGCATTGGAAAACTGTGGCAGCCCTGCAATGAAAAGAGTGGATGGAGATGTCAGT 879 
               ************************************************************ 
 
RAD9B-001      GAAGTATCAGAAAGCAGTGTCAGCAACACAGAGGAAGTGCCAGGGTCTCTGTGTCTCAGA 1231 
RAD9B-002      GAAGTATCAGAAAGCAGTGTCAGCAACACAGAGGAAGTGCCAGGGTCTCTGTGTCTCAGA 1169 
RAD9B-003      GAAGTATCAGAAAGCAGTGTCAGCAACACAGAGGAAGTGCCAGGGTCTCTGTGTCTCAGA 1221 
RAD9B-005      GAAGTATCAGAAAGCAGTGTCAGCAACACAGAGGAAGTGCCAGGGTCTCTGTGTCTCAGA 1162 
RAD9B-009      GAAGTATCAGAAAGCAGTGTCAGCAACACAGAGGAAGTGCCAGGGTCTCTGTGTCTCAGA 939 
               ************************************************************ 
 
RAD9B-001      AAGTTTTCTTGCATGTTCTTTGGAGCAGTTTCTTCTGACCAGCAAGAACACTTCAACCAC 1291 
RAD9B-002      AAGTTTTCTTGCATGTTCTTTGGAGCAGTTTCTTCTGACCAGCAAGAACACTTCAACCAC 1229 
RAD9B-003      AAGTTTTCTTGCATGTTCTTTGGAGCAGTTTCTTCTGACCAGCAAGAACACTTCAACCAC 1281 
RAD9B-005      AAGTTTTCTTGCATGTTCTTTGGAGCAGTTTCTTCTGACCAGCAAGAACACTTCAACCAC 1222 
RAD9B-009      AAG--------------------------------------------------------- 942 
               ***                                                          
 
RAD9B-001      CCTTTCGACAGTCTGGCAAGAGCAAGTGACAGTGAAGAGGACATGAATAATGGCAGTTTC 1351 
RAD9B-002      CCTTTCGACAGTCTGGCAAGAGCAAGTGACAGTGAAGAGGACATGAATAATGGCAGTTTC 1289 
RAD9B-003      CCTTTCGACAGTCTGGCAAGAGCAAGTGACAGTGAAGAGGACATGAATAATGTGTGCTGC 1341 
RAD9B-005      CCTTTCGACAGTCTGGCAAGAGCAAGTGACAGTGAAGAGGACATGAATAATGGCAGTTTC 1282 
RAD9B-009      ----------------------------------------------------TGTGCTGC 950 
                                                                      * * * 
 
RAD9B-001      TCTATATTCTAATGCTTAATGATGGCTGAGCTGGGCCCCAGC-CCAGTGACTGGCTCATT 1410 
RAD9B-002      TCTATATTCTAATGCTTAATGATGGCTGAGCTGGGCCCCAGC-CCAGTGACTGGCTCATT 1348 
RAD9B-003      AGGAAAGAATTTAATGGAAGTGATGCCAAATATTTCTGTATTATCTGACATAGAACAGTA 1401 
RAD9B-005      TCTATATTCTAATGCTTAATGATGGCTGAGCTGGGCCCCAGC-CCAGTGACTGGCTCATT 1341 
RAD9B-009      AGGAAAGAATTTAATGGAAGTGATGCCAAATATTTCTGTATTATCTGACATAGAACAGTA 1010 
                  * *   *       **     **  *      *   *    * *  *  *     *  
 
RAD9B-001      TGCCCCTCAAGCACGAG--TTTGCATGTTTAGTGTCTAAAAGAGGTTGTCCAGGACTTCC 1468 
RAD9B-002      TGCCCCTCAAGCACGAG--TTTGCATGTTTAGTGTCTAAAAGAGGTTGTCCAGGACTTCC 1406 
RAD9B-003      TCCTCCACTGCCAAGACAGCCTGAGTTTGGAGTGGAATAAGGTGGAAGACAAATGTCTCT 1461 
RAD9B-005      TGCCCCTCAAGCACGAG--TTTGCATGTTTAGTGTCTAAAAGAGGTTGTCCAGGACTTCC 1399 
RAD9B-009      TCCTCCACTGCCAAGACAGCCTGAGTTTGGAGTGGAATAAGGTGGAAGACAAATGTCTCT 1070 
               * * ** *   ** **     **  * *  ****    ** * **  * * *     **  
 
RAD9B-001      TTTTAATGG-------AGGATGGGCTTTTAAACCACATCATCTTGTACAACAACCATATC 1521 
RAD9B-002      TTTTAATGG-------AGGATGGGCTTTTAAACCACATCATCTTGTACAACAACCATATC 1459 
RAD9B-003      GTTCTTTGGCCCTTTAAGAGTTAGCTTTTTACCTGC-ACAAATGGACTAAAAAATCTGGC 1520 
RAD9B-005      TTTTAATGG-------AGGATGGGCTTTTAAACCACATCATCTTGTACAACAACCATATC 1452 
RAD9B-009      GTTCTTTGGCCCTTTAAGAGTTAGCTTTTTACCTGC-ACAAATGGACTAAAAAATCTGGC 1129 
                **   ***       **  *  ****** * *  *  **  * *   ** **   *  * 
 
RAD9B-001      TAGAAATAGCTGTTTGTCAAGTGTATGTAACTTGCTTTAAATCCATTATGCTACTTGTGA 1581 
RAD9B-002      TAGAAATAGCTGTTTGTCAAGTGTATGTAACTTGCTTTAAATCCATTATGCTACTTGTGA 1519 
RAD9B-003      ACAAAACA--TTGTTATGTAATGTCTTATG----------ATGTGTGC--CTCTCCCTCC 1566 
RAD9B-005      TAGAAATAGCTGTTTGTCAAGTGTATGTAACTTGCTTTAAATCCATTATGCTACTTGTGA 1512 
RAD9B-009      ACAAAACA--TTGTTATGTAATGTCTTATG----------ATGTGTGC--CTCTCCCTCC 1175 
                  *** *  *  ** *  * *** *              **   *    **     *   
 
RAD9B-001      GGCAGAAGAGTTTTCTGTGAAGGAAAAAAGCCCATTAGAGTTCTTCAATTCAATGCACGT 1641 
RAD9B-002      GGCAGAAGAGTTTTCTGTGAAGGAAAAAAGCCCATTAGAGTTCTTCAATTCAATGCACGT 1579 
RAD9B-003      CCCAAACCTGTTTACAGTCAATTATAACCTGACAAACGAGACTTT--------------T 1612 
RAD9B-005      GGCAGAAGAGTTTTCTGTGAAGGAAAAAAGCCCATTAGAGTTCTTCAATTCAATGCACGT 1572 
RAD9B-009      CCCAAACCTGTTTACAGTCAATTATAACCTGACAAACGAGACTTT--------------T 1221 
                 ** *   **** * ** **  * **     **   ***   **              * 
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RAD9B-001      TCACCCTAGAGCTTTTAACATCTTTGCTA-GTTTTATAAAGGTATTTAAACTTTATTCAA 1700 
RAD9B-002      TCACCCTAGAGCTTTTAACATCTTTGCTA-GTTTTATAAAGGTATTTAAACTTTATTCAA 1638 
RAD9B-003      GTAACATAT-TATTGTTACATCTTTCTGAAACCTTCAAACCGTAAGGAAGTGTTAA---- 1667 
RAD9B-005      TCACCCTAGAGCTTTTAACATCTTTGCTA-GTTTTATAAAGGTATTTAAACTTTATTCAA 1631 
RAD9B-009      GTAACATAT-TATTGTTACATCTTTCTGAAACCTTCAAACCGTAAGGAAGTGTTAA---- 1276 
                 * * **    ** * ********   *    **  **  ***   **   ***      
 
RAD9B-001      CAGCCATTTAGAGTGCCATCAAGATGGCTTGAAATGGAATTTTGTGATTTGTAGTCAGGT 1760 
RAD9B-002      CAGCCATTTAGAGTGCCATCAAGATGGCTTGAAATGGAATTTTGTGATTTGTAGTCAGGT 1698 
RAD9B-003      ------------C-----------TGGCAAGCAGTTGTACTTTAGACTTTGTGAGAAATT 1704 
RAD9B-005      CAGCCATTTAGAGTGCCATCAAGATGGCTTGAAATGGAATTTTGTGATTTGTAGTCAGGT 1691 
RAD9B-009      ------------C-----------TGGCAAGCAGTTGTACTTTAGACTTTGTGAGAAATT 1313 
                                       ****  * * * * * ***    *****    *  * 
 
RAD9B-001      ATCTTTTGTA-----TTTGATTGCAAACATTTGGATTT-----TAGTTTTCTCATGTAAT 1810 
RAD9B-002      ATCTTTTGTA-----TTTGATTGCAAACATTTGGATTT-----TAGTTTTCTCATGTAAT 1748 
RAD9B-003      CATAAAGGTGGCTGAGTGGATTTGCATGCTTTAGAACTGTGAATAGAGTTCTAACTGAAA 1764 
RAD9B-005      ATCTTTTGTA-----TTTGATTGCAAACATTTGGATTT-----TAGTTTTCTCATGTAAT 1741 
RAD9B-009      CATAAAGGTGGCTGAGTGGATTTGCATGCTTTAGAACTGTGAATAGAGTTCTAACTGAAA 1373 
                      **       * ****   *   *** **  *     ***  **** *   **  
 
RAD9B-001      ACCATGGCCTTTTTTGTGCATTGTTTTTTATATTTTAAGACTTTAAGTAGAATAAACCCT 1870 
RAD9B-002      ACCATGGCCTTTTTTGTGCATTGTTTTTTATATTTTAAGACTTTAAGTAGAATAAACCCT 1808 
RAD9B-003      C-CA-GAATTAATTTGGCTCTTGTAGCTTAGTA-ATGAGTCATAGCTACCCACAATAACC 1821 
RAD9B-005      ACCATGGCCTTTTTTGTGCATTGTTTTTTATATTTTAAGACTTTAAGTAGAATAAACCCT 1801 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      GGAAAAAAGATCAAGAGTAAAAATATATAGTCACTTTCACTTGGCTTTTTTAGACGGAGT 1930 
RAD9B-002      GGAAAAAAGATCAAGAGTAAAAATATATAGTCACTTTCACTTGGCTTTTTTAGACGGAGT 1868 
RAD9B-003      TAATAAAAACTCAAGTTC---------------ATCCCAA-------------------- 1846 
RAD9B-005      GGAAAAAAGATCAAGAGTAAAAATATATAGTCACTTTCACTTGGCTTTTTTAGACGGAGT 1861 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      CTCACTTTGTCACTCAGGCTCAAGTGCAGTGGTGCAATCTCTGCTCACTGCAACATCTGC 1990 
RAD9B-002      CTCACTTTGTCACTCAGGCTCAAGTGCAGTGGTGCAATCTCTGCTCACTGCAACATCTGC 1928 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      CTCACTTTGTCACTCAGGCTCAAGTGCAGTGGTGCAATCTCTGCTCACTGCAACATCTGC 1921 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      CTCCCAGGTCCAAGCGATTCTCCTGCCTCAGCCTCCCGTGCAGCTGGGATTGCAGGTGCG 2050 
RAD9B-002      CTCCCAGGTCCAAGCGATTCTCCTGCCTCAGCCTCCCGTGCAGCTGGGATTGCAGGTGCG 1988 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      CTCCCAGGTCCAAGCGATTCTCCTGCCTCAGCCTCCCGTGCAGCTGGGATTGCAGGTGCG 1981 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      TGCCACCATGCCTGGCTAATTTCTGGTATTTTGTAGAGACAGGGTTTCGCCATGTTGGCC 2110 
RAD9B-002      TGCCACCATGCCTGGCTAATTTCTGGTATTTTGTAGAGACAGGGTTTCGCCATGTTGGCC 2048 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      TGCCACCATGCCTGGCTAATTTCTGGTATTTTGTAGAGACAGGGTTTCGCCATGTTGGCC 2041 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      AGGGTGGTCTTGAACTCCTGGCCTCAAGTGATCTGCCCACCTCGGCCTCCCAAAGTGCTG 2170 
RAD9B-002      AGGGTGGTCTTGAACTCCTGGCCTCAAGTGATCTGCCCACCTCGGCCTCCCAAAGTGCTG 2108 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      AGGGTGGTCTTGAACTCCTGGCCTCAAGTGATCTGCCCACCTCGGCCTCCCAAAGTGCTG 2101 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      GGATTACAGACTTGAGCCACTGCGCCCAACCTGGAGTGTTTTTACATATTGTAAAATTTT 2230 
RAD9B-002      GGATTACAGACTTGAGCCACTGCGCCCAACCTGGAGTGTTTTTACATATTGTAAAATTTT 2168 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      GGATTACAGACTTGAGCCACTGCGCCCAACCTGGAGTGTTTTTACATATTGTAAAATTTT 2161 
RAD9B-009      ------------------------------------------------------------ 1373 
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RAD9B-001      ATTTCCTAACCTCAAATTGTTCTGATTTTCAGATGTGATTTTTTATTTTGCAGTGTGCTG 2290 
RAD9B-002      ATTTCCTAACCTCAAATTGTTCTGATTTTCAGATGTGATTTTTTATTTTGCAGTGTGCTG 2228 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      ATTTCCTAACCTCAAATTGTTCTGATTTTCAGATGTGATTTTTTATTTTGCAGTGTGCTG 2221 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      CAGGAAAGAATTTAATGGAAGTGATGCCAAATATTTCTGTATTATCTGACATAGAACAGT 2350 
RAD9B-002      CAGGAAAGAATTTAATGGAAGTGATGCCAAATATTTCTGTATTATCTGACATAGAACAGT 2288 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      CAGGAAAGAATTTAATGGAAGTGATGCCAAATATTTCTGTATTATCTGACATAGAACAGT 2281 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      ATCCTCCACTGCCAAGACAGCCTGAGTTTGGAGTGGAATAAGGTGGAAGACAAATGTCTC 2410 
RAD9B-002      ATCCTCCACTGCCAAGACAGCCTGAGTTTGGAGTGGAATAAGGTGGAAGACAAATGTCTC 2348 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      ATCCTCCACTGCCAAGACAGCCTGAGTTTGGAGTGGAATAAGGTGGAAGACAAATGTCTC 2341 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      TGTTCTTTGGCCCTTTAAGAGTTAGCTTTTTACCTGCACAAATGGACTAAAAAATCTGGC 2470 
RAD9B-002      TGTTCTTTGGCCCTTTAAGAGTTAGCTTTTTACCTGCACAAATGGACTAAAAAATCTGGC 2408 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      TGTTCTTTGGCCCTTTAAGAGTTAGCTTTTTACCTGCACAAATGGACTAAAAAATCTGGC 2401 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      ACAAAACATTGTTATGTAATGTCTTATGATGTGTGCCTCTCCCTCCCCCAAACCTGTTTA 2530 
RAD9B-002      ACAAAACATTGTTATGTAATGTCTTATGATGTGTGCCTCTCCCTCCCCCAAACCTGTTTA 2468 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      ACAAAACATTGTTATGTAATGTCTTATGATGTGTGCCTCTCCCTCCCCCAAACCTGTTTA 2461 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      CAGTCAATTATAACCTGACAAACGAGACTTTTGTAACATATTATTGTTACATCTTTCTGA 2590 
RAD9B-002      CAGTCAATTATAACCTGACAAACGAGACTTTTGTAACATATTATTGTTACATCTTTCTGA 2528 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      CAGTCAATTATAACCTGACAAACGAGACTTTTGTAACATATTATTGTTACATCTTTCTGA 2521 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      AACCTTCAAACCGTAAGGAAGTGTTAACTGGCAAGCAGTTGTACTTTAGACTTTGTGAGA 2650 
RAD9B-002      AACCTTCAAACCGTAAGGAAGTGTTAACTGGCAAGCAGTTGTACTTTAGACTTTGTGAGA 2588 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      AACCTTCAAACCGTAAGGAAGTGTTAACTGGCAAGCAGTTGTACTTTAGACTTTGTGAGA 2581 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      AATTCATAAAGGTGGCTGAGTGGATTTGCATGCTTTAGAACTGTGAATAGAGTTCTAACT 2710 
RAD9B-002      AATTCATAAAGGTGGCTGAGTGGATTTGCATGCTTTAGAACTGTGAATAGAGTTCTAACT 2648 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      AATTCATAAAGGTGGCTGAGTGGATTTGCATGCTTTAGAACTGTGAATAGAGTTCTAACT 2641 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      GAAACCAGAATTAATTTGGCTCTTGTAGCTTAGTAATGAGTCATAGCTACCCACAATAAC 2770 
RAD9B-002      GAAACCAGAATTAATTTGGCTCTTGTAGCTTAGTAATGAGTCATAGCTACCCACAATAAC 2708 
RAD9B-003      ------------------------------------------------------------ 1846 
RAD9B-005      GAAACCAGAATTAATTTGGCTCTTGTAGCTTAGTAATGAGTCATAGCTACCCACAATAAC 2701 
RAD9B-009      ------------------------------------------------------------ 1373 
                                                                            
 
RAD9B-001      CTAATAAAAACTCAAGTTCATCCC-- 2794 
RAD9B-002      CTAATAAAAACTCAAGTTCATCCC-- 2732 
RAD9B-003      -------------------------- 1846 
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RAD9B-005      CTAATAAAAACTCAAGTTCATCCCAA 2727 
RAD9B-009      -------------------------- 1373 
 
Appendix 3 
 
Alignment of RAD9B-001,002, 003, 005 and 009 proteins 
 
RAD9B-001      ------------------------------------------------------------ 0 
RAD9B-002      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
RAD9B-003      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
RAD9B-005      ------------------------------------------------------------ 0 
RAD9B-009      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
                                                                            
 
RAD9B-001      ------------MSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 48 
RAD9B-002      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 120 
RAD9B-003      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 120 
RAD9B-005      ------------MSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 48 
RAD9B-009      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 120 
                           ************************************************ 
 
RAD9B-001      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 108 
RAD9B-002      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 180 
RAD9B-003      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 180 
RAD9B-005      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 108 
RAD9B-009      VVIQFFYRHD-------------------------------------------------- 130 
               *********.                                                   
 
RAD9B-001      LAVTPLNFCLKSSNEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 168 
RAD9B-002      LAVTPLNFCLKSSNEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 240 
RAD9B-003      LAVTPLNFCLKSSNEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 240 
RAD9B-005      LAVTPLNFCLKSSNEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 168 
RAD9B-009      -------------------LSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFS 171 
                                  ***************************************** 
 
RAD9B-001      EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 228 
RAD9B-002      EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 300 
RAD9B-003      EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 300 
RAD9B-005      EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 228 
RAD9B-009      EATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRKRSDL 231 
               ************************************************************ 
 
RAD9B-001      IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 288 
RAD9B-002      IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 360 
RAD9B-003      IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 360 
RAD9B-005      IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 288 
RAD9B-009      IEKKAGKNVTGQALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESS 291 
               ************************************************************ 
 
RAD9B-001      VSNTEEVPGSLCLRKFSCMFFGA--VSSDQQEHFNHPFDSLARASDSEEDMNNGSFSIF- 345 
RAD9B-002      VSNTEEVPGSLCLRKFSCMFFGA--VSSDQQEHFNHPFDSLARASDSEEDMNNGSFSIF- 417 
RAD9B-003      VSNTEEVPGSLCLRKFSCMFFGA--VSSDQQEHFNHPFDSLARASDSEEDMNNVCCRKEF 418 
RAD9B-005      VSNTEEVPGSLCLRKFSCMFFGA--VSSDQQEHFNHPFDSLARASDSEEDMNNGSFSIF- 345 
RAD9B-009      VSNTEEVPGSLCLRKCAAGKNLMEVMPNISVLSDIEQYPPLPRQPEFGVE---------- 341 
               *************** :.       : . .     . :  * *  :   :           
 
RAD9B-001      ----------- 345 
RAD9B-002      ----------- 417 
RAD9B-003      NGSDAKYFCII 429 
RAD9B-005      ----------- 345 
RAD9B-009      ----------- 341 
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Appendix 4 
 
Alignment of RAD9B-001 with RAD9A 
 
RAD9A-001      MKCLVTGGNVKVLGKAVHSLSRIGDELYLEPLEDGLSLRTVNSSRSAYACFLFAPLFFQQ 60 
RAD9B-001      -----------------------------------------------------------M 1 
                                                                            
 
RAD9A-001      YQAATPGQDLLRCKILMKSFLSVFRSLAMLEKTVEKCCISLNGRSSRLVVQLHCKFGVRK 120 
RAD9B-001      SENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCKVVIQFFYRHGIKR 61 
                :        *:**: ***:* :**.*  **:.:*** *  .. ..::*:*:. :.*::: 
 
RAD9A-001      THNLSFQDCESLQAVFDPASCPHMLRAPARVLGEAVLPFSPALAEVTLGIGRGRRVILRS 180 
RAD9B-001      THNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVTLAVTPLNFC-LKS 120 
               ***:.**:.: **.:**   * : *    *:*.:*:: *: :  ****.:   .   *:* 
 
RAD9A-001      YHEEEADSTAKAMVTEMCLGEEDFQQLQAQEGVAITFCLKEFRGLLSFAESANLNLSIHF 240 
RAD9B-001      S-NEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILTFSEATHAPISIYF 179 
                 :**: . ::*: :** :*.::*: :*   .. ****:**::*:*:*:*:::  :**:* 
 
RAD9A-001      DAPGRPAIFTIKDSLLDGHFVLATLSDTDSHSQDLGSPERHQPVPQLQAHSTPHPDDFAN 300 
RAD9B-001      DFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRK----RSDL-IEKKAG 234 
               * **:*  ::*.* *::.:*:****:* :*::..  *    *       :*    :. *. 
 
RAD9A-001      DDIDSYMIAMETTIG-NEGSRVLPSISL--------SPGPQPPKSPGPHS--EEEDEAEP 349 
RAD9B-001      KNVTGQA--LECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESSVSNT 292 
               .:: .    :*         *: *. :*        . .*   :  *  *  .*.. ::  
 
RAD9A-001      STVPGTPPPKKFRSLFFGSILAPVRSPQ-GPSPVLAEDSEGEG---------- 391 
RAD9B-001      EEVPGSLCLRKFSCMFFGAVSSDQQEHFNHPFDSLARASDSEEDMNNGSFSIF 345 
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Appendix 5 
 
Alignment of RAD9B-002 with RAD9A 
 
RAD9A-001      ----MKCLVTGGNVKVLGKAVHSLSRIGDELYLEPLEDGLSLRTVNSSRSAYACFLFAPL 56 
RAD9B-002      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
                   :**:::*.:***:****::****.**::*:* :.**:** ********.*.**:*: 
 
RAD9A-001      FFQQYQAATP---------GQDLLRCKILMKSFLSVFRSLAMLEKTVEKCCISLNGRSSR 107 
RAD9B-002      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 120 
               ***:** ::              *:**: ***:* :**.*  **:.:*** *  .. ..: 
 
RAD9A-001      LVVQLHCKFGVRKTHNLSFQDCESLQAVFDPASCPHMLRAPARVLGEAVLPFSPALAEVT 167 
RAD9B-002      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 180 
               :*:*:. :.*:::***:.**:.: **.:**   * : *    *:*.:*:: *: :  *** 
 
RAD9A-001      LGIGRGRRVILRSYHEEEADSTAKAMVTEMCLGEEDFQQLQAQEGVAITFCLKEFRGLLS 227 
RAD9B-002      LAVTPLNFC-LKSS-NEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILT 238 
               *.:   .   *:*  :**: . ::*: :** :*.::*: :*   .. ****:**::*:*: 
 
RAD9A-001      FAESANLNLSIHFDAPGRPAIFTIKDSLLDGHFVLATLSDTDSHSQDLGSPERHQPVPQL 287 
RAD9B-002      FSEATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRK-- 296 
               *:*:::  :**:** **:*  ::*.* *::.:*:****:* :*::..  *    *      
 
RAD9A-001      QAHSTPHPDDFANDDIDSYMIAMETTIG-NEGSRVLPSISL--------SPGPQPPKSPG 338 
RAD9B-002      --RSDL-IEKKAGKNVTGQA-—LECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDG 351 
                 :*    :. *..:: .    :*         *: *. :*        . .*   :  * 
 
RAD9A-001      PHS--EEEDEAEPSTVPGTPPPKKFRSLFFGSILAPVRSPQ-GPSPVLAEDSEGEG---- 391 
RAD9B-002      DVSEVSESSVSNTEEVPGSLCLRKFSCMFFGAVSSDQQEHFNHPFDSLARASDSEEDMNN 411 
                 *  .*.. :: . ***:   :** .:***:: :  :.    *   **. *:.*      
 
RAD9A-001      ------ 391 
RAD9B-002      GSFSIF 417 
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Appendix 6 
 
Alignment of RAD9B-001 and RAD9B-002 with RAD9A 
 
RAD9A-001      ----MKCLVTGGNVKVLGKAVHSLSRIGDELYLEPLEDGLSLRTVNSSRSAYACFLFAPL 56 
RAD9B-001      ------------------------------------------------------------ 0 
RAD9B-002      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
                                                                            
 
RAD9A-001      FFQQYQAATP---------GQDLLRCKILMKSFLSVFRSLAMLEKTVEKCCISLNGRSSR 107 
RAD9B-001      ------------MSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 48 
RAD9B-002      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCLNSLERNIEKCRIFTRSDKCK 120 
                                      *:**: ***:* :**.*  **:.:*** *  .. ..: 
 
RAD9A-001      LVVQLHCKFGVRKTHNLSFQDCESLQAVFDPASCPHMLRAPARVLGEAVLPFSPALAEVT 167 
RAD9B-001      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 108 
RAD9B-002      VVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNTLMIQPRLLADAIVLFTSSQEEVT 180 
               :*:*:. :.*:::***:.**:.: **.:**   * : *    *:*.:*:: *: :  *** 
 
RAD9A-001      LGIGRGRRVILRSYHEEEADSTAKAMVTEMCLGEEDFQQLQAQEGVAITFCLKEFRGLLS 227 
RAD9B-001      LAVTPLNFC-LKSS-NEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILT 166 
RAD9B-002      LAVTPLNFC-LKSS-NEESMDLSNAVHSEMFVGSDEFDFFQIGMDTEITFCFKELKGILT 238 
               *.:   .   *:*  :**: . ::*: :** :*.::*: :*   .. ****:**::*:*: 
 
RAD9A-001      FAESANLNLSIHFDAPGRPAIFTIKDSLLDGHFVLATLSDTDSHSQDLGSPERHQPVPQL 287 
RAD9B-001      FSEATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRK-- 224 
RAD9B-002      FSEATHAPISIYFDFPGKPLALSIDDMLVEANFILATLADEQSRASSPQSLCLSQKRK-- 296 
               *:*:::  :**:** **:*  ::*.* *::.:*:****:* :*::..  *    *      
 
RAD9A-001      QAHSTPHPDDFANDDIDSYMIAMETTIG-NEGSRVLPSISL--------SPGPQPPKSPG 338 
RAD9B-001      --RSDL-IEKKAGKNVTGQA--LECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDG 279 
RAD9B-002      --RSDL-IEKKAGKNVTGQA--LECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDG 351 
                 :*    :. *..:: .    :*         *: *. :*        . .*   :  * 
 
RAD9A-001      PHS--EEEDEAEPSTVPGTPPPKKFRSLFFGSILAPVRSPQ-GPSPVLAEDSEGEG---- 391 
RAD9B-001      DVSEVSESSVSNTEEVPGSLCLRKFSCMFFGAVSSDQQEHFNHPFDSLARASDSEEDMNN 339 
RAD9B-002      DVSEVSESSVSNTEEVPGSLCLRKFSCMFFGAVSSDQQEHFNHPFDSLARASDSEEDMNN 411 
                 *  .*.. :: . ***:   :** .:***:: :  :.    *   **. *:.*      
 
RAD9A-001      ------ 391 
RAD9B-001      GSFSIF 345 
RAD9B-002      GSFSIF 417 
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Appendix 7 
 
Alignment of RAD9B-001 with SpRad9-M50 
 
 
 
RAD9B-001      -------------------MSENELDTTLHLKCKLGMKSILPIFRCL-----------NS 30 
Rad9-M50       MVTLKKAFFDKYIFQPDSVLLTGLMTPT--IRIRTQVKPILSVFRNKIFDFIPTVVTTNS 58 
                                  :  . :  *  :: :  :* ** :**             ** 
RAD9B-001      L-----------ERNIEK-CRIFTRSDKCKVVIQFFYRHGIKRTHNICFQESQPLQVIFD 78 
Rad9-M50       KNGYGSESASRKDVIVENVQISISTGSECRIIFKFLCKHGVIKTYKISYEQTQTLHAVFD 118 
                           :  :*:    :: ..:*:::::*: :**: :*::*.::::* *:.:** 
 
RAD9B-001      KNVCTNTLMIQPRLLADAIVLFTSSQEEVTLAVTPLNFCLKSSNEESMD----LSNAVHS 134 
Rad9-M50       KSLSHNNFQINSKILKDLTEHFGQRTEELTIQPLQERVLLTSFTEEVVHNRDILKQPTQT 178 
               *.:. *.: *: ::* *    * .  **:*:     .. *.* .** :.    *.: .:: 
 
RAD9B-001      EMFVGSDEFDFFQIGMDTEITFCFKELKGILTFSEATHAPISIYFDFPGKPLALSIDD-- 192 
Rad9-M50       TVSIDGKEFERVALNEGVSVTLSLREFRAAVILAEALGSSICAYYGVPGKPILLTFAKGK 238 
                : :...**: . :. ...:*:.::*::. : ::**  : *. *:..****: *:: .   
 
RAD9B-001      -MLVEANFILATLADEQSRA------------SSPQSLCLSQKRKRSDLIEKKAGKNVTG 239 
Rad9-M50       NSEIEAQFILATVVGSDEQEVSSMMGNRWQHSSTPASLFNSVERNNSLTA--V-AHNPPG 295 
                  :**:*****:...:.:             *:* **  * :*:.*       .:*  * 
 
RAD9B-001      QALECISKKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESSVSNTEEVPGSL 299 
Rad9-M50       S-IGWQTDQSDSSRMFNS---------------ALDRSDE-TNGIKEPST--TNDAGQS- 335 
               . :   :.::   *:: .               *:.* *  .. :.* *.  *::.  *  
 
RAD9B-001      CLRKFSCMFFGAVS-SDQQEHFNHPFDSLARA-SDSEEDMNNGSFSIF- 345 
Rad9-M50       -------LFLDGIPNESELAAFNNDVNDDAEFGPTQAEQSYHGIFSQED 377 
                      :*:..:  ..:   **: .:. *.    . *:  :* **    
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Appendix 8 
 
Alignment of RAD9B-002 with SpRad9-M50 
 
 
 
RAD9B-002      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
Rad9-M50       -----------------------------------------------------MVTLKKA 7 
                                                                     * :. . 
RAD9B-002      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCL-----------NSL------ 103 
Rad9-M50       FFDKYIFQPDSVLLTGLMTPTIRI--RTQVKPILSVFRNKIFDFIPTVVTTNSKNGYGSE 65 
               **::* :.    :  . :  *:::  :  :* ** :**             **        
 
RAD9B-002      -----ERNIEK-CRIFTRSDKCKVVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNT 157 
Rad9-M50       SASRKDVIVENVQISISTGSECRIIFKFLCKHGVIKTYKISYEQTQTLHAVFDKSLSHNN 125 
                    :  :*:    :: ..:*:::::*: :**: :*::*.::::* *:.:***.:. *. 
 
RAD9B-002      LMIQPRLLADAIVLFTSSQEEVTLAVTPLNFCLKSSNEESMD----LSNAVHSEMFVGSD 213 
Rad9-M50       FQINSKILKDLTEHFGQRTEELTIQPLQERVLLTSFTEEVVHNRDILKQPTQTTVSIDGK 185 
               : *: ::* *    * .  **:*:     .. *.* .** :.    *.: .:: : :... 
 
RAD9B-002      EFDFFQIGMDTEITFCFKELKGILTFSEATHAPISIYFDFPGKPLALSIDD---MLVEAN 270 
Rad9-M50       EFERVALNEGVSVTLSLREFRAAVILAEALGSSICAYYGVPGKPILLTFAKGKNSEIEAQ 245 
               **: . :. ...:*:.::*::. : ::**  : *. *:..****: *:: .     :**: 
 
RAD9B-002      FILATLADEQSRA------------SSPQSLCLSQKRKRSDLIEKKAGKNVTGQALECIS 318 
Rad9-M50       FILATVVGSDEQEVSSMMGNRWQHSSTPASLFNSVERNNSLTA--V-AHNPPGS-IGWQT 301 
               *****:...:.:             *:* **  * :*:.*       .:*  *. :   : 
 
RAD9B-002      KKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESSVSNTEEVPGSLCLRKFSC 378 
Rad9-M50       DQSDSSRMFNS---------------ALDRSDE-TNGIKEPST--TNDAGQS-------- 335 
               .::   *:: .               *:.* *  .. :.* *.  *::.  *         
 
RAD9B-002      MFFGAVS-SDQQEHFNHPFDSLARA-SDSEEDMNNGSFSIF- 417 
Rad9-M50       LFLDGIPNESELAAFNNDVNDDAEFGPTQAEQSYHGIFSQED 377 
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Appendix 9 
 
Alignment of RAD9B-001 and RAD9B-002 with SpRad9-M50 
 
RAD9B-001      ------------------------------------------------------------ 0 
RAD9B-002      MAAMLKCVMSGSQVKVFGKAVQALSRISDEFWLDPSKKGLALRCVNSSRSAYGCVLFSPV 60 
Rad9-M50       -----------------------------------------------------MVTLKKA 7 
                                                                            
 
RAD9B-001      ------------MSENELDTTLHLKCKLGMKSILPIFRCL-----------NSL------ 31 
RAD9B-002      FFQHYQWSALVKMSENELDTTLHLKCKLGMKSILPIFRCL-----------NSL------ 103 
Rad9-M50       FFDKYIFQPDSVLLTGLMTPTIRI--RTQVKPILSVFRNKIFDFIPTVVTTNSKNGYGSE 65 
                           :  . :  *:::  :  :* ** :**             **        
 
RAD9B-001      -----ERNIEK-CRIFTRSDKCKVVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNT 85 
RAD9B-002      -----ERNIEK-CRIFTRSDKCKVVIQFFYRHGIKRTHNICFQESQPLQVIFDKNVCTNT 157 
Rad9-M50       SASRKDVIVENVQISISTGSECRIIFKFLCKHGVIKTYKISYEQTQTLHAVFDKSLSHNN 125 
                    :  :*:    :: ..:*:::::*: :**: :*::*.::::* *:.:***.:. *. 
 
RAD9B-001      LMIQPRLLADAIVLFTSSQEEVTLAVTPLNFCLKSSNEESMD----LSNAVHSEMFVGSD 141 
RAD9B-002      LMIQPRLLADAIVLFTSSQEEVTLAVTPLNFCLKSSNEESMD----LSNAVHSEMFVGSD 213 
Rad9-M50       FQINSKILKDLTEHFGQRTEELTIQPLQERVLLTSFTEEVVHNRDILKQPTQTTVSIDGK 185 
               : *: ::* *    * .  **:*:     .. *.* .** :.    *.: .:: : :... 
 
RAD9B-001      EFDFFQIGMDTEITFCFKELKGILTFSEATHAPISIYFDFPGKPLALSIDD---MLVEAN 198 
RAD9B-002      EFDFFQIGMDTEITFCFKELKGILTFSEATHAPISIYFDFPGKPLALSIDD---MLVEAN 270 
Rad9-M50       EFERVALNEGVSVTLSLREFRAAVILAEALGSSICAYYGVPGKPILLTFAKGKNSEIEAQ 245 
               **: . :. ...:*:.::*::. : ::**  : *. *:..****: *:: .     :**: 
 
RAD9B-001      FILATLADEQSRA------------SSPQSLCLSQKRKRSDLIEKKAGKNVTGQALECIS 246 
RAD9B-002      FILATLADEQSRA------------SSPQSLCLSQKRKRSDLIEKKAGKNVTGQALECIS 318 
Rad9-M50       FILATVVGSDEQEVSSMMGNRWQHSSTPASLFNSVERNNSLTA--V-AHNPPGS-IGWQT 301 
               *****:...:.:             *:* **  * :*:.*       .:*  *. :   : 
 
RAD9B-001      KKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESSVSNTEEVPGSLCLRKFSC 306 
RAD9B-002      KKAAPRRLYPKETLTNISALENCGSPAMKRVDGDVSEVSESSVSNTEEVPGSLCLRKFSC 378 
Rad9-M50       DQSDSSRMFNS---------------ALDRSDE-TNGIKEPST--TNDAGQS-------- 335 
               .::   *:: .               *:.* *  .. :.* *.  *::.  *         
 
RAD9B-001      MFFGAVS-SDQQEHFNHPFDSLARA-SDSEEDMNNGSFSIF- 345 
RAD9B-002      MFFGAVS-SDQQEHFNHPFDSLARA-SDSEEDMNNGSFSIF- 417 
Rad9-M50       LFLDGIPNESELAAFNNDVNDDAEFGPTQAEQSYHGIFSQED 377 
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Appendix 10 
 
Alignment of SpRad9-M50 with C12orf32 
 
 
 
Rad9-M50      MVTLKKAFFDKYIFQPDSVLLTGLMTPTIRIRTQVKPILSVFRNKIFDFIPTVVTTNSKN 60 
C12ORF32      ------------------------MPPRKKRRQPSQKAPLLFHQQ-----P-------LE 24 
                                      * *  : *   :    :*:::     *        : 
 
Rad9-M50      GYGSESASRKDVIVENVQISISTGSECRIIFKFLCKHGVIKTYKISYEQTQTLHAVFDKS 120 
C12ORF32      GPKHSCASTQLPITHTRQVP-----------SKPIDHSTITSW----------------- 56 
              *   ..** :  *... *:            .   .*..*.::                  
 
Rad9-M50      LSHNNFQINSKILKDLTEHFGQRTEELTIQPLQERVLLTSFTEEVVHNRDILKQPTQTTV 180 
C12ORF32      -----------VSPDFDTAAG--------------SLFPAYQKHQNRARHSSRKPTTSK- 90 
                         :  *:    *               *: :: :.  : *.  ::** :.  
 
Rad9-M50      SIDGKEFERVALNEGVSVTLSLREFRA----------AVILAEALGSSICAYYGVPGK-- 228 
C12ORF32      -FPHLTFESPQSS--SSETLGIPLIRECPSESEKDVSRRPLVPVLSPQSCGNMSVQALQS 147 
               :    **    .   * **.:  :*              *. .*. . *.  .* .    
 
Rad9-M50      -PILL---TFAKGKNSEIEAQFILATVVGSDEQEVSSMMGNRWQHSSTPASLFNSVERNN 284 
C12ORF32      LPYVFIPPDIQTPESSSVKEE-----LIPQDQKE-NSLLSCTL-HTGTPNS----PEPG- 195 
               * ::    : . :.*.:: :     :: .*::* .*::.    *:.** *     * .  
 
Rad9-M50      SLTAVAHNPPG----SIGWQTDQSDSSRMFNSALDRSDETNGIKEPSTTNDAGQSLFLDG 340 
C12ORF32      -PVLVKDTPEDKYGIKVTWRRRQHLLAYL----RERG-------------KLSRSQFLVK 237 
                . * ..* .    .: *:  *   : :     :*.             . .:* **   
 
Rad9-M50      IPNESELAAFNNDVNDDAEFGPTQAEQSYHGIFSQED 377 
C12ORF32      S------------------------------------ 238 
 
 
 
 
 
 
 
 
 
 
 
 
 233 
 
Appendix 11 
 
Alignment of the amplified RAD9B-S003 with the full length RAD9B-003 
 
RAD9B-003      GCAGAGACGAGATCGCGAAGCTTTGAAAAGCGCGGGCAACATCCGGGCACCTGGGCCGTC 60 
RAD9B-S003     ------------------------------------------------------------ 0 
                                                                             
 
RAD9B-003      GAGCTGAGGCGCGCCTTCCGAGCCTGCTTTTTAGGGCGGATGGCAGCCATGCTGAAGTGC 120 
RAD9B-S003     ---------------------------------------ATGGCAGCCATGCTGAAGTGC 21 
                                                       ********************* 
 
RAD9B-003      GTGATGAGCGGCAGTCAGGTGAAAGTATTTGGGAAAGCAGTTCAAGCTCTATCACGAATT 180 
RAD9B-S003     GTGATGAGCGGCAGTCAGGTGAAAGTATTTGG-GAAGCAGTTCAAGCTCTATCACGAATT 80 
               ********************************  ************************** 
 
RAD9B-003      AGTGACGAGTTCTGGCTAGACCCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCT 240 
RAD9B-S003     AGTGACGAGTTCTGGCTAGACCCATCTAAAAAAGGTCTTGCTCTAAGATGTGTGAATTCT 140 
               ************************************************************ 
 
RAD9B-003      TCTCGGTCAGCATATGGATGTGTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGG 300 
RAD9B-S003     TCTCGGTCAGCATATGGATGTGTCCTGTTCTCTCCTGTGTTTTTTCAGCATTATCAATGG 200 
               ************************************************************ 
 
RAD9B-003      TCAGCTTTAGTGAAAATGAGTGAAAATGAACTTGACACAACACTGCATTTAAAATGCAAA 360 
RAD9B-S003     TCAGCTTTAGTGAAAATGAGTGAAAATGAACTTGACACAACACTGCATTTAAAATGCAAA 260 
               ************************************************************ 
 
RAD9B-003      TTGGGAATGAAGTCAATTTTGCCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATA 420 
RAD9B-S003     TTGGGAATGAAGTCAATTTTGCCCATCTTTAGATGTCTGAATTCCCTTGAAAGAAATATA 320 
               ************************************************************ 
 
RAD9B-003      GAGAAGTGCAGAATATTCACCAGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTAC 480 
RAD9B-S003     GAGAAGTGCAGAATATTCACCAGATCTGATAAATGCAAAGTAGTTATTCAATTCTTCTAC 380 
               ************************************************************ 
 
RAD9B-003      AGACATGGTATTAAAAGAACTCATAATATATGTTTTCAAGAAAGTCAGCCTTTGCAAGTT 540 
RAD9B-S003     AGACATGGTATTAAAAGAACTCATAATATATGTTTTCAAGAAAGTCAGCCTTTGCAAGTT 440 
               ************************************************************ 
 
RAD9B-003      ATTTTTGACAAGAATGTTTGTACTAATACGCTAATGATTCAACCAAGATTGCTTGCTGAT 600 
RAD9B-S003     ATTTTTGACAAGAATGTTTGTACTAATACGCTAATGATTCAACCAAGATTGCTTGCTGAT 500 
               ************************************************************ 
 
RAD9B-003      GCCATTGTTCTTTTTACATCAAGTCAAGAGGAAGTTACTCTTGCTGTTACTCCACTGAAT 660 
RAD9B-S003     GCCAAATATTTCTGTATTATCTGACTCGAGATCCTAAAGT-------------------- 540 
               ****    * * * **      * *  ***    * *                        
 
RAD9B-003      TTTTGCCTCAAGAGTTCTAATGAGGAATCAATGGATTTGAGCAATGCTGTACACAGTGAG 720 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      ATGTTTGTTGGCTCAGATGAGTTTGACTTCTTTCAAATTGGAATGGACACTGAGATAACA 780 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      TTTTGTTTCAAAGAATTGAAGGGAATACTGACATTTTCAGAAGCTACACATGCTCCTATA 840 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      TCCATTTATTTTGATTTCCCTGGGAAACCTCTGGCTTTGAGTATTGATGATATGTTAGTG 900 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      GAAGCTAACTTTATTTTGGCCACATTAGCTGATGAACAAAGTAGAGCATCTTCACCACAG 960 
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RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      TCACTGTGTCTTTCACAGAAACGAAAAAGGTCAGATCTGATTGAAAAAAAGGCTGGCAAA 1020 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      AATGTAACTGGCCAGGCCCTGGAATGTATTTCAAAAAAAGCAGCACCAAGAAGGCTTTAT 1080 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      CCTAAGGAGACTCTCACAAACATATCTGCATTGGAAAACTGTGGCAGCCCTGCAATGAAA 1140 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      AGAGTGGATGGAGATGTCAGTGAAGTATCAGAAAGCAGTGTCAGCAACACAGAGGAAGTG 1200 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      CCAGGGTCTCTGTGTCTCAGAAAGTTTTCTTGCATGTTCTTTGGAGCAGTTTCTTCTGAC 1260 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      CAGCAAGAACACTTCAACCACCCTTTCGACAGTCTGGCAAGAGCAAGTGACAGTGAAGAG 1320 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      GACATGAATAATGTGTGCTGCAGGAAAGAATTTAATGGAAGTGATGCCAAATATTTCTGT 1380 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      ATTATCTGACATAGAACAGTATCCTCCACTGCCAAGACAGCCTGAGTTTGGAGTGGAATA 1440 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      AGGTGGAAGACAAATGTCTCTGTTCTTTGGCCCTTTAAGAGTTAGCTTTTTACCTGCACA 1500 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      AATGGACTAAAAAATCTGGCACAAAACATTGTTATGTAATGTCTTATGATGTGTGCCTCT 1560 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      CCCTCCCCCAAACCTGTTTACAGTCAATTATAACCTGACAAACGAGACTTTTGTAACATA 1620 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      TTATTGTTACATCTTTCTGAAACCTTCAAACCGTAAGGAAGTGTTAACTGGCAAGCAGTT 1680 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      GTACTTTAGACTTTGTGAGAAATTCATAAAGGTGGCTGAGTGGATTTGCATGCTTTAGAA 1740 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      CTGTGAATAGAGTTCTAACTGAAACCAGAATTAATTTGGCTCTTGTAGCTTAGTAATGAG 1800 
RAD9B-S003     ------------------------------------------------------------ 540 
                                                                             
 
RAD9B-003      TCATAGCTACCCACAATAACCTAATAAAAACTCAAGTTCATCCCAA 1846 
RAD9B-S003     ---------------------------------------------- 540 
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